

JC02 Rec'd PCT/PTO 29 JAN 2001

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

ATTORNEY'S DOCKET NUMBER

1241.17

Box 594

U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5)

09/744748

INTERNATIONAL APPLICATION NO.

PCT/JP99/04092

INTERNATIONAL FILING DATE

29 July 1999 (29.07.99)

PRIORITY DATE CLAIMED

29 July 1998 (29.07.98)

TITLE OF INVENTION

A NOVEL POLYPEPTIDE

APPLICANT(S) FOR DO/EO/US

HISASHI NARIMATSU ET AL.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the application time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☐ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☒ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☒ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern other document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☒ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A **FIRST** preliminary amendment.
 - ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items or information: paper sequence listing, Statement under 37 C.F.R. §1.821(f), computer readable form sequence listing, Receipt in the Case of an Original Deposit, translation of International Preliminary Examination Report, 16 sheets of drawing including one photograph, preliminary amendment

09/744748

JCM2 Rec'd PCT/PTO 29 JAN 2001

U.S. APPLICATION NO. (If known, see 37 C.F.R.1.5)

INTERNATIONAL APPLICATION NO.

ATTORNEY'S DOCKET NUMBER

PCT/JP99/04092

1241.17

17. ☒ The following fees are submitted:**Basic National Fee (37 CFR 1.492(a)(1)-(5):**

Search Report has been prepared by the EP or JPO \$860.00

International preliminary examination fee paid to USPTO

(37 CFR 1.492(a)(1)) \$690.00

No international preliminary examination fee paid to USPTO (37 CFR 1.492

(a)(1)) but international search fee paid to USPTO (37 CFR 1.492(a)(2)) \$710.00

Neither international preliminary examination fee (37 CFR 1.492(a)(1))

nor international search fee (37 CFR 1.492(a)(2)) paid to USPTO \$1,000.00

International preliminary examination fee paid to USPTO (37 CFR 1.492

(a)(4)) and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00

ENTER APPROPRIATE BASIC FEE AMOUNT =Surcharge of \$130.00 for furnishing the oath or declaration later than ☐ 20 ☐ 30 months
from the earliest claimed priority date (37 CFR 1.492(e)).

Claims	Number Filed	Number Extra	Rate
Total Claims	-20 =		X \$18.00
Independent Claims	-3 =		X 80.00
Multiple dependent claim(s) (if applicable)			+ \$270.00

TOTAL OF ABOVE CALCULATIONS =Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity statement
must also be filed. (Note 37 CFR 1.9, 1.27, 1.28).**SUBTOTAL =**Processing fee of \$130.00 for furnishing the English translation later than ☐ 20
☐ 30 months from the earliest claimed priority date (37 CFR 1.492(f)).**TOTAL NATIONAL FEE =**Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be
accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +**TOTAL FEES ENCLOSED =**

Amount to be:

refunded \$

charged \$

a. ☒ A check in the amount of \$40.00 to cover the above fees is enclosed.b. ☐ Please charge my Deposit Account No. _____ in the amount of \$_____ to cover the above fees. A duplicate copy of
this sheet is enclosed.c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to
Deposit Account No. 06-1205. A duplicate copy of this sheet is enclosed.**NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR
1.137(a) or (b)) must be filed and granted to restore the application to pending status.**

SEND ALL CORRESPONDENCE TO:

SIGNATURE

Elizabeth F. Holowacz

NAME

42,667

REGISTRATION NUMBER

09/744748

JC02 Rec'd PCT/PTO 29 JAN 2001
PATENT APPLICATION

1241.17

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
: Examiner: Unassigned
HISASHI NARIMATSU ET AL.)
: Group Art Unit: Unassigned
Based on PCT/JP99/04092)
:
Filed: Herewith)
:
For: A NOVEL POLYPEPTIDE) January 26, 2001

Assistant Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

Prior to examination on the merits in the above-identified national phase application, please amend the application as follows and consider the following remarks.

In the Claims:

Please add new claim 50 as follows:


--50. A method for treating renal diseases or cancers using a method of any one of claims 31 to 34.--

Remarks

The claims are 1-50, with claims 1 and 2 being independent. New claim 50 has been added. Consideration of the present claims is respectfully requested.

Applicants' undersigned attorney may be reached in our New York office by telephone at (212) 218-2100. All correspondence should continue to be directed to our below listed address.

Respectfully submitted,


Attorney for Applicants

Registration No. _____

FITZPATRICK, CELLA, HARPER & SCINTO
30 Rockefeller Plaza
New York, New York 10112-3801
Facsimile: (212) 218-2200

NY_MAIN 142368 v 1



1241.17

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
HISASHI NARIMATSU, ET AL.	:	Examiner: Not Yet Assigned
Application No.: 09/744,748)	
	:	Group Art Unit: N/Y/A
Filed: January 29, 2001)	
	:	
For: A NOVEL POLYPEPTIDE)	September 19, 2001

Commissioner for Patents
Washington, D.C. 20231

SUPPLEMENTAL PRELIMINARY AMENDMENT

Sir:

Prior to action on the merits, please amend the above-identified application as follows:

IN THE CLAIMS:

Please amend Claims 3, 4, 6-13, 15-27 and 29-50, and add new Claims 51-75 to read as follows. A marked-up copy of these claims, showing the changes made thereto, is attached.

3. (Amended) The polypeptide according to claim 1, wherein the activity of transferring fucose to an N-acetylglucosamine residue in the Gal β 1-4GlcNAc structure existing in a nonreducing terminus of a sugar chain via an α 1,3-linkage is the Lewis x sugar chain [Gal β 1-4(Fuc α 1-3)GlcNAc] and the Lewis y sugar chain [Fuc α 1-2Gal β 1-4(Fuc α 1-3)GlcNAc] synthesizing activity, and the activity of transferring fucose to an N-acetylglucosamine residue in the NeuAc α 2-3Gal β 1-4GlcNAc structure existing in a

nonreducing terminus of a sugar chain via an α 1,3-linkage is the sialyl Lewis x sugar chain [NeuAc α 2-3Gal β 1-4(Fuc α 1-3)GlcNAc] synthesizing activity.

4. (Amended) A DNA selected from the following (a), (b), (c), (d), (e), (f), (g) and (h):

(a) a DNA encoding the polypeptide according to any one of claims 1, 2, 3 and 51,

(b) a DNA having nucleotides 280 to 1194 of a nucleotide sequence represented by SEQ ID NO: 3,

(c) a DNA having nucleotides 115 to 1194 of a nucleotide sequence represented by SEQ ID NO: 3,

(d) a DNA having nucleotides 1454 to 2368 of a nucleotide sequence represented by SEQ ID NO: 4,

(e) a DNA having nucleotides 1289 to 2368 of a nucleotide sequence represented by SEQ ID NO: 4,

(f) a DNA having nucleotides 460 to 1374 of a nucleotide sequence represented by SEQ ID NO: 5,

(g) a DNA having nucleotides 295 to 1374 of a nucleotide sequence represented by SEQ ID NO: 5, and

(h) a DNA hybridizing under stringent conditions with DNA selected from (a), (b), (c), (d), (e), (f) and (g); and said DNA encodes a polypeptide having an activity to transfer fucose to an N-acetylglucosamine residue in an N-acetyllactosamine (Gal β 1-4GlcNAc) structure existing in a nonreducing terminus of a sugar chain via an α 1,3-linkage, but not having an activity to transfer fucose to an α 2,3-sialyl

N-acetyllactosamine (NeuAc α 2-3Gal β 1-4GlcNAc) structure existing in a nonreducing terminus of a sugar chain via an α 1,3-linkage.

6. (Amended) The recombinant DNA according to claim 5 wherein the recombinant DNA is plasmid pAMo-mFT9 or plasmid pBS-hFT9 (S2).

7. (Amended) A transformant having the recombinant DNA according to claim 5.

8. (Amended) The transformant according to claim 7 or 52, wherein the transformant is selected from the group consisting of microorganisms, animal cells, plant cells, insect cells, non-human transgenic animals, and transgenic plants.

9. (Amended) The transformant according to claim 8, wherein the microorganism belongs to *Escherichia*.

10. (Amended) The transformant according to claim 8, wherein the animal cell is selected from the group consisting of mouse myeloma cells, rat myeloma cells, mouse hybridoma cells, CHO cell, BHK cell, African green monkey kidney cells, Namalwa cell, Namalwa KJM-1 cell, human fetal kidney cells, and human leukemia cells.

11. (Amended) The transformant according to claim 8, wherein the insect cell is selected from the group consisting of *Spodoptera frugiperda* ovarian cells, *Trichoplusia ni* ovarian cells, and silkworm ovarian cells.

12. (Amended) A method for producing a polypeptide according to any one of claims 1, 2, 3 and 51, which comprises the steps of:

culturing in a medium a transformant having a recombinant DNA obtained by inserting a DNA encoding the polypeptide into a vector;
producing and accumulating said polypeptide in said medium; and
collecting said polypeptide from said medium.

13. (Amended) A method for producing a polypeptide according to any one of claims 1, 2, 3 and 51, which comprises the steps of:

feeding a non-human transgenic animal having a recombinant DNA obtained by inserting a DNA encoding the polypeptide into a vector;
producing and accumulating said polypeptide in said non-human transgenic animal; and
collecting said polypeptide from said non-human transgenic animal.

15. (Amended) A method for producing a polypeptide according to any one of claims 1, 2, 3 and 51, which comprises the steps of:

growing a transgenic plant having a recombinant DNA obtained by inserting a DNA encoding the polypeptide into a vector;
producing and accumulating said polypeptide in said transgenic plant; and
collecting said polypeptide from said transgenic plant.

16. (Amended) A method for producing a polypeptide according to any one of claims 1, 2, 3 and 51, which comprises the steps of:

using a DNA encoding the polypeptide, and

synthesizing said polypeptide by an *in vitro* transcription-translation system.

17. (Amended) A method for producing a reaction product wherein fucose is added to an N-acetylglucosamine residue in the N-acetylglucosamine structure of an acceptor substrate via an α 1,3-linkage, using a polypeptide selected from a polypeptide according to any one of claims 1, 2, 3 and 51 as an enzyme source, which comprises the steps of:

placing in an aqueous medium (a) said enzyme source, (b) an acceptor substrate selected from (i) N-acetylglucosamine(Gal β 1-4GlcNAc), (ii) oligosaccharides having the N-acetylglucosamine structure in a nonreducing terminus thereof, (iii) complex carbohydrates having the N-acetylglucosamine structure in a nonreducing terminus of sugar chains, (iv) their derivatives wherein the N-acetylglucosamine structure is modified by sulfate group, and (v) their derivatives wherein the N-acetylglucosamine structure is modified by sugar, but a galactose residue in the N-acetylglucosamine structure is not modified by sialic acid via an α 2,3-linkage, and (c) guanosine-5'-diphosphate fucose;

producing and accumulating the reaction product, in the aqueous medium;

and

collecting said reaction product from said aqueous medium.

18. (Amended) The method for producing the reaction product according to claim 17, wherein a derivative is selected from sugar chains having, in a nonreducing terminus thereof, any one of the following oligosaccharide structures: Fuc α 1-2Gal β 1-4GlcNAc, Gal α 1-3Gal β 1-4GlcNAc, Gal α 1-3(Fuc α 1-2)Gal β 1-4GlcNAc, GalNAc α 1-3(Fuc α 1-2)Gal β 1-4GlcNAc, Gal α 1-4Gal β 1-4GlcNAc, Gal β 1-4GlcNAc(6S₀₃); and complex carbohydrates containing said sugar chains.

19. (Amended) A method for producing a reaction product wherein fucose is added to a glucose residue in a lactose structure of an acceptor substrate via an α 1,3-linkage, using a polypeptide according to any one of claims 1, 2, 3 and 51 as an enzyme source, which comprises the steps of:

placing in an aqueous medium (a) said enzyme source, (b) an acceptor substrate selected from (i) lactose (Gal β 1-4Glc), (ii) oligosaccharides having a lactose structure in a nonreducing terminus thereof, (iii) complex carbohydrates having a lactose structure in a nonreducing terminus of sugar chains, (iv) their derivatives wherein a lactose structure is modified by sulfate group, and (v) their derivatives wherein a lactose structure is modified by sugar(s), but a galactose residue in the lactose structure is not modified by sialic acid via an α 2,3-linkage, and (c) guanosine-5' -diphosphate fucose;

producing and accumulating the reaction product, in said aqueous medium;

and

collecting said reaction product from said aqueous medium.

20. (Amended) The method for producing the reaction product according to claim 19, wherein a derivative is selected from sugar chains having, in a nonreducing terminus thereof, any one of the following oligosaccharide structures: Gal α 1-3Gal β 1-4Glc, Gal α 1-3(Fuc α 1-2)Gal β 1-4Glc, GalNAc α 1-3(Fuc α 1-2)Gal β 1-4Glc, Gal α 1-4Gal β 1-4Glc, Gal β 1-4Glc(6SO₃⁻); and complex carbohydrates containing said sugar chains.

21. (Amended) A method for producing a sugar chain having a structure wherein fucose is added to an N-acetylglucosamine residue or a glucose residue via an α

1,3-linkage, or a complex carbohydrate containing said sugar chain, which comprises the steps of:

culturing in a medium a transformant selected from the transformants derived from microorganisms, animal cells, plant cells, and insect cells according to claim 8;

producing and accumulating the sugar chain or the complex carbohydrate in said medium; and

collecting said sugar chain or said complex carbohydrate from said medium.

22. (Amended) A method for producing a sugar chain having structure wherein fucose is added to an N-acetylglucosamine residue or a glucose residue via an α 1,3-linkage, or a complex carbohydrate containing said sugar chain, which comprises the steps of:

feeding a nonhuman transgenic animal according to claim 8;

producing and accumulating the sugar chain or the complex carbohydrate in the non-human transgenic animal; and

collecting said sugar chain or said complex carbohydrate from said non-human transgenic animal.

23. (Amended) A method for producing a sugar chain having a structure wherein fucose is added to an N-acetylglucosamine residue or a glucose residue via an α 1,3-linkage, or a complex carbohydrate containing said sugar chain, which comprises the steps of:

growing a transgenic plant according to claim 8;

producing and accumulating the sugar chain or the complex carbohydrate in said transgenic plant; and

collecting said sugar chain or said complex carbohydrate from said transgenic plant.

24. (Amended) The production method according to claim 17, wherein the complex carbohydrate is selected from the group consisting of glycoproteins, glycolipids, proteoglycans, glycopeptides, lipopolysaccharides, peptideglycans and glycosides wherein a sugar chain binds to compounds such as steroids.

25. (Amended) The method for producing the sugar chain or the complex carbohydrate according to claim 22, wherein the generation and accumulation of said sugar chain or said complex carbohydrate is carried out in the milk of said non-human transgenic animal.

26. (Amended) A method for determining the expression level of a gene encoding a polypeptide according to any one of claims 1, 2, 3 and 51, by hybridization using DNA encoding the polypeptide.

27. (Amended) An oligonucleotide selected from the following oligonucleotides: an oligonucleotide having an identical sequence to 10 to 50 contiguous nucleotides in a nucleotide sequence of DNA selected from a DNA encoding the polypeptide according to any one of claims 1, 2, 3 and 51; a DNA having the nucleotide sequence represented by SEQ ID NO: 3; a DNA having the nucleotide sequence represented by SEQ ID NO: 4; and a DNA having the nucleotide sequence represented by

SEQ ID NO: 5; and, an oligonucleotide having a complementary sequence to said oligonucleotide and a derivative of each of said oligonucleotides.

29. (Amended) A method for determining the expression level of a gene encoding a polypeptide according to any one of claims 1, 2, 3 and 51 by polymerase chain reaction, using an oligonucleotide selected from the following oligonucleotides: an oligonucleotide having an identical sequence to 10 to 50 contiguous nucleotides in a nucleotide sequence of DNA selected from a DNA encoding the polypeptide according to any one of claims 1, 2, 3 and 51; a DNA having the nucleotide sequence represented by SEQ ID NO: 3; a DNA having the nucleotide sequence represented by SEQ ID NO: 4; and a DNA having the nucleotide sequence represented by SEQ ID NO: 5; and, an oligonucleotide having a complementary sequence to said oligonucleotide and a derivative of each of said oligonucleotides.

30. (Amended) A method for detecting encephalopathy, renal diseases and cancers, using the method according to claim 26.

31. (Amended) A method for suppressing the transcription of a DNA encoding a polypeptide according to any one of claims 1, 2, 3 and 51, using a DNA selected from a DNA encoding the polypeptide, a DNA having the nucleotide sequence represented by SEQ ID NO: 3, a DNA having the nucleotide sequence represented by SEQ ID NO: 4, and a DNA having the nucleotide sequence represented by SEQ ID NO: 5.

32. (Amended) A method for suppressing the translation of an mRNA encoding a polypeptide according to any one of claims 1, 2, 3 and 51, using a DNA

selected from a DNA encoding the polypeptide, a DNA having the nucleotide sequence represented by SEQ ID NO: 3, a DNA having the nucleotide sequence represented by SEQ ID NO: 4, and a DNA having the nucleotide sequence represented by SEQ ID NO: 5.

33. (Amended) A method for suppressing the transcription of a DNA encoding the polypeptide according to any one of claims 1, 2, 3 and 51, using an oligonucleotide selected from the following oligonucleotides: an oligonucleotide having an identical sequence to 10 to 50 contiguous nucleotides in a nucleotide sequence of DNA selected from a DNA encoding the polypeptide according to any one of claims 1, 2, 3 and 51; a DNA having the nucleotide sequence represented by SEQ ID NO: 3; a DNA having the nucleotide sequence represented by SEQ ID NO: 4; and a DNA having the nucleotide sequence represented by SEQ ID NO: 5; and, an oligonucleotide having a complementary sequence to said oligonucleotide and a derivative of each of said oligonucleotides.

34. (Amended) A method for suppressing the translation of an mRNA encoding the polypeptide according to any one of claims 1, 2, 3 and 51, using an oligonucleotide selected from the following oligonucleotides: an oligonucleotide having an identical sequence to 10 to 50 contiguous nucleotides in a nucleotide sequence of DNA selected from a DNA encoding the polypeptide according to any one of claims 1, 2, 3 and 51; a DNA having the nucleotide sequence represented by SEQ ID NO: 3; a DNA having the nucleotide sequence represented by SEQ ID NO: 4; and a DNA having the nucleotide sequence represented by SEQ ID NO: 5; and, an oligonucleotide having a complementary sequence to said oligonucleotide and a derivative of each of said oligonucleotides.

35. (Amended) An antibody recognizing a polypeptide according to any one of claims 1, 2, 3 and 51.

36. (Amended) An immunoassay which detects a polypeptide according to any one of claims 1, 2, 3 and 51, using an antibody recognizing said polypeptide.

37. (Amended) An immunohistological staining method which detects a polypeptide according to any one of claims 1, 2, 3 and 51, using an antibody recognizing said polypeptide.

38. (Amended) A reagent for immunohistological staining which contains the antibody of claim 35.

39. (Amended) An agent for diagnosing encephalopathy, renal diseases and cancers, which contains the antibody of claim 35.

40. (Amended) A method for screening a substance that changes the activity of a polypeptide according to any one of claims 1, 2, 3 and 51, which comprises contacting said polypeptide with test samples.

41. (Amended) A method for screening a substance that changes the expression of a gene encoding a polypeptide according to any one of claims 1, 2, 3 and 51, which comprises the steps of:

contacting a cell expressing said polypeptide with test samples, and

measuring the amount of the Lewis x or Lewis y sugar chain using an anti-Lewis x or anti-Lewis y antibody.

42. (Amended) A method for screening a substance that changes the expression of a gene encoding a polypeptide according to any one of claims 1, 2, 3 and 51, which comprises the steps of:

contacting a cell expressing said polypeptide with test samples, and
measuring the amount of said polypeptide using an antibody recognizing said polypeptide.

43. (Amended) A promoter DNA for the transcription of a gene encoding a polypeptide according to any one of claims 1, 2, 3 and 51.

44. (Amended) The promoter DNA according to claim 43 which functions in a cell selected from the group consisting of neurons, kidney cells, gastric epithelium cells, leukocyte cells, cerebral tumor cells, neuroblastoma cells, melanoma cells, renal cancer cells, stomach cancer cells, colon cancer cells, and pancreatic cancer cells.

45. (Amended) The promoter DNA according to claim 43 which is derived from human or mouse.

46. (Amended) A method for screening a substance that changes the efficiency of transcription by a promoter DNA according to claim 43, which comprises the steps of:

transforming an animal cell with a plasmid comprising the promoter DNA and a reporter gene ligated downstream of said promoter DNA;
contacting transformant with a test sample; and
measuring the amount of the translation product of said reporter gene.

47. (Amended) The screening method according to claim 46, wherein the reporter gene is a gene selected from the group consisting of chloramphenicol acetyltransferase genes, β -galactosidase genes, luciferase genes and green fluorescent protein genes.

48. (Amended) A non-human knockout animal wherein a DNA encoding the polypeptide according to any one of claims 1, 2, 3 and 51 is deleted or mutated.

49. (Amended) The non-human knockout animal according to claim 48, wherein the non-human knockout animal is a mouse.

50. (Amended) A method for treating renal diseases or cancers using a method according to claim 31.

51. (New) The polypeptide according to claim 2, wherein the activity of transferring fucose to an N-acetylglucosamine residue in the Gal β 1-4GlcNAc structure existing in a nonreducing terminus of a sugar chain via an α 1,3-linkage is the Lewis x sugar chain [Gal β 1-4(Fuc α 1-3)GlcNAc] and the Lewis y sugar chain [Fuc α 1-2Gal β 1-4(Fuc α 1-3)GlcNAc] synthesizing activity, and the activity of transferring fucose to an N-acetylglucosamine residue in the NeuAc α 2-3Gal β 1-4GlcNAc structure existing in a

nonreducing terminus of a sugar chain via an α 1,3-linkage is the sialyl Lewis x sugar chain [NeuAc α 2-3Gal β 1-4(Fuc α 1-3)GlcNAc] synthesizing activity.

52. (New) A transformant having the recombinant DNA according to claim 6.

53. (New) The production method according to claim 18, wherein the complex carbohydrate is selected from the group consisting of glycoproteins, glycolipids, proteoglycans, glycopeptides, lipopolysaccharides, peptideglycans and glycosides wherein a sugar chain binds to compounds such as steroids.

54. (New) The production method according to claim 19, wherein the complex carbohydrate is selected from the group consisting of glycoproteins, glycolipids, proteoglycans, glycopeptides, lipopolysaccharides, peptideglycans and glycosides wherein a sugar chain binds to compounds such as steroids.

55. (New) The production method according to claim 20, wherein the complex carbohydrate is selected from the group consisting of glycoproteins, glycolipids, proteoglycans, glycopeptides, lipopolysaccharides, peptideglycans and glycosides wherein a sugar chain binds to compounds such as steroids.

56. (New) The production method according to claim 21, wherein the complex carbohydrate is selected from the group consisting of glycoproteins, glycolipids, proteoglycans, glycopeptides, lipopolysaccharides, peptideglycans and glycosides wherein a sugar chain binds to compounds such as steroids.

57. (New) The production method according to claim 22, wherein the complex carbohydrate is selected from the group consisting of glycoproteins, glycolipids, proteoglycans, glycopeptides, lipopolysaccharides, peptideglycans and glycosides wherein a sugar chain binds to compounds such as steroids.

58. (New) The production method according to claim 23, wherein the complex carbohydrate is selected from the group consisting of glycoproteins, glycolipids, proteoglycans, glycopeptides, lipopolysaccharides, peptideglycans and glycosides wherein a sugar chain binds to compounds such as steroids.

59. (New) A method for determining the expression level of a gene encoding a polypeptide according to any one of claims 1, 2, 3, and 51 by polymerase chain reaction, using an oligonucleotide selected from the following oligonucleotides: an oligonucleotide having an identical sequence to 10 to 50 contiguous nucleotides in a nucleotide sequence of DNA selected from a DNA encoding the polypeptide according to any one of claims 1, 2, 3, and 51; a DNA having the nucleotide sequence represented by SEQ ID NO: 3; a DNA having the nucleotide sequence represented by SEQ ID NO: 4; and a DNA having the nucleotide sequence represented by SEQ ID NO: 5; and, an oligonucleotide having a complementary sequence to said oligonucleotide and a derivative of each of said oligonucleotides,

wherein said oligonucleotide derivative is selected from the following oligonucleotide derivatives: an oligonucleotide derivative obtained by converting a phosphodiester bond into a phosphorothioate bond in an oligonucleotide; an oligonucleotide derivative obtained by converting a phosphodiester bond into a N3'-P5' phosphoamidate bond in an oligonucleotide; an oligonucleotide derivative obtained by

converting a ribose and phosphodiester bond into a peptide-nucleic-acid bond in an oligonucleotide; an oligonucleotide derivative obtained by substituting uracil with C-5 propynyl uracil in an oligonucleotide; an oligonucleotide derivative obtained by substituting uracil with C-5 thiazolyl uracil in an oligonucleotide; an oligonucleotide derivative obtained by substituting cytosine with C-5 propynylcytosine in an oligonucleotide; an oligonucleotide derivative obtained by substituting cytosine with phenoxazine-modified cytosine in an oligonucleotide; an oligonucleotide derivative obtained by substituting ribose with 2'-O-propylribose in a DNA; and an oligonucleotide derivative obtained by substituting ribose with 2'-methoxyethoxyribose in the oligonucleotide.

60. (New) A method for suppressing the transcription of a DNA encoding the polypeptide according to any one of claims 1, 2, 3 and 51, using an oligonucleotide selected from the following oligonucleotides: an oligonucleotide having an identical sequence to 10 to 50 contiguous nucleotides in a nucleotide sequence of DNA selected from a DNA encoding the polypeptide according to any one of claims 1, 2, 3 and 51; a DNA having the nucleotide sequence represented by SEQ ID NO: 3; a DNA having the nucleotide sequence represented by SEQ ID NO: 4; and a DNA having the nucleotide sequence represented by SEQ ID NO: 5; and, an oligonucleotide having a complementary sequence to said oligonucleotide and a derivative of each of said oligonucleotides,

wherein said oligonucleotide derivative is selected from the following oligonucleotide derivatives: an oligonucleotide derivative obtained by converting a phosphodiester bond into a phosphorothioate bond in an oligonucleotide; an oligonucleotide derivative obtained by converting a phosphodiester bond into a N3'-P5' phosphoamidate bond in an oligonucleotide; an oligonucleotide derivative obtained by

converting a ribose and phosphodiester bond into a peptide-nucleic-acid bond in an oligonucleotide; an oligonucleotide derivative obtained by substituting uracil with C-5 propynyl uracil in an oligonucleotide; an oligonucleotide derivative obtained by substituting uracil with C-5 thiazolyl uracil in an oligonucleotide; an oligonucleotide derivative obtained by substituting cytosine with C-5 propynylcytosine in an oligonucleotide; an oligonucleotide derivative obtained by substituting cytosine with phenoxazine-modified cytosine in an oligonucleotide; an oligonucleotide derivative obtained by substituting ribose with 2'-O-propylribose in a DNA; and an oligonucleotide derivative obtained by substituting ribose with 2'-methoxyethoxyribose in the oligonucleotide.

61. (New) A method for suppressing the translation of an mRNA encoding the polypeptide according to any one of claims 1, 2, 3 and 51, using an oligonucleotide selected from the following oligonucleotides: an oligonucleotide having an identical sequence to 10 to 50 contiguous nucleotides in a nucleotide sequence of DNA selected from a DNA encoding the polypeptide according to any one of claims 1, 2, 3 and 51; a DNA having the nucleotide sequence represented by SEQ ID NO: 3; a DNA having the nucleotide sequence represented by SEQ ID NO: 4; and a DNA having the nucleotide sequence represented by SEQ ID NO: 5; and, an oligonucleotide having a complementary sequence to said oligonucleotide and a derivative of each of said oligonucleotides,

wherein said oligonucleotide derivative is selected from the following oligonucleotide derivatives: an oligonucleotide derivative obtained by converting a phosphodiester bond into a phosphorothioate bond in an oligonucleotide; an oligonucleotide derivative obtained by converting a phosphodiester bond into a N3'-P5' phosphoamidate bond in an oligonucleotide; an oligonucleotide derivative obtained by

converting a ribose and phosphodiester bond into a peptide-nucleic-acid bond in an oligonucleotide; an oligonucleotide derivative obtained by substituting uracil with C-5 propynyl uracil in an oligonucleotide; an oligonucleotide derivative obtained by substituting uracil with C-5 thiazolyl uracil in an oligonucleotide; an oligonucleotide derivative obtained by substituting cytosine with C-5 propynylcytosine in an oligonucleotide; an oligonucleotide derivative obtained by substituting cytosine with phenoxazine-modified cytosine in an oligonucleotide; an oligonucleotide derivative obtained by substituting ribose with 2'-O-propylribose in a DNA; and an oligonucleotide derivative obtained by substituting ribose with 2'-methoxyethoxyribose in the oligonucleotide.

62. (New) The promoter DNA according to claim 44 which is derived from human or mouse.

63. (New) A method for screening a substance that changes the efficiency of transcription by a promoter DNA according to claim 44, which comprises the steps of:
transforming an animal cell with a plasmid comprising the promoter DNA and a reporter gene ligated downstream of said promoter DNA;
contacting transformant with a test sample; and
measuring the amount of the translation product of said reporter gene.

64. (New) A method for screening a substance that changes the efficiency of transcription by a promoter DNA according to claim 45, which comprises the steps of:
transforming an animal cell with a plasmid comprising the promoter DNA and a reporter gene ligated downstream of said promoter DNA;

contacting transformant with a test sample; and
measuring the amount of the translation product of said reporter gene.

65. (New) A method for screening a substance that changes the efficiency of transcription by a promoter DNA according to claim 62, which comprises the steps of:
transforming an animal cell with a plasmid comprising the promoter DNA and a reporter gene ligated downstream of said promoter DNA;
contacting transformant with a test sample; and
measuring the amount of the translation product of said reporter gene.

66. (New) The screening method according to claim 63, wherein the reporter gene is a gene selected from the group consisting of chloramphenicol acetyltransferase genes, β -galactosidase genes, luciferase genes and green fluorescent protein genes.

67. (New) The screening method according to claim 64, wherein the reporter gene is a gene selected from the group consisting of chloramphenicol acetyltransferase genes, β -galactosidase genes, luciferase genes and green fluorescent protein genes.

68. (New) The screening method according to claim 65, wherein the reporter gene is a gene selected from the group consisting of chloramphenicol acetyltransferase genes, β -galactosidase genes, luciferase genes and green fluorescent protein genes.

69. (New) A method for treating renal diseases or cancers using a method according to claim 32.

70. (New) A method for treating renal diseases or cancers using a method according to claim 33.

71. (New) A method for treating renal diseases or cancers using a method according to claim 60.

72. (New) A method for treating renal diseases or cancers using a method according to claim 34.

73. (New) A method for treating renal diseases or cancers using a method according to claim 61.

74. (New) A method for detecting encephalopathy, renal diseases and cancers, using the method according to claim 29.

75. (New) A method for detecting encephalopathy, renal diseases and cancers, using the method according to claim 59.


REMARKS

The claims have been amended to better conform with accepted U.S. practice and idiomatic format. No new matter has been added.

Entry hereof is earnestly solicited.

Applicants' undersigned attorney may be reached in our New York office by telephone at (212) 218-2100. All correspondence should continue to be directed to our below listed address.

Respectfully submitted,


Lawrence S. Perry
Attorney for Applicants
Registration No. 31,865

FITZPATRICK, CELLA, HARPER & SCINTO
30 Rockefeller Plaza
New York, New York 10112-3801
Facsimile: (212) 218-2200

LSP\ac

NY_MAIN 198311 v1



Application No. 09/744,748
Attorney Docket No. 1241.17

VERSION WITH MARKINGS TO SHOW CHANGES MADE TO CLAIMS

3. (Amended) The polypeptide according to claim 1 [or 2], wherein the activity of transferring fucose to an N-acetylglucosamine residue in the Gal β 1-4GlcNAc structure existing in a nonreducing terminus of a sugar chain via an α 1,3-linkage is the Lewis x sugar chain [Gal β 1-4(Fuc α 1-3)GlcNAc] and the Lewis y sugar chain [Fuc α 1-2Gal β 1-4(Fuc α 1-3)GlcNAc] synthesizing activity, and the activity of transferring fucose to an N-acetylglucosamine residue in the NeuAc α 2-3Gal β 1-4GlcNAc structure existing in a nonreducing terminus of a sugar chain via an α 1,3-linkage is the sialyl Lewis x sugar chain [NeuAc α 2-3Gal β 1-4(Fuc α 1-3)GlcNAc] synthesizing activity.

4. (Amended) A DNA selected from the following (a), (b), (c), (d), (e), (f), (g) and (h):

(a) a DNA encoding the polypeptide [selected from the polypeptides] according to any one of claims 1, 2, [and] 3 and 51,

(b) a DNA having nucleotides 280 to 1194 of a nucleotide sequence represented by SEQ ID NO: 3,

(c) a DNA having nucleotides 115 to 1194 of a nucleotide sequence represented by SEQ ID NO: 3,

(d) a DNA having nucleotides 1454 to 2368 of a nucleotide sequence represented by SEQ ID NO: 4,

(e) a DNA having nucleotides 1289 to 2368 of a nucleotide sequence represented by SEQ ID NO: 4,

- (f) a DNA having nucleotides 460 to 1374 of a nucleotide sequence represented by SEQ ID NO: 5,
- (g) a DNA having nucleotides 295 to 1374 of a nucleotide sequence represented by SEQ ID NO: 5, and
- (h) a DNA hybridizing under stringent conditions with DNA selected from (a), (b), (c), (d), (e), (f) and (g); and said DNA encodes a polypeptide having an activity to transfer fucose to an N-acetylglucosamine residue in an N-acetyllactosamine (Gal β 1-4GlcNAc) structure existing in a nonreducing terminus of a sugar chain via an α 1,3-linkage, but not having an activity to transfer fucose to an α 2,3-sialyl N-acetyllactosamine (NeuAc α 2-3Gal β 1-4GlcNAc) structure existing in a nonreducing terminus of a sugar chain via an α 1,3-linkage.

6. (Amended) The recombinant DNA according to claim 5 wherein [it] the recombinant DNA is plasmid pAMo-mFT9 or plasmid pBS-hFT9 (S2).

7. (Amended) A transformant having the recombinant DNA according to claim 5 [or 6].

8. (Amended) The transformant according to claim 7 or 52, wherein [it is a] the transformant is selected from the group consisting of microorganisms, animal cells, plant cells, insect cells, non-human transgenic animals, and transgenic plants.

9. (Amended) The transformant according to claim 8, wherein the microorganism belongs to *Escherichia*.

10. (Amended) The transformant according to claim 8, wherein the animal cell is selected from the group consisting of mouse myeloma cells, rat myeloma cells, mouse hybridoma cells, CHO cell, BHK cell, African green monkey kidney cells, Namalwa cell, Namalwa KJM-1 cell, human fetal kidney cells, and human leukemia cells.

11. (Amended) The transformant according to claim 8, wherein the insect cell is selected from the group consisting of *Spodoptera frugiperda* ovarian cells, *Trichoplusia ni* ovarian cells, and silkworm ovarian cells.

12. (Amended) A method for producing a polypeptide [selected from the polypeptides] according to any one of claims 1, 2, [and] 3 and 51, which comprises the steps of:

culturing in a medium a transformant having a recombinant DNA obtained by inserting a DNA encoding the polypeptide into a vector;
producing and accumulating said polypeptide in said medium; and
collecting said polypeptide from said medium.

13. (Amended) A method for producing a polypeptide [selected from the polypeptides] according to any one of claims 1, 2, [and] 3 and 51, which comprises the steps of:

feeding a non-human transgenic animal having a recombinant DNA obtained by inserting a DNA encoding the polypeptide into a vector;
producing and accumulating said polypeptide in said non-human transgenic animal; and

collecting said polypeptide from said non-human transgenic animal.

15. (Amended) A method for producing a polypeptide [selected from the polypeptides] according to any one of claims 1, 2, [and] 3 and 51, which comprises the steps of:

growing a transgenic plant having a recombinant DNA obtained by inserting a DNA encoding the polypeptide into a vector;

producing and accumulating said polypeptide in said transgenic plant; and

collecting said polypeptide from said transgenic plant.

16. (Amended) A method for producing a polypeptide [selected from the polypeptides] according to any one of claims 1, 2, [and] 3 and 51, which comprises the steps of:

using a DNA encoding the polypeptide, and

synthesizing said polypeptide by an *in vitro* transcription-translation system.

17. (Amended) A method for producing a reaction product wherein fucose is added to an N-acetylglucosamine residue in the N-acetyllactosamine structure of an acceptor substrate via an α 1,3-linkage, using a polypeptide selected from [the polypeptides] a polypeptide according to any one of claims 1, 2, [and] 3 and 51 as an enzyme source[;], which comprises the steps of:

placing [the following (a), (b) and (c)] in an aqueous medium[:] (a) said enzyme source, (b) an acceptor substrate selected from (i) N-acetyllactosamine(Gal β 1-4GlcNAc), (ii) oligosaccharides having the N-acetyllactosamine structure in a nonreducing

terminus thereof, (iii) complex carbohydrates having the N-acetyllactosamine structure in a nonreducing terminus of sugar chains, (iv) their derivatives wherein the N-acetyllactosamine structure is modified by sulfate group, and (v) their derivatives wherein the N-acetyllactosamine structure is modified by sugar, but a galactose residue in the N-acetyllactosamine structure is not modified by sialic acid via an α 2,3-linkage, and (c) guanosine-5'-diphosphate fucose;

producing and accumulating the reaction product, in the aqueous medium;

and

collecting said reaction product from said aqueous medium.

18. (Amended) The method for producing the reaction product according to claim 17, wherein a derivative is selected from sugar chains having, in a nonreducing terminus thereof, any one of the following oligosaccharide structures: Fuc α 1-2Gal β 1-4GlcNAc, Gal α 1-3Gal β 1-4GlcNAc, Gal α 1-3(Fuc α 1-2)Gal β 1-4GlcNAc, GalNAc α 1-3(Fuc α 1-2)Gal β 1-4GlcNAc, Gal α 1-4Gal β 1-4GlcNAc, Gal β 1-4GlcNAc(6S0₃⁻); and complex carbohydrates containing said sugar chains.

19. (Amended) A method for producing a reaction product wherein fucose is added to a glucose residue in a lactose structure of an acceptor substrate via an α 1,3-linkage, using a polypeptide [selected from the polypeptides] according to any one of claims 1, 2, [and] 3 and 51 as an enzyme source[;], which comprises the steps of:

placing [the following (a), (b) and (c)] in an aqueous medium[:] (a) said enzyme source, (b) an acceptor substrate selected from (i) lactose (Gal β 1-4Glc), (ii) oligosaccharides having a lactose structure in a nonreducing terminus thereof,

(iii) complex carbohydrates having a lactose structure in a nonreducing terminus of sugar chains, (iv) their derivatives wherein a lactose structure is modified by sulfate group, and (v) their derivatives wherein a lactose structure is modified by sugar(s), but a galactose residue in the lactose structure is not modified by sialic acid via an α 2,3-linkage, and (c) guanosine-5' -diphosphate fucose;

producing and accumulating the reaction product, in said aqueous medium;

and

collecting said reaction product from said aqueous medium.

20. (Amended) The method for producing the reaction product according to claim 19, wherein a derivative is selected from sugar chains having, in a nonreducing terminus thereof, any one of the following oligosaccharide structures: Gal α 1-3Gal β 1-4Glc, Gal α 1-3(Fuc α 1-2)Gal β 1-4Glc, GalNAc α 1-3(Fuc α 1-2)Gal β 1-4Glc, Gal α 1-4Gal β 1-4Glc, Gal β 1-4Glc(6SO₃⁻); and complex carbohydrates containing said sugar chains.

21. (Amended) A method for producing a sugar chain having a structure wherein fucose is added to an N-acetylglucosamine residue or a glucose residue via an α 1,3-linkage, or a complex carbohydrate containing said sugar chain[;], which comprises[,]
the steps of:

culturing in a medium a transformant selected from the transformants derived from microorganisms, animal cells, plant cells, and insect cells according to claim 8;

producing and accumulating the sugar chain or the complex carbohydrate in said medium; and
collecting said sugar chain or said complex carbohydrate from said medium.

22. (Amended) A method for producing a sugar chain having structure wherein fucose is added to an N-acetylglucosamine residue or a glucose residue via an α 1,3-linkage, or a complex carbohydrate containing said sugar chain[;], which comprises[,]
the steps of:

feeding a nonhuman transgenic animal according to claim 8;
producing and accumulating the sugar chain or the complex carbohydrate in the non-human transgenic animal; and
collecting said sugar chain or said complex carbohydrate from said non-human transgenic animal.

23. (Amended) A method for producing a sugar chain having a structure wherein fucose is added to an N-acetylglucosamine residue or a glucose residue via an α 1,3-linkage, or a complex carbohydrate containing said sugar chain[;], which comprises[,]
the steps of:

growing a transgenic plant according to claim 8;
producing and accumulating the sugar chain or the complex carbohydrate in said transgenic plant; and
collecting said sugar chain or said complex carbohydrate from said transgenic plant.

24. (Amended) The production method according to [any one of claims] claim 17, [to 23] wherein the complex carbohydrate is selected from the group consisting of glycoproteins, glycolipids, proteoglycans, glycopeptides, lipopolysaccharides, peptideglycans and glycosides wherein a sugar chain binds to compounds such as steroids.

25. (Amended) The method for producing the sugar chain or the complex carbohydrate according to claim 22, wherein the generation and accumulation of said sugar chain or said complex carbohydrate is carried out in the milk of said non-human transgenic animal.

26. (Amended) A method for determining the expression level of a gene encoding a polypeptide [selected from the polypeptides] according to any one of claims 1, 2, [and] 3 and 51, by hybridization using DNA encoding the polypeptide.

27. (Amended) An oligonucleotide selected from the following oligonucleotides: an oligonucleotide having an [identical] identical sequence to 10 to 50 contiguous nucleotides in a nucleotide sequence of DNA selected from a DNA encoding the polypeptide [selected from the polypeptides] according to any one of claims 1, 2, [and] 3 and 51; a DNA having the nucleotide sequence represented by SEQ ID NO: 3; a DNA having the nucleotide sequence represented by SEQ ID NO: 4; and a DNA having the nucleotide sequence represented by SEQ ID NO: 5; and, an oligonucleotide having a complementary sequence to said oligonucleotide and a derivative of each of said oligonucleotides.

29. (Amended) A method for determining the expression level of a gene encoding a polypeptide [selected from the polypeptides] according to any one of claims 1, 2, [and] 3 and 51 by polymerase chain reaction, using [the] an oligonucleotide [according to claim 27 or 28] selected from the following oligonucleotides: an oligonucleotide having an identical sequence to 10 to 50 contiguous nucleotides in a nucleotide sequence of DNA selected from a DNA encoding the polypeptide according to any one of claims 1, 2, 3 and 51; a DNA having the nucleotide sequence represented by SEQ ID NO: 3; a DNA having the nucleotide sequence represented by SEQ ID NO: 4; and a DNA having the nucleotide sequence represented by SEQ ID NO: 5; and, an oligonucleotide having a complementary sequence to said oligonucleotide and a derivative of each of said oligonucleotides.

30. (Amended) A method for detecting encephalopathy, renal diseases and cancers, using the method according to claim 26 [or 29].

31. (Amended) A method for [suppressing] suppressing the transcription of a DNA encoding a polypeptide [selected from the polypeptides] according to any one of claims 1, 2, [and] 3 and 51, using a DNA selected from a DNA encoding the polypeptide, a DNA having the nucleotide sequence represented by SEQ ID NO: 3, a DNA having the nucleotide sequence represented by SEQ ID NO: 4, and a DNA having the nucleotide sequence represented by SEQ ID NO: 5.

32. (Amended) A method for [suppressing] suppressing the translation of an mRNA encoding a polypeptide [selected from the polypeptides] according to any one of claims 1, 2, [and] 3 and 51, using a DNA selected from a DNA encoding the polypeptide, a

DNA having the nucleotide sequence represented by SEQ ID NO: 3, a DNA having the nucleotide sequence represented by SEQ ID NO: 4, and a DNA having the nucleotide sequence represented by SEQ ID NO: 5.

33. (Amended) A method for [supressing] suppressing the transcription of a DNA encoding the polypeptide according to any one of claims 1, 2, [or] 3 and 51, using [the] an oligonucleotide [according to claim 27 or 28] selected from the following oligonucleotides: an oligonucleotide having an identical sequence to 10 to 50 contiguous nucleotides in a nucleotide sequence of DNA selected from a DNA encoding the polypeptide according to any one of claims 1, 2, 3 and 51; a DNA having the nucleotide sequence represented by SEQ ID NO: 3; a DNA having the nucleotide sequence represented by SEQ ID NO: 4; and a DNA having the nucleotide sequence represented by SEQ ID NO: 5; and, an oligonucleotide having a complementary sequence to said oligonucleotide and a derivative of each of said oligonucleotides.

34. (Amended) A method for [supressing] suppressing the translation of an mRNA encoding the polypeptide according to any one of claims 1, 2, [or] 3 and 51, using [the] an oligonucleotide [according to claim 27 or 28] selected from the following oligonucleotides: an oligonucleotide having an identical sequence to 10 to 50 contiguous nucleotides in a nucleotide sequence of DNA selected from a DNA encoding the polypeptide according to any one of claims 1, 2, 3 and 51; a DNA having the nucleotide sequence represented by SEQ ID NO: 3; a DNA having the nucleotide sequence represented by SEQ ID NO: 4; and a DNA having the nucleotide sequence represented by

SEQ ID NO: 5; and, an oligonucleotide having a complementary sequence to said oligonucleotide and a derivative of each of said oligonucleotides.

35. (Amended) An antibody recognizing a polypeptide [selected from the polypeptides] according to any one of claims 1, 2, [and] 3 and 51.

36. (Amended) An immunoassay which detects a polypeptide [selected from the polypeptides] according to any one of claims 1, 2, [and] 3 and 51, using [the] said antibody [according to claim 35].

37. (Amended) An immunohistological staining method which detects a polypeptide [selected from the polypeptides] according to any one of claims 1, 2, [and] 3 and 51, using [the] said antibody [according to claim 35].

38. (Amended) A reagent for immunohistological staining which contains the antibody of [clam] claim 35.

39. (Amended) An agent for diagnosing encephalopathy, renal diseases and cancers, which contains the antibody of [clam] claim 35.

40. (Amended) A method for screening a substance that changes the activity of a polypeptide [selected from the polypeptides] according to any one of claims 1, 2, [and] 3 and 51, which comprises contacting said polypeptide with test samples.

41. (Amended) A method for screening a substance that changes the expression of a gene encoding a polypeptide [selected from the polypeptides] according to any one of claims 1, 2, [and] 3 and 51, which comprises the steps of:

contacting a cell expressing said polypeptide with test samples, and
measuring the amount of the Lewis x or Lewis y sugar chain using an anti-Lewis x or anti-Lewis y antibody.

42. (Amended) A method for screening a substance that changes the expression of a gene encoding a polypeptide [selected from the polypeptides] according to any one of claims 1, 2, [and] 3 and 51, which comprises the steps of:

contacting a cell expressing said polypeptide with test samples, and
measuring the amount of said polypeptide using [the] an antibody [of claim 35] recognizing said polypeptide.

43. (Amended) A promoter DNA for the transcription of a gene encoding a polypeptide [selected from the polypeptides] according to any one of claims 1, 2, [and] 3 and 51.

44. (Amended) The promoter DNA according to claim 43 which functions in a cell selected from the group consisting of neurons, kidney cells, gastric epithelium cells, leukocyte cells, cerebral tumor cells, neuroblastoma cells, melanoma cells, renal cancer cells, stomach cancer cells, colon cancer cells, and pancreatic cancer cells.

45. (Amended) The promoter DNA according to claim 43 [or 44] which is derived from human or mouse.

46. (Amended) A method for screening a substance that changes the efficiency of transcription by a promoter DNA [selected from the promoter DNAs] according to claim[s] 43, [44 and 45,] which comprises the steps of:

transforming an animal cell with a plasmid comprising the promoter DNA and a reporter gene ligated downstream of said promoter DNA;

contacting transformant with a test sample; and

measuring the amount of the translation product of said reporter gene.

47. (Amended) The screening method according to claim 46, wherein the reporter gene is a gene selected from the group consisting of chloramphenicol acetyltransferase genes, β -galactosidase genes, luciferase genes and green fluorescent protein genes.

48. (Amended) A non-human knockout animal wherein a DNA encoding the polypeptide [selected from the polypeptides] according to any one of claims 1, 2, [and] 3 and 51 is deleted or mutated.

49. (Amended) The non-human knockout animal according to claim 48, wherein the non-human knockout [animal] animal is a mouse.

50. (Amended) A method for treating renal diseases or cancers using a method [of any one of claims] according to claim 31 [to 34].

NY_MAIN 198311 v 1

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

16/ PPRB

09/744748
JC02 Rec'd PCT/PTO 29 JAN 2001

SPECIFICATION

A Novel polypeptide

Technical Field

The present invention relates to a novel polypeptide having α 1,3-fucosyltransferase activity, a method for producing the polypeptide, a DNA encoding the polypeptide, a recombinant vector into which the DNA is integrated, a transformant having the recombinant vector, an antibody recognizing the polypeptide, a method for producing a fucose-containing sugar chain and a complex carbohydrate containing the sugar chain using the polypeptide, and a method for producing a fucose-containing sugar chain and a complex carbohydrate containing the sugar chain using a transformant having the recombinant vector.

Background Art

It is thought that fucose-containing sugar chains are not only associated with such vital phenomena as development, differentiation and cell recognition, but are also associated with the onset and progression of inflammations, cancers, autoimmune diseases and many other diseases (Edited by Akira KOHATA, Senichiro HAKOMORI, Katsutaka NAGAI, *Glycobiology Series 1-6*, Kodansya, (1993), *Glycobiology*, **3**, 97 (1993)).

Fucose-containing sugar chains are bound to proteins or lipids, and thus exist not only in the form of glycoproteins, proteoglycans and glycolipids, but also in the form of oligosaccharides.

The Lewis x sugar chain [Gal β 1-4(Fuc α 1-3)GlcNAc], one of the fucose-

containing sugar chains, appears regularly in each developmental stage of the early embryo, brain and kidney. For the reasons that the Lewis x sugar chains have affinity with one another and that they are associated with the cell compaction which occurs in the developmental stage of mouse early embryos, it is considered that the Lewis x sugar chain plays an important role in the development of early embryo, brain and kidney, acting as an adhesion molecule or a sugar chain signal.

For this reason, by cloning a gene of α 1,3-fucosyltransferase involved in the synthesis of the Lewis x sugar chain appearing in the developmental stage of those organs, and analyzing its role, it is possible to clarify the relation between the gene and hereditary diseases.

The sialyl Lewis x sugar chain [NeuAc α 2-3Gal β 1-4(Fuc α 1-3)GlcNAc], the sialyl Lewis a sugar chain [NeuAc α 2-3Gal β 1-3(Fuc α 1-4)GlcNAc], the Lewis x sugar chain and the Lewis y sugar chain [Fuc α 1-2Gal β 1-4(Fuc α 1-3)GlcNAc] are known as cancer-associated sugar chains.

The sialyl Lewis a sugar chain is detected mainly in cancers developing in the digestive system such as colon cancer and pancreatic cancer with high frequency. On the other hand, the sialyl Lewis x sugar chain, the Lewis x sugar chain and the Lewis y sugar chain are detected in lung cancer, ovarian cancer and renal cancer as well as the cancers developing in the digestive system.

Since it is clear that, even if the same sugar chain appears, glycosyltransferase involved in the synthesis of the sugar chain varies depending on the cell, it is considered possible to diagnose cancers more correctly, for example, by identifying α 1,3-fucosyltransferase involved in the biosynthesis of the Lewis x sugar chains in each cancer cell and clarifying the correlation between the transferase and the specific cancer.

The Lewis x sugar chain is also involved in both the clearance in the blood and targeting to the organ of interest in respect of the glycoprotein containing the sugar chain. It is considered possible to control the clearance rate of any protein in the blood or to target to the liver by artificially adding the Lewis x sugar chain to any protein (*J. Biol. Chem.*, 270, 24024-24031 (1995)).

Furthermore, since the Lewis x sugar chain is known to have an activity to adhere reciprocally among the sugar chains (*Glycoconjugate J.*, 11, 238-248 (1994), *Glycobiology*, 8, 139-146 (1998)), after adding the Lewis x sugar chain to any protein, it is also possible to make the protein target to a cancer organ which highly expresses the Lewis x sugar chain.

In the case where the sialyl Lewis x sugar chain is added to a protein, it is thought that the protein targets a cell expressing selectin (e.g. vascular endothelial cell in inflammatory site).

Hence, in order to make any protein target to the liver or cancer tissues effectively, it is desirable that the Lewis x sugar chain is effectively added to the protein, while the sialyl Lewis x sugar chain is not added thereto. It is an industrially important object to develop a method for effectively adding the Lewis x sugar chain to any recombinant glycoprotein, without adding the sialyl Lewis x sugar chain thereto, in a host cell suitable for producing the recombinant glycoprotein (e.g. Namalwa cell, Namalwa KJM-1 cell, CHO cell etc.)

It has been reported that, when an α 1,3-fucosyltransferase (Fuc-TIV) is expressed in a specific CHO cell line, the Lewis x sugar chain is expressed without expression of sialyl Lewis x sugar chain (*J. Biol. Chem.*, 266, 17467-17477(1991), *J. Biol. Chem.*, 266, 21777-21783(1991)). However, since Fuc-TIV originally has an

activity to synthesize the sialyl Lewis x sugar chain, when Fuc-TIV is expressed in other cells (e.g. other types of CHO cell lines or Namalwa KJM-1 cell), the sialyl Lewis x sugar chain is expressed in addition to the Lewis x sugar chain (*Cell.*, 63, 1349-1356, *J. Biol. Chem.*, 269, 14730-14737(1994)).

Some reasons why the amount of the sialyl Lewis x sugar chain synthesized by Fuc-TIV is different depending on the cells into which Fuc-TIV is introduced may be that the amount and kind of sugar chain acting as a substrate in these cells is different, and that the expression level of the expressed Fuc-TIV or other glycosyltransferases (e.g. α 2,3-sialyltransferase) is different among these cells.

It is thought that, for example, α 2,3-sialyltransferase (ST3Gal III or ST3Gal IV) and Fuc-TIV compete for the same substrate (a sugar chain having an N-acetyllactosamine structure).

When the activity of α 2,3-sialyltransferase is relatively stronger than that of Fuc-TIV, an α 2,3-sialyl-N-acetyllactosamine sugar chain is generated with higher priority, and then fucose is added to the sugar chain by Fuc-TIV to synthesize the sialyl Lewis x sugar chain. In contrast, when the activity of Fuc-TIV is relatively stronger than that of α 2,3-sialyltransferase, fucosyl-N-acetyllactosamine sugar chain (the Lewis x sugar chain) is synthesized with higher priority. Since α 2,3-sialyltransferase has low activity to add sialic acid to the Lewis x sugar chain, it is difficult to synthesize sialyl Lewis x sugar chain with α 2,3-sialyltransferase.

Thus, it is considered that, if a novel α 1,3-fucosyltransferase, which has an activity to synthesize the Lewis x sugar chain but does not have an activity to synthesize the sialyl Lewis x sugar chain, can be obtained, it is possible to effectively synthesize the Lewis x sugar chain without synthesizing the sialyl Lewis x sugar chain by expressing the transferase in a host cell. Many cells including cells suitable for

substance production have N-acetyllactosamine structure which is a precursor of the Lewis x sugar chain. Accordingly, the isolation of the above-stated novel enzyme will make it possible to effectively synthesize the Lewis x sugar chain by using various kinds of cells as host cells, without synthesizing the sialyl Lewis x sugar chain. However, such an enzyme is still unknown.

Since anti-CD15 antibody which recognizes the Lewis x sugar chain binds to human sperm after acrosome reaction and inhibits the interaction between the sperm and an egg, it is assumed that the Lewis x sugar chain is deeply involved in fertilization (*American Journal of Reproductive Immunology*, 37, 172-183 (1997)) . So, for the diagnosis and treatment of infertility disease, it is useful to identify an α 1,3-fucosyltransferase involved in the biosynthesis of the Lewis x sugar chain existing in a human sperm and clarify the relation between the transferase and infertility disease. Also, there is a possibility of establishing a safe and reliable contraception method, using a protein to which the Lewis x sugar chain or the Lewis y sugar chain is added.

Therefore, for these purposes also, the development of a method for effectively adding the Lewis x sugar chain to any protein is very important.

It has been found that the binding between selectins (E-, P- and L- selectin), an adhesive molecules and their sugar chain ligand (the sialyl Lewis x sugar chain or its relative sugar chains) is involved in the accumulation of leukocytes into inflammatory sites or homing of lymphocytes to a lymph nodes.

The sialyl Lewis x sugar chain and its stereo isomer, the sialyl Lewis a sugar chain are known as cancer-associated antigens whose expression level increases with canceration, and the antibodies recognizing these sugar chains are used for the serodiagnosis of cancers.

Since these sugar chains bind to selectins, it is assumed that these sugar chains are also involved in the metastasis of cancers. Recently, it has been discovered that glycolipid containing the Lewis x sugar chains existing in mouse kidney strongly bind to E-selectin (Biochem. Biophys. Res. Commun., 218, 610-615 (1996)).

A sugar chain having a strong binding activity to selectins is useful for the treatment and prevention of inflammation and metastasis of cancers, acting as a selectin antagonist. α 1,3-fucosyltransferases expressed in a mouse kidney are assumed to be useful in the effective synthesis of selectin antagonists, and identification and production of the above enzymes are considered to be significant. Nevertheless, the above enzymes have not been identified yet.

To date, genes for 5 types of α 1,3-fucosyltransferases (Fuc-TIII, Fuc-TIV, Fuc-TV, Fuc-TVI and Fuc-TVII) have been cloned, and acceptor substrate specificity of each enzyme has been analyzed (Kukowska-Latallo *et al.*, *Genes & Dev.* 4, 1288-1303 (1990), Goelz *et al.*, *Cell* 63, 1349-1356(1990), Lowe *et al.*, *J. Biol. Chem.* 266, 17467-17477(1991), Kumar *et al.*, *J. Biol. Chem.* 266, 21777-21783(1991), Weston *et al.*, *J. Biol. Chem.* 267, 4152-4160(1992), Weston *et al.*, *J. Biol. Chem.* 267, 24575-24584(1992), Koszdin *et al.*, *Biochem. Biophys. Res. Commun.* 187, 152-157(1992), Sasaki *et al.*, *J. Biol. Chem.* 269, 14730-14737(1994), Natsuka *et al.*, *J. Biol. Chem.* 269, 16789-16794(1994)).

Fuc-TIII has both α 1,3-fucosyltransferase activity and α 1,4-fucosyltransferase activity and is capable of synthesizing the sialyl Lewis x sugar chain, the Lewis x sugar chain, the Lewis y sugar chain, the sialyl Lewis a sugar chain, the Lewis a sugar chain [Gal β 1-3 (Fuc α 1-4) GlcNAc] and the Lewis b sugar chain [Fuc α 1-2Gal β 1-3 (Fuc α 1-4) GlcNAc] (Fuc-TIII has a strong activity to synthesize the Lewis a sugar chain and Lewis b sugar chains).

Fuc-TIV is capable of synthesizing the sialyl Lewis x sugar chain, the Lewis x sugar chain and the Lewis y sugar chain (Fuc-TIV has a strong activity to synthesize the Lewis x sugar chain and the Lewis y sugar chain).

Fuc-TV is capable of synthesizing the sialyl Lewis x sugar chain, the Lewis x sugar chain and the Lewis y sugar chain.

Fuc-TVI is capable of synthesizing the sialyl Lewis x sugar chain, the Lewis x sugar chain and the Lewis y sugar chain.

Fuc-TVII is capable of synthesizing only the sialyl Lewis x sugar chain.

As described above, each of the cloned 5 types of α 1,3-fucosyltransferases seems to have a somewhat-similar acceptor substrate specificity, but in the strict sense, each enzyme has a distinct acceptor substrate specificity. Furthermore, it is clear that the expression of each enzyme is specific for a cell or stage and that multiple enzymes may be expressed in one cell simultaneously. Even though the above enzymes can synthesize fucose-containing sugar chains having similar structure, it is thought that respective enzyme has a distinct function, because of the difference in cells or stages of their expression.

By an enzymological analysis using the extracts from cells or tissues as an enzyme source, it is possible, to a certain extent, to identify an α 1,3-fucosyltransferase which expresses in a tissue or cell (Mollicone *et al.*, *Carbohydrate Research*, 228, 265-276 (1992), Weston *et al.*, *J. Biol. Chem.*, 267, 24575-24584 (1992)). However, with the enzymological analysis, it is impossible to identify respective α 1,3-fucosyltransferases expressed in a cell or tissue expressing multiple α 1,3-fucosyltransferase, and to clarify the enzymologic characteristic of each α 1,3-fucosyltransferase.

In order to detect the expression of a specific α 1,3-fucosyltransferase, it is necessary to use an immunological detection method using a specific antibody or a detection method based on the nucleotide sequence of genes (e.g. Northern hybridization or PCR).

Disclosure of the Invention

The object of the present invention is to provide medical agents such as anti-inflammatory agents, anti-infective agents or antimetastatic agents; food such as dairy products, a method for improving proteins, and a method for diagnosing diseases such as encephalopathy, renal diseases and cancers, using a polypeptide having a novel α 1,3-fucosyltransferase activity.

The present invention relates to the following inventions 1 to 50.

1. A polypeptide having an activity to transfer fucose to an N-acetylglucosamine residue in an N-acetyllactosamine ($\text{Gal } \beta \text{ 1-4GlcNAc}$) structure existing in a nonreducing terminus of a sugar chain via an α 1,3-linkage, but not having an activity to transfer fucose to an N-acetylglucosamine residue in an α 2,3-sialyl N-acetyllactosamine ($\text{NeuAc } \alpha \text{ 2-3Gal } \beta \text{ 1-4GlcNAc}$) structure existing in a nonreducing terminus of a sugar chain via an α 1,3-linkage.
2. A polypeptide selected from the following (a), (b) and (c):
 - (a) a polypeptide comprising the amino acid sequence represented by SEQ ID NO: 1 or 2,
 - (b) a polypeptide comprising amino acid sequence of residues 56 to 359 represented by SEQ ID NO: 1 or 2,
 - (c) a polypeptide comprising an amino acid sequence wherein one or more amino

acids are deleted, substituted, or added in the amino acid sequence of the polypeptide of (a) or (b), having an activity to transfer fucose to an N-acetylglucosamine residue in an N-acetyllactosamine ($\text{Gal } \beta \text{ 1-4GlcNAc}$) structure existing in a nonreducing terminus of a sugar chain via an $\alpha \text{ 1,3-}$ linkage, but not having an activity to transfer fucose to the $\alpha \text{ 2,3-sialyl N-}$ acetyllactosamine ($\text{NeuAc } \alpha \text{ 2-3Gal } \beta \text{ 1-4GlcNAc}$) structure existing in a nonreducing terminus of a sugar chain via an $\alpha \text{ 1,3-}$ linkage.

The deletion, substitution or addition of the above amino acid(s) can be performed by site-directed mutagenesis which was known prior to the filing date of the present application, and "one or more amino acids" means amino acid(s) which can be deleted, substituted or added by site-directed mutagenesis.

A polypeptide comprising an amino acid sequence wherein one or more amino acids are deleted, substituted or added, and having a novel $\alpha \text{ 1,3-}$ fucosyltransferase activity can be prepared according to methods described in *Molecular Cloning, The Second Edition, Current Protocols in Molecular Biology Supplement 1-38, Nucleic Acids Research*, 10, 6487 (1982), *Proc. Natl. Acad. Sci., USA*, 79, 6409(1982), *Gene*, 34, 315 (1985), *Nucleic Acids Research*, 13, 4431 (1985), *Proc. Natl. Acad. Sci. USA*, 82, 488 (1985), *Proc. Natl. Acad. Sci., USA*, 81, 5662 (1984), *Science*, 224, 1431 (1984), PCT WO85/00817(1985), *Nature*, 316, 601 (1985) etc.

3. The polypeptide according to the above 1 or 2, wherein the activity of transferring fucose to an N-acetylglucosamine residue in the $\text{Gal } \beta \text{ 1-4GlcNAc}$ structure existing in a nonreducing terminus of a sugar chain via an $\alpha \text{ 1,3-}$ linkage is the Lewis x sugar chain [$\text{Gal } \beta \text{ 1-4(Fuc } \alpha \text{ 1-3)GlcNAc}$] and the Lewis y sugar chain [$\text{Fuc } \alpha \text{ 1-2Gal } \beta \text{ 1-4(Fuc } \alpha \text{ 1-3)GlcNAc}$] synthesizing activity, and the activity of transferring fucose to an N-acetylglucosamine residue in the $\text{NeuAc } \alpha \text{ 2-3Gal } \beta \text{ 1-4GlcNAc}$ structure existing in a nonreducing terminus of a sugar chain via an α

1,3-linkage is the sialyl Lewis x sugar chain [NeuAc α 2-3Gal β 1-4(Fuc α 1-3)GlcNAc] synthesizing activity.

4. A DNA selected from the following (a), (b), (c), (d), (e), (f), (g) and (h):
- (a) a DNA encoding the polypeptide selected from the polypeptides according to the above 1, 2 and 3,
 - (b) a DNA having nucleotides 280 to 1194 of a nucleotide sequence represented by SEQ ID NO: 3,
 - (c) a DNA having nucleotides 115 to 1194 of a nucleotide sequence represented by SEQ ID NO: 3,
 - (d) a DNA having nucleotides 1454 to 2368 of a nucleotide sequence represented by SEQ ID NO: 4,
 - (e) a DNA having nucleotides 1289 to 2368 of a nucleotide sequence represented by SEQ ID NO: 4,
 - (f) a DNA having nucleotides 460 to 1374 of a nucleotide sequence represented by SEQ ID NO: 5,
 - (g) a DNA having nucleotides 295 to 1374 of a nucleotide sequence represented by SEQ ID NO: 5, and
 - (h) a DNA hybridizing under stringent conditions with DNA selected from (a), (b), (c), (d), (e), (f) and (g); and the DNA encodes a polypeptide having an activity to transfer fucose to an N-acetylglucosamine residue in an N-acetyllactosamine (Gal β 1-4GlcNAc) structure existing in a nonreducing terminus of a sugar chain via an α 1,3-linkage, but not having an activity to transfer fucose to an α 2,3-sialyl N-acetyllactosamine (NeuAc α 2-3Gal β 1-4GlcNAc) structure existing in a nonreducing terminus of a sugar chain via an α 1,3-linkage.

The above stated "a DNA hybridizing under stringent conditions" means a DNA obtained by colony hybridization, plaque hybridization, Southern blot hybridization or the like, using as a probe, DNA selected from the above (a), (b), (c), (d),

(e), (f) and (g). Specifically, it means a DNA identified by subjecting a filter to which DNAs derived from colonies or plaques are immobilized, hybridizing at 65°C in the presence of 0.7-1.0M of NaCl, followed by washing the filter at 65°C with 0.1-2.0 standard concentration of SSC (saline-sodium citrate) solution (one standard concentration of SSC solution consists of 150mM sodium chloride and 15mM sodium citrate).

The hybridization can be carried out according to methods described in the following protocols: *Molecular Cloning , A Laboratory Manual*, Second Edition, Cold Spring Harbor Laboratory Press (1989) (hereinafter, referred to as “*Molecular Cloning 2nd Edit.*”), *Current Protocols in Molecular Biology Supplement 1-38*, John Wiley & Sons (1987-1997) (hereinafter, referred to as “*Current Protocols in Molecular Biology, Supplement 1-38*”), *DNA Cloning 1: Core Techniques, A Practical Approach*, Second Edition, Oxford University Press (1995) etc.

Examples of the DNAs capable of hybridizing include a DNA having at least 60% homology with the nucleotide sequence of a DNA encoding the polypeptide having an amino acid sequence represented by SEQ ID NO: 1 or 2, preferably a DNA having more than 80% homology, and more preferably a DNA having more than 95% homology.

5. A recombinant DNA obtained by integrating the DNA according to the above 4 into a vector.
6. The recombinant DNA according to the above 5 wherein it is plasmid pAMo-mFT9 or plasmid pBS-hFT9 (S2).
7. A transformant having the recombinant DNA according to the above 5 or 6.

8. The transformant according to the above 7 wherein it is a transformant selected from microorganisms, animal cells, plant cells, insect cells, non-human transgenic animals, and transgenic plants.
9. The transformant according to the above 8 wherein the microorganism belongs to *Escherichia*.
10. The transformant according to the above 8 wherein the animal cell is selected from mouse myeloma cells, rat myeloma cells, mouse hybridoma cells, CHO cell, BHK cell, African green monkey kidney cells, Namalwa cell, Namalwa KJM-1 cell, human fetal kidney cells, and human leukemia cells.
11. The transformant according to the above 8 wherein the insect cell is selected from *Spodoptera frugiperda* ovarian cells, *Trichoplusia ni* ovarian cells, and silkworm ovarian cells.
12. A method for producing a polypeptide selected from the polypeptides according to the above 1, 2 and 3, which comprises culturing in a medium a transformant having a recombinant DNA obtained by inserting a DNA encoding the polypeptide into a vector; producing and accumulating the polypeptide in the medium; and collecting the polypeptide from the medium.
13. A method for producing a polypeptide selected from the polypeptides according to the above 1, 2 and 3, which comprises feeding a non-human transgenic animal having a recombinant DNA obtained by inserting a DNA encoding the polypeptide into a vector; producing and accumulating the polypeptide in the non-human transgenic animal; and collecting the polypeptide from the non-human transgenic animal.

14. The method for producing the polypeptide according to the above 13, wherein the production and accumulation of the polypeptide is carried out in the milk of the non-human transgenic animal.
15. A method for producing a polypeptide selected from the polypeptides according to the above 1, 2 and 3, which comprises growing a transgenic plant having a recombinant DNA obtained by inserting a DNA encoding the polypeptide into a vector; producing and accumulating the polypeptide in the transgenic plant; and collecting the polypeptide from the transgenic plant.
16. A method for producing a polypeptide selected from the polypeptides according to the above 1, 2 and 3, which comprises using a DNA encoding the polypeptide, and synthesizing the polypeptide by an *in vitro* transcription-translation system.
17. A method for producing a reaction product wherein Fuc is added to an N-acetylglucosamine residue in the N-acetylactosamine structure of an acceptor substrate via an α 1,3-linkage, using a polypeptide selected from the polypeptides according to the above 1, 2 and 3 as an enzyme source; which comprises placing the following (a), (b) and (c) in an aqueous medium:
 - (a) the enzyme source,
 - (b) an acceptor substrate selected from: (i) N-acetylactosamine(Gal β 1-4GlcNAc), (ii) oligosaccharides having the N-acetylactosamine structure in a nonreducing terminus thereof, (iii) complex carbohydrates having the N-acetylactosamine structure in a nonreducing terminus of sugar chains, (iv) derivatives wherein the N-acetylactosamine structure is modified by sulfate group, and (v) their derivatives wherein the N-acetylactosamine structure is modified by sugar, but a galactose residue in the N-acetylactosamine structure is not modified by sialic acid via an α 2,3-linkage, and
 - (c) guanosine-5' -diphosphate fucose;

producing and accumulating the reaction product, in the aqueous medium; and collecting the reaction product from the aqueous medium.

18. The method for producing the reaction product according to the above 17 wherein a derivative is selected from sugar chains having, in a nonreducing terminus thereof, any one of the following oligosaccharide structures: Fuc α 1-2Gal β 1-4GlcNAc, Gal α 1-3Gal β 1-4GlcNAc, Gal α 1-3(Fuc α 1-2)Gal β 1-4GlcNAc, GalNAc α 1-3(Fuc α 1-2)Gal β 1-4GlcNAc, Gal α 1-4Gal β 1-4GlcNAc, Gal β 1-4GlcNAc(6SO₃⁻); and complex carbohydrates containing the sugar chains.
19. A method for producing a reaction product wherein fucose is added to a glucose residue in a lactose structure of an acceptor substrate via an α 1,3-linkage, using a polypeptide selected from the polypeptides according to the above 1, 2 and 3 as an enzyme source; which comprises placing the following (a), (b) and (c) in an aqueous medium:
- (a) the enzyme source,
 - (b) an acceptor substrate selected from (i) lactose (Gal β 1-4Glc), (ii) oligosaccharides having a lactose structure in a nonreducing terminus thereof, (iii) complex carbohydrates having a lactose structure in a nonreducing terminus of sugar chains, (iv) their derivatives wherein a lactose structure is modified by sulfate group, and (v) their derivatives wherein a lactose structure is modified by sugar(s), but a galactose residue in the lactose structure is not modified by sialic acid via an α 2,3-linkage, and
 - (c) guanosine-5' -diphosphate fucose;
- producing and accumulating the reaction product, in the aqueous medium; and collecting the reaction product from the aqueous medium.
20. The method for producing the reaction product according to the above 19 wherein a derivative is selected from sugar chains having, in a nonreducing terminus thereof,

any one of the following oligosaccharide structures: Gal α 1-3Gal β 1-4Glc, Gal α 1-3(Fuc α 1-2)Gal β 1-4Glc, GalNAc α 1-3(Fuc α 1-2)Gal β 1-4Glc, Gal α 1-4Gal β 1-4Glc, Gal β 1-4Glc(6SO₃⁻); and complex carbohydrates containing the sugar chains.

21. A method for producing a sugar chain having a structure wherein fucose is added to an N-acetylglucosamine residue or a glucose residue via an α 1,3-linkage, or a complex carbohydrate containing the sugar chain; which comprises, culturing in a medium a transformant selected from the transformants derived from microorganisms, animal cells, plant cells, and insect cells according to the above 8; producing and accumulating the sugar chain or the complex carbohydrate in the medium; and collecting the sugar chain or the complex carbohydrate from the medium.
22. A method for producing a sugar chain having structure wherein fucose is added to an N-acetylglucosamine residue or a glucose residue via an α 1,3-linkage, or a complex carbohydrate containing the sugar chain; which comprises, feeding a non-transgenic animal according to the above 8; producing and accumulating the sugar chain or the complex carbohydrate in the non-transgenic animal; and collecting the sugar chain or the complex carbohydrate from the non-transgenic animal.
23. A method for producing a sugar chain having a structure wherein fucose is added to an N-acetylglucosamine residue or a glucose residue via an α 1,3-linkage, or a complex carbohydrate containing the sugar chain; which comprises, growing a transgenic plant according to the above 8; producing and accumulating the sugar chain or the complex carbohydrate in the transgenic plant; and

collecting the sugar chain or the complex carbohydrate from the transgenic plant.

24. The production method according to any one of the above 17 to 23 wherein the complex carbohydrate is selected from glycoproteins, glycolipids, proteoglycans, glycopeptides, lipopolysaccharides, peptideglycans and glycosides wherein a sugar chain binds to compounds such as steroids.
25. The method for producing the sugar chain or the complex carbohydrate according to the above 22 wherein the generation and accumulation of the sugar chain or the complex carbohydrate is carried out in the milk of the non-human transgenic animal.
26. A method for determining the expression level of a gene encoding a polypeptide selected from the polypeptides according to the above 1, 2 and 3, by hybridization using DNA encoding the polypeptide.
27. An oligonucleotide selected from the following oligonucleotides:
an oligonucleotide having an identical sequence to 10 to 50 contiguous nucleotides in a nucleotide sequence of DNA selected from a DNA encoding the polypeptide selected from the polypeptides according to the above 1, 2 and 3; a DNA having the nucleotide sequence represented by SEQ ID NO: 3; a DNA having the nucleotide sequence represented by SEQ ID NO: 4; and a DNA having the nucleotide sequence represented by SEQ ID NO: 5; and,
an oligonucleotide having a complementary sequence to the oligonucleotide and a derivative of each of the oligonucleotides.
28. The oligonucleotide according to the above 27, wherein the oligonucleotide derivative is selected from the following oligonucleotide derivatives: an oligonucleotide derivative obtained by converting a phosphodiester bond into a

phosphorothioate bond in an oligonucleotide; an oligonucleotide derivative obtained by converting a phosphodiester bond into a N3'-P5' phosphoamidate bond in an oligonucleotide; an oligonucleotide derivative obtained by converting a ribose and phosphodiester bond into a peptide nucleic acid bond in an oligonucleotide; an oligonucleotide derivative obtained by substituting uracil with C-5 propynyl uracil in an oligonucleotide; an oligonucleotide derivative obtained by substituting uracil with C-5 thiazolyl uracil in an oligonucleotide; an oligonucleotide derivative obtained by substituting cytosine with C-5 propynylcytosine in an oligonucleotide; an oligonucleotide derivative obtained by substituting cytosine with phenoxazine-modified cytosine in an oligonucleotide; an oligonucleotide derivative obtained by substituting ribose with 2'-O-propylribose in a DNA; and an oligonucleotide derivative obtained by substituting ribose with 2'-methoxyethoxyribose in the oligonucleotide.

29. A method for determining the expression level of a gene encoding a polypeptide selected from the polypeptides according to the above 1, 2 and 3 by polymerase chain reaction, using the oligonucleotide according to the above 27 or 28.
30. A method for detecting encephalopathy, renal diseases and cancers, using the method according to the above 26 or 29.
31. A method for suppressing the transcription of a DNA encoding a polypeptide selected from the polypeptides according to the above 1, 2 and 3, using a DNA selected from a DNA encoding the polypeptide, a DNA having the nucleotide sequence represented by SEQ ID NO: 3, a DNA having the nucleotide sequence represented by SEQ ID NO: 4, and a DNA having the nucleotide sequence represented by SEQ ID NO: 5.
32. A method for suppressing the translation of an mRNA encoding a polypeptide

selected from the polypeptides according to the above 1, 2 and 3, using a DNA selected from a DNA encoding the polypeptide, a DNA having the nucleotide sequence represented by SEQ ID NO: 3, a DNA having the nucleotide sequence represented by SEQ ID NO: 4, and a DNA having the nucleotide sequence represented by SEQ ID NO: 5.

33. A method for suppressing the transcription of a DNA encoding the polypeptide according to the above 1, 2 or 3, using the oligonucleotide according to the above 27 or 28.
34. A method for suppressing the translation of an mRNA encoding the polypeptide according to the above 1, 2 or 3, using the oligonucleotide according to the above 27 or 28.
35. A method for treating renal diseases or cancers using a method of any one of the above 31 to 34.
36. An antibody recognizing a polypeptide selected from the polypeptides of the above 1, 2 and 3.
37. An immunoassay which detects a polypeptide selected from the polypeptides of the above 1, 2, and 3 using the antibody of the above 36.
38. An immunohistological staining method which detects a polypeptide selected from the polypeptides according to the above 1, 2 and 3 using the antibody according to the above 36.
39. A reagent for immunohistological staining which contains the antibody of the above 36.

40. An agent for diagnosing encephalopathy, renal diseases and cancers, which contains the antibody of the above 36.
41. A method for screening a substance that changes the activity of a polypeptide selected from the polypeptides according to the above 1, 2 and 3, which comprises contacting the polypeptide with test samples.
42. A method for screening a substance that changes the expression of a gene encoding a polypeptide selected from the polypeptides according to the above 1, 2 and 3, which comprises contacting a cell expressing the polypeptide with test samples, and measuring the amount of the Lewis x or Lewis y sugar chain using an anti-Lewis x or anti-Lewis y antibody.
43. A method for screening a substance that changes the expression of a gene encoding a polypeptide selected from the polypeptides according to the above 1, 2 and 3, which comprises contacting a cell expressing the polypeptide with test samples, and measuring the amount of the polypeptide using the antibody of the above 36.
44. A promoter DNA for the transcription of a gene encoding a polypeptide selected from the polypeptides according to the above 1, 2 and 3.
45. A promoter DNA according to above 44 which functions in a cell selected from neurons, kidney cells, gastric epithelium cells, leukocyte cells, cerebral tumor cells, neuroblastoma cells, melanoma cells, renal cancer cells, stomach cancer cells, colon cancer cells, and pancreatic cancer cells.
46. A promoter DNA according to the above 44 or 45 which is derived from human or mouse.

47. A method for screening a substance that changes the efficiency of transcription by a promoter DNA selected from the promoter DNAs according to the above 44, 45, and 46, which comprises transforming an animal cell with a plasmid comprising the promoter DNA and a reporter gene ligated downstream of the promoter DNA; contacting transformant with a test sample; and measuring the amount of the translation product of the reporter gene.
48. The screening method according to the above 47 wherein a reporter gene is a gene selected from chloramphenicol acetyltransferase genes, β -galactosidase genes, luciferase genes and green fluorescent protein genes.
49. A non-human knockout animal wherein a DNA encoding the polypeptide selected from the polypeptides according to the above 1, 2 and 3 is deleted or mutated.
50. A non-human knockout animal according to the above 49 wherein the non-human knockout animal is a mouse.

The present invention will be described in more detail below.

- (1) Obtaining a novel DNA encoding the polypeptide having α 1,3-fucosyltransferase activity, hereinafter also called a novel α 1,3-fucosyltransferase gene, and production of the DNA and oligonucleotide

A cDNA library is constructed from cells expressing the Lewis x or Lewis y sugar chains by a conventional method.

The cDNA library may be constructed by methods as described in Molecular Cloning, Second Edition and Current Protocols in Molecular Biology Supplement 1-38,

or by using commercially available kits such as SuperScript Plasmid System for cDNA Synthesis and Plasmid Cloning (manufactured by Gibco BRL) and ZAP-cDNA Synthesis Kit (manufactured by Stratagene).

For this purpose, any cells expressing the Lewis x or the Lewis y sugar chains may be used, including mouse or human tissues such as brain, kidney, stomach, bladder, or testis; mouse F9 cells; and a human neuroblastoma cell line.

To construct the cDNA library, any cloning vectors capable of autonomously replicating in *E. coli* K12 may be used, including a phage vector and plasmid vector. Specific examples include ZAP Express [manufactured by Stratagene, Strategies, 5, 58 (1992)], pBluescript II SK(+) [Nucleic Acids Research, 17, 9494 (1989)], λzap II (manufactured by Stratagene), λgt10, λgt11 [DNA Cloning, A Practical Approach, 1, 49 (1985)], λTriplEx (CloneTech), λExCell (manufactured by Pharmacia), pT7T3 18U (manufactured by Pharmacia), pcD2 [Mol. Cell. Biol., 3, 280 (1983)], pUC 18 [Gene, 33, 103 (1985)], and pAMo [J. Biol. Chem., 268, 22782-22787 (1993); also called pAMoPRC3Sc (Japanese Patent Laid-Open Publication No. 05-336963)].

As a host microorganism, any microorganisms belonging to *E. coli* may be used. Specific examples include *Escherichia coli* XL1-Blue MRF' [manufactured by Stratagene, Strategies, 5, 81 (1992)], *Escherichia coli* C600 [Genetics, 39, 440 (1954)], *Escherichia coli* Y1088 [Science, 222, 778 (1983)], *Escherichia coli* Y1090 [Science, 222, 778 (1983)], *Escherichia coli* NM522 [J. Mol. Biol., 166, 1 (1983)], *Escherichia coli* K802 [J. Mol. Biol., 16, 118 (1966)], *Escherichia coli* JM105 [Gene, 38, 275 (1985)], *Escherichia coli* SOLR™ Strain (manufactured by Stratagene), and *E. coli* LE392 (Molecular Cloning, Second Edition).

For example, the cDNA library may be constructed as follows.

cDNAs are synthesized from mRNAs derived from mouse brain using a cDNA Synthesis System kit commercially available from Gibco BRL.

After addition of a *Sfi* I linker to each terminus of the cDNAs, the cDNAs are inserted into *Sfi* I sites of cloning vector pAMo to prepare plasmids.

The above plasmids are then used to transform *E. coli* LE392 to construct a cDNA library.

A clone containing the DNA of interest may be selected from the constructed cDNA library as follows.

Plasmids are prepared from the above cDNA library by a conventional method or by using a plasmid preparation kit such as /plasmid/maxi kit (manufactured by Qiagen, product No. 41031).

Since pAMo is an expression vector for animal cells, a cDNA library constructed using this plasmid may be used in the subsequent manipulations without any modification.

If a cDNA library is constructed using any vectors other than expression vectors, there is a need to excise inserted cDNAs from the cDNA library and then insert them again into an expression vector capable of expressing in animal or insect cells.

For this purpose, any expression vectors capable of expressing the cDNA inserted therein may be used, including pcDNAI/Amp, pcDNAI, pCDM8 (commercially available from Funakoshi, respectively), pAGE107 [Japanese Patent Laid-Open Publication No. 3-22979; Cytotechnology, 3, 133 (1990)], pREP4 (manufactured by Invitrogen), pAGE103 [J. Biochem., 101, 1307 (1987)], pAMo,

pAMoA [J. Biol. Chem., 268, 22782-22787 (1993); also called pAMoPRSA (Japanese Patent Laid-Open Publication No. 05-336963)], pAS3-3 (Japanese Patent Laid-Open Publication No. 2-227075), pVL1392 (manufactured by Invitrogen), pVL1393 (manufactured by Invitrogen), and pBlueBacIII (manufactured by Invitrogen).

The expression vector containing the inserted cDNA is introduced into animal or insect cells capable of being screened for the cDNA of interest, thereby obtaining transformed cells.

The expression vector may be introduced by any methods for introducing DNA into animal or insect cells, for example, electroporation method [Cytotechnology, 3, 133 (1990)], calcium phosphate method (Japanese Patent Laid-Open Publication No. 2-227075), lipofection method [Proc. Natl. Acad. Sci. USA, 84, 7413 (1987)] and methods as described in Baculovirus Expression Vectors, W. H. Freeman and Company, New York (1992); Molecular Biology, A Laboratory Manual, Current Protocols in Molecular Biology; Bio/Technology, 6, 47 (1988) and Virology, 52, 456 (1973).

The animal cells include human Namalwa cells, Namalwa KJM-1 cells (subline of Namalwa cell), monkey COS cells, chinese hamster CHO cells, and HBT5637 (Japanese Patent Laid-Open Publication No. 63-299), with Namalwa cells or Namalwa KJM-1 cells being preferred.

As an insect cell, Sf9 or Sf21 cell [ovarian cells of *Spodoptera frugiperda*; Baculovirus Expression Vectors (1992)], High 5 cell (ovarian cells of *Trichoplusia ni*; manufactured by Invitrogen) and the like may be used.

The resulting transformed cells are cultured by a conventional method.

Specifically, the culturing may be carried out according to the following

procedure for culturing transformants.

When the transformant is an animal cell, the cell may be cultured in a conventional medium such as RPMI 1640 medium [The Journal of the American Medical Association, 199, 519 (1967)], Eagle's MEM medium [Science, 122, 501 (1952)], DMEM medium [Virology, 8, 396 (1959)], 199 medium [Proceeding of the Society for the Biological Medicine, 73, 1 (1950)] or these media supplemented with fetal calf serum etc.

The culturing may generally be carried out for 1 to 7 days under the following conditions: at pH 6 to 8, at 30 °C to 40 °C, under 5% CO₂ etc.

An antibiotic such as kanamycin or penicillin may be added to the medium during the culturing, if necessary.

When an insect cell is used as a host cell for transformation, the resulting transformants may be cultured in a conventional medium such as TNM-FH medium (manufactured by Pharmingen), Sf-900 II SFM medium (manufactured by Gibco BRL), ExCell 400 (manufactured by JRH Biosciences), ExCell 405 (manufactured by JRH Biosciences), and Grace's Insect Medium [Grace, T.C.C., Nature, 195, 788 (1962)].

The culturing may be carried out preferably at pH 6 to 7, at 25 °C to 30 °C, generally for 1 to 5 days.

An antibiotic such as gentamicin may be added to the medium during the culturing, if necessary.

The resulting cultured cells are fluorescently stained with antibodies against the Lewis x or Lewis y sugar chains so as to concentrate and isolate cells having an

increased binding capacity toward the above antibodies using a Fluorescence Activated Cell Sorter (FACS).

As an antibody against the Lewis x or Lewis y sugar chains, any antibodies reacting with the Lewis x or Lewis y sugar chains may be used, including the anti-Lewis x sugar chain antibody 73-30 (manufactured by Seikagaku Corporation) or PM-81, or the anti-Lewis y sugar chain antibody AH-6 (manufactured by Otsuka Pharmaceutical Co., Ltd). SSEA-1 antibody may also be used that recognizes the Lewis x sugar chains on poly-N-acetyllactosamine sugar chains.

From the cells thus concentrated and isolated, a plasmid containing the DNA of the present invention may be collected by a known method such as Hirt method [Mol. Cell. Biol., 8, 2837 (1988)], thereby obtaining a DNA fragment containing the DNA.

For example, a plasmid containing the DNA of the present invention may be pAMo-mFT9.

Nucleotide sequence of the obtained DNA is determined by: integrating into a vector the obtained DNA, after cleaving with a suitable restriction enzyme, or without any treatment, according to a conventional method; and then analyzing it according to a conventional sequencing method such as dideoxy method described by Sanger [Proc. Natl. Acad. Sci. USA, 74, 5463 (1977)] or using a sequencer such as a 373A DNA sequencer (manufactured by Perkin Elmer).

DNAs obtainable by the above procedure include a DNA encoding the peptide represented by SEQ ID NO: 1, more specifically a DNA having the nucleotide sequence represented by SEQ ID NO: 3.

In addition, selection of DNAs hybridizing under stringent conditions with the

DNA obtained by the above procedure may provide DNAs of interest derived from other tissues or animals, such as human.

Such DNAs include a DNA encoding the peptide represented by SEQ ID NO: 2, more specifically a DNA having the nucleotide sequence represented by SEQ ID NO: 4 or 5.

For example, a plasmid containing the DNA represented by SEQ ID NO: 5 may be pBS-hFT9(S2).

The DNA of interest may also be prepared by chemical synthesis using a DNA synthesizer based on the nucleotide sequence of the sequenced DNA. Examples of the DNA synthesizer include a DNA synthesizer based on thiophosphite method (manufactured by Shimadzu Corporation) and a DNA synthesizer model 392 based on phosphoramidite method (manufactured by Perkin Elmer).

Alternatively, the DNA of interest may also be prepared by Polymerase Chain Reaction (PCR) using the below-mentioned oligonucleotides as sense and antisense primers and using as a template cDNAs prepared from cells expressing mRNAs complementary to the DNA of interest [Molecular Cloning, Second Edition; PCR Protocols Academic Press (1990)].

The DNA or DNA fragments obtained by the above procedure may be used to prepare oligonucleotides, such as antisense and sense oligonucleotides, containing a partial sequence of the DNA of the present invention according to a conventional method as described in Molecular Cloning, Second Edition or using a DNA synthesizer.

The above oligonucleotides comprise a sequence identical or complementary to 10-50 successive nucleotides in the nucleotide sequence of the above DNA.

Specifically, the oligonucleotides comprise a sequence identical or complementary to 10-50 successive nucleotides in the nucleotide sequence represented by SEQ ID NO: 3, 4 or 5. For sense and antisense primers, it is preferable to use the oligonucleotides whose melting temperatures (T_m) and nucleotide numbers are not extremely different from each other.

Further, derivatives of these oligonucleotides may also be used as the oligonucleotides of the present invention.

The oligonucleotide derivatives include an oligonucleotide derivative obtained by converting a phosphodiester bond in the oligonucleotide into a phosphorothioate bond; an oligonucleotide derivative obtained by converting a phosphodiester bond in the oligonucleotide into a N3'-P5' phosphoramidate bond; an oligonucleotide derivative obtained by converting a ribose and a phosphodiester bond in the oligonucleotide into a peptide-nucleic-acid bond; an oligonucleotide derivative obtained by replacing uracil in the oligonucleotide with C-5 propynyl uracil; an oligonucleotide derivative obtained by replacing uracil in the oligonucleotide with C-5 thiazolyl uracil; an oligonucleotide derivative obtained by replacing cytosine in the oligonucleotide with C-5 propynylcytosine; an oligonucleotide derivative obtained by replacing cytosine in the oligonucleotide with phenoxazine-modified cytosine; an oligonucleotide derivative obtained by replacing ribose in the oligonucleotide with 2'-O-propylribose; or the oligonucleotide derivative obtained by replacing ribose in the oligonucleotide with 2'-methoxyethoxyribose [Cell Technology, 16, 1463 (1997)].

(2) Preparation of a novel polypeptide having an α 1,3-fucosyltransferase activity

The DNA of the present invention obtained by the above procedure may be expressed in a host cell to produce the polypeptide of the present invention using a method as described in Molecular Cloning, Second Edition or Current Protocols in

Namely, the DNA of the present invention may be inserted into an appropriate expression vector downstream of a promoter, thereby constructing a recombinant vector. The recombinant vector may be introduced into a host cell to obtain a transformant expressing the polypeptide of the present invention, which may then be cultured for production of the polypeptide of the present invention.

As a host cell, any cells capable of expressing the gene of interest may be used, including prokaryotic cells, yeast cells, animal cells, insect cells, and plant cells. An animal or plant individual may also be used.

As an expression vector, it is possible to use any vectors that can autonomously replicate in the above host cells or can be integrated into chromosomes thereof and that contain a promoter at a suitable site for transcription of the novel α 1,3-fucosyltransferase gene.

When a prokaryotic cell (e.g., a bacterial cell) is used as a host cell, a preferable expression vector for the novel α 1,3-fucosyltransferase gene may be autonomously replicative in prokaryotic organisms and may comprise a promoter, a ribosome-binding sequence, the novel α 1,3-fucosyltransferase gene and a terminator. The vector may further comprise a gene regulating the promoter.

The preferable expression vectors include pBTrp2, pBTac1, pBTac2 (commercially available from Boehringer Mannheim, respectively), pSE280 (Invitrogen), pGEMEX-1 (manufactured by Promega), pQE-8 (manufactured by QIAGEN), pKYP10 (Japanese Patent Laid-Open Publication No. 58-110600), pKYP200 [Agric. Biol. Chem., 48, 669 (1984)], pLSA1 [Agric. Biol. Chem., 53, 277 (1989)], pGEL1 [Proc. Natl. Acad. Sci., USA, 82, 4306 (1985)], pBluescript II SK(-)

(manufactured by Stratagene), pTrs30 (FERM BP-5407), pTrs32 (FERM BP-5408), pGHA2 (FERM BP-400), pGKA2 (FERM B-6798), pTerm2 (Japanese Patent Laid-Open Publication No. 3-22979, US4686191, US4939094, US5160735), pKK233-2 (manufactured by Pharmacia), pGEX (manufactured by Pharmacia), pET system (manufactured by Novagen), pSupex, pUB110, pTP5, pC194, pTrxFus (manufactured by Invitrogen), and pMAL-c2 (manufactured by New England Biolabs).

As a promoter, any promoters capable of expressing in host cells, such as *E. coli*, may be used, including promoters derived from *E. coli* or a phage such as *trp* promoter (*P_{trp}*), *lac* promoter (*P_{lac}*), *P_L* promoter, *P_R* promoter and *P_{SE}* promoter, SPO1 promoter, SPO2 promoter, and penP promoter. An artificially designed, modified promoter may also be used, including a promoter obtained by binding two *P_{trp}* promoters in series (*P_{trp}* × 2), *tac* promoter, lac T7 promoter, and let I promoter.

As a ribosome-binding sequence, it is preferable to use a plasmid having an appropriate interval (e.g., 6-18 nucleotides) between Shine-Dalgarno sequence and an initiation codon.

A terminator is not necessarily required for expression of the DNA of the present invention, but it is desirably located immediately downstream of a structural gene.

The host cells include microorganisms belonging to *Escherichia*, *Serratia*, *Bacillus*, *Brevibacterium*, *Corynebacterium*, *Microbacterium*, *Pseudomonas*, and the like: for example, *Escherichia coli* XL1-Blue, *Escherichia coli* XL2-Blue, *Escherichia coli* DH1, *Escherichia coli* MC1000, *Escherichia coli* KY3276, *Escherichia coli* W1485, *Escherichia coli* JM109, *Escherichia coli* HB101, *Escherichia coli* No.49, *Escherichia coli* W3110, *Escherichia coli* NY49, *Serratia ficaria*, *Serratia fonticola*, *Serratia liquefaciens*, *Serratia marcescens*, *Bacillus subtilis*, *Bacillus amyloliquefaciens*,

Brevibacterium ammoniagenes, *Brevibacterium immariophilum* ATCC14068, *Brevibacterium saccharolyticum* ATCC14066, *Corynebacterium glutamicum* ATCC13032, *Corynebacterium glutamicum* ATCC14067, *Corynebacterium glutamicum* ATCC13869, *Corynebacterium acetoacidophilum* ATCC13870, *Microbacterium ammoniaphilum* ATCC15354, and *Pseudomonas* sp. D-0110.

The recombinant vector may be introduced by any methods for introducing DNAs into these host cells: for example, electroporation method [Nucleic Acids Res., 16, 6127 (1988)], calcium ion-based method [Proc. Natl. Acad. Sci. USA, 69, 2110 (1972)], protoplast method (Japanese Patent Laid-Open Publication No. 63-248394) and the methods described in Gene, 17, 107 (1982) and Molecular & General Genetics, 168, 111 (1979).

When a yeast cell is used as a host cell, expression vectors include YEp13 (ATCC37115), YEp24 (ATCC37051), YCp50 (ATCC37419), pHS19, and pHS15.

As a promoter, any promoters capable of expressing in yeast cells may be used, including PHO5 promoter, PGK promoter, GAP promoter, ADH promoter, gal 1 promoter, gal 10 promoter, heat shock protein promoter, MF α 1 promoter, and CUP 1 promoter.

The host cells include yeast strains belonging to *Saccharomyces*, *Schizosaccharomyces*, *Kluyveromyces*, *Trichosporon*, *Schwanniomyces*, and the like: for example, *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, *Kluyveromyces lactis*, *Trichosporon pullulans*, and *Schwanniomyces alluvius*.

The recombinant vectors may be introduced by any methods for introducing DNAs into yeast cells: for example, electroporation method [Methods. Enzymol., 194, 182 (1990)], spheroplast method [Proc. Natl. Acad. Sci. USA, 84, 1929 (1978)], lithium

acetate method [J. Bacteriol., 153, 163 (1983)] and the method described in Proc. Natl. Acad. Sci. USA, 75, 1929 (1978).

When an animal cell is used as a host cell, expression vectors include pcDNAI/Amp, pcDNAI, pCDM8, pAGE107, pREP4, pAGE103, pAMo, pAMoA, and pAS3-3.

As a promoter, any promoters capable of expressing in animal cells may be used, including a promoter for immediate early (IE) gene of human cytomegalovirus (human CMV), SV40 early promoter, long terminal repeat promoter of moloney murine leukemia virus, retroviral promoter, heat shock promoter, SR α promoter, and metallothionein promoter. An enhancer for IE gene of Human CMV may also be used together with such a promoter.

The host cells include mouse myeloma cells, rat myeloma cells, mouse hybridoma cells, chinese hamster CHO cells, BHK cells, African green monkey kidney cells, human Namalwa or Namalwa KJM-1 cells, human fetal kidney cells, human leukemia cells, and HBT5637 (Japanese Patent Laid-Open Publication No. 63-299).

Specific examples may be SP2/O and NSO for the mouse myeloma cells, YB2/O for the rat myeloma cells, HEK293 and 293 for human fetal kidney cells, BALL-1 for human leukemia cells, and COS-1 and COS-7 for African green monkey kidney cells.

The recombinant vectors may be introduced by any methods for introducing DNAs into animal cells: for example, electroporation method [Cytotechnology, 3, 133 (1990)], calcium phosphate method (Japanese Patent Laid-Open Publication No. 2-227075), lipofection method [Proc. Natl. Acad. Sci. USA, 84, 7413 (1987)] and the method described in Virology, 52, 456 (1973). The transformants may be obtained and

cultured according to the method described in Japanese Patent Laid-Open Publication No. 2-227075 or 2-257891.

When an insect cell is used as a host cell, polypeptides may be expressed by methods as described in *Baculovirus Expression Vectors, A Laboratory Manual*, W. H. Freeman and Company, New York (1992); *Molecular Biology, A Laboratory Manual*; *Current Protocols in Molecular Biology Supplement* 1-38; and *Bio/Technology*, 6, 47 (1988).

Namely, the recombinant vector for gene transfer and a baculovirus may be co-introduced into insect cells to obtain recombinant viruses in the supernatant from the cultured insect cells. Thereafter, insect cells may be infected with the resulting recombinant viruses to express the polypeptides.

The vectors for gene transfer to be used in the above procedure include pVL1392, pVL1393 and pBlueBacIII (commercially available from Invitrogen, respectively).

As a baculovirus, for example, *Autographa californica* nuclear polyhedrosis virus may be used, which infects *Noctuidae* insects.

The insect cells include *Spodoptera frugiperda* ovarian cells, *Trichoplusia ni* ovarian cells, and cultured cells derived from silk worm ovary.

Specific examples may be Sf9 and Sf21 (*Baculovirus Expression Vectors, A Laboratory Manual*) for *Spodoptera frugiperda* ovarian cells, High 5 and BTI-TN-5B1-4 (manufactured by Invitrogen) for *Trichoplusia ni* ovarian cells, and *Bombyx mori* N4 for the cultured cells derived from silk worm ovary.

The recombinant vector for gene transfer and the baculovirus may be co-introduced into insect cells by phosphate calcium method (Japanese Patent Laid-Open Publication No. 2-227075) or lipofection method [Proc. Natl. Acad. Sci. USA, 84, 7413 (1987)] in order to prepare the recombinant viruses.

Alternatively, DNAs may be introduced into insect cells using the same methods as described for DNA introduction into animal cells: for example, electroporation method [Cytotechnology, 3, 133 (1990)], calcium phosphate method (Japanese Patent Laid-Open Publication No. 2-227075), and lipofection method [Proc. Natl. Acad. Sci. USA, 84, 7413 (1987)].

When a plant cell or a plant individual is used as a host, polypeptides may be produced according to a known method as described in Tissue Culture, 20 (1994); Tissue Culture, 21 (1995); and Trends in Biotechnology, 15, 45 (1997).

As a promoter for gene expression, any promoters capable of expressing in plant cells may be used: including cauliflower mosaic virus (CaMV) 35S promoter and rice actin 1 promoter. Further, efficiency of gene expression can be improved by inserting Intron 1 of maize alcohol dehydrogenase gene between the promoter and the gene to be expressed.

The host cells include plant cells such as potato, tobacco, maize, rice, Brassica, soy bean, tomato, wheat, barley, rye, alfalfa, and flax.

The recombinant vectors may be introduced by any methods for introducing DNAs into plant cells: for example, *Agrobacterium*-based method, electroporation method [Cytotechnology, 3, 133 (1990)], and particle gun method.

Plant cells and organs having the transgene may be cultured on a large scale

using a jar fermenter. Also, plant cells having the transgene may be redifferentiated to create a plant individual (transgenic plant) having the transgene.

Alternatively, an animal individual may be used to produce the polypeptide of the present invention. For example, the polypeptide of the present invention can be produced in an animal having the transgene according to a known method as described in American Journal of Clinical Nutrition, 63, 639S (1996); American Journal of Clinical Nutrition, 63, 627S (1996); and Bio/Technology, 9, 830 (1991).

As a promoter, any promoters capable of expressing within an animal may be used: for example, mammary gland cell-specific promoters such as α -casein promoter, β -casein promoter, β -lactoglobulin promoter and whey acidic protein promoter are preferred.

The polypeptide of the present invention may be obtained by culturing a microorganism-, animal cell-, or plant cell-derived transformant having a recombinant vector into which a DNA encoding the polypeptide has been introduced in accordance with a conventional culture method to produce and accumulate the polypeptide, and then collecting the polypeptide from the culture.

When the transformant is an animal or plant individual, the polypeptide may be obtained by feeding or cultivating the individual according to a conventional method to produce and accumulate the polypeptide, and then collecting the polypeptide from the individual.

Namely, in the case of an animal individual, for example, a non-human transgenic animal having the DNA of the present invention may be fed to produce and accumulate therein a novel polypeptide having an α 1,3-fucosyltransferase activity, which is encoded by the recombinant DNA. The polypeptide may then be collected

from the animal, thereby obtaining the polypeptide having an α 1,3-fucosyltransferase activity. The polypeptide may be produced and accumulated in the animal's milk, egg, and the like.

In the case of a plant individual, for example, a transgenic plant having the DNA of the present invention may be cultivated to produce and accumulate therein a novel polypeptide having an α 1,3-fucosyltransferase activity, which is encoded by the recombinant DNA. The polypeptide may then be collected from the plant, thereby obtaining the polypeptide having α 1,3-fucosyltransferase activity.

If the transformants for producing the polypeptide of the present invention are prokaryotes such as *E. coli* etc. or eukaryotes such as yeast etc., the medium for culture of these organisms may be natural or synthetic medium insofar as the medium contains a carbon source, a nitrogen source, inorganic salts etc. which can be assimilated by the said organisms and in which the transformants can be efficiently cultured.

Any carbon source can be used insofar as it can be assimilated by the microorganisms, and the following can be used: carbohydrates such as glucose, fructose, sucrose, molasses containing them, starch or starch hydrolysates; organic acids such as acetic acid, propionic acid; alcohols such as ethanol, propanol, and the like.

As a nitrogen source, the following can be used: ammonium salts of various inorganic acids and organic acids, such as ammonia, ammonium chloride, ammonium sulfate, ammonium acetate, and ammonium phosphate; other nitrogen-containing compounds; and peptone, meat extracts, yeast extracts, corn steep liquor, casein hydrolysates, soy bean meal, soy bean meal hydrolysates, various fermented cells and hydrolysates thereof and the like.

The inorganic salts used include potassium dihydrogen phosphate, dipotassium

hydrogen phosphate, magnesium phosphate, magnesium sulfate, sodium chloride, ferrous sulfate, manganese sulfate, copper sulfate, calcium carbonate, and the like.

The culturing is conducted under aerobic conditions using e.g. shake culture or aeration stirring culture or the like means. The culturing temperature is preferably 15 to 40°C, and the culturing period is usually 16 to 96 hours. During culturing, pH is maintained at 3.0 to 9.0. Adjustment of the medium pH is conducted using an inorganic or organic acid, an alkaline solution, urea, calcium carbonate, ammonia and the like.

If necessary, additionally, antibiotics such as ampicillin and tetracycline may be added to the medium during the culturing.

For culturing a microorganism transformed with an expression vector using an inductive promoter as a promoter, an inducer may be added to the medium, if necessary. For example, for culturing a microorganism transformed with an expression vector using *lac* promoter, isopropyl-β-D-thiogalactopyranoside (IPTG) or the like may be added to the medium; for culturing a microorganism transformed with an expression vector using *trp* promoter, indole acrylic acid (IAA) or the like may satisfactorily be added to the medium.

If the transformants for producing the polypeptide of the present invention are animal cells, the medium for culturing the cells is a generally used medium such as RPMI1640 medium [The Journal of the American Medical Association, 199, 519 (1967)], Eagle's MEM medium [Science, 122, 501 (1952)], DMEM medium [Virology, 8, 396 (1959)], 199 medium [Proceeding of the Society for the Biological Medicine, 73, 1 (1950)] or any one of these media further supplemented with fetal calf serum.

The culturing is conducted usually for 1 to 7 days at pH 6 to 8, at 30 to 40°C in

the presence of 5% CO₂.

If necessary, antibiotics such as kanamycin and penicillin may be added to the medium during the culturing.

The medium for culturing the transformant obtained from insect cells as host may be a generally used medium such as TNM-FH medium (manufactured by Pharmingen), Sf-900 II SFM medium (manufactured by Gibco BRL), ExCell 400 and ExCell 405 [both are products of JRH Biosciences], Grace's Insect Medium [Grace, T. C. C., *Nature*, 195, 788 (1962)] or the like.

The culturing is conducted preferably at pH 6 to 7, at a temperature of 25 to 30°C for a period of usually 1 to 5 days.

If necessary, antibiotics such as gentamycin may be added to the medium during the culturing.

The gene may be expressed not only as a full-length polypeptide, but also as a partial polypeptide containing a region having an α 1,3-fucosyltransferase activity. In general, a glycosyltransferase has the topology of a type II transmembrane protein and comprises a cytoplasmic region of several to several tens of N-terminal amino acids, a transmembrane region with hydrophobic amino acids, a stem region of several to several tens of amino acids, and a C-terminal region, which is most of the remaining part including a catalytic region. The stem region and the C-terminal region, which is most of the remaining part including a catalytic region are thought to be exposed to the lumen of the Golgi body. The boundary between the stem region and the catalytic region can be experimentally determined by preparing various polypeptides which lack N-terminal regions with varying lengths, and then examining which polypeptide loses its activity. Alternatively, the stem region and the catalytic region can be predicted

from amino-acid sequence comparison with a similar glycosyltransferase having the informations concerning the stem and catalytic regions.

The novel α 1,3-fucosyltransferase of the present invention had a similar structure to that of other glycosyltransferases. That is, the novel α 1,3-fucosyltransferase was thought to comprise a cytoplasmic region of 10 N-terminal amino acids, a hydrophobic transmembrane region of 20 amino acids following the cytoplasmic region, a stem region of at least 25 amino acids, and a C-terminal region, which is most of the remaining part including a catalytic region. The stem region was expected to contain at least 25 amino acids based on the amino-acid sequence homology with other α 1,3-fucosyltransferases as well as the findings concerning the stem and catalytic regions of other α 1,3-fucosyltransferases [J. Biol. Chem., 269, 14730-14737 (1994); J. Biol. Chem., 270, 8712-8722 (1995); Glycobiology, 7, 921-927 (1997)]. Accordingly, a polypeptide containing amino acids 56 to 359 is thought to include the catalytic region.

The above full-length polypeptide or a partial polypeptide containing a region having an α 1,3-fucosyltransferase activity (catalytic region) may be either expressed directly, or expressed as a secreted protein or a fusion protein according to a method as described in Molecular Cloning, Second Edition. A protein to be fused with the polypeptide includes β -galactosidase, protein A, IgG-binding region of protein A, chloramphenicol acetyltransferase, poly(Arg), poly(Glu), protein G, maltose-binding protein, glutathione-S-transferase, polyhistidine chain (His-tag), S peptide, DNA-binding protein domain, Tac antigen, thioredoxin, green fluorescent protein, and an epitope of an antibody of interest [Akio Yamakawa, Experimental Medicine, 13, 469-474 (1995)].

The method of producing the polypeptide of the present invention includes intracellular production by host cells, extracellular secretion by host cells or production

on outer membranes by host cells, and the method can be selected depending on the host cells used or on alternation of the structure of the polypeptide to be produced.

If the polypeptide of the present invention is produced in host cells or on outer membranes of host cells, the polypeptide can be efficiently secreted to extracellular portion from the host cells by use of the method of Paulson et al. [J. Biol. Chem., 264, 17619 (1989)], the method of Lowe et al. [Proc. Nat. Acad. Sci., USA, 86, 8227 (1989), Genes Develop., 4, 1288 (1990)] or methods described in e.g. Japanese Patent Laid-Open Publication Nos. 5-336963 and 6-823021.

That is, the polypeptide of the present invention can be efficiently secreted by expressing it as a form in which a signal peptide was added upstream of a polypeptide portion containing the active site of the polypeptide of the present invention, which can be achieved using gene manipulation techniques.

Specifically, the polypeptide of the present invention may be secreted efficiently from the host cells by expressing a polypeptide consisting of amino acids 56 to 359, which is thought to include the catalytic region, with a signal peptide added upstream of the polypeptide. Further, a tag for purification and detection may be inserted between the signal peptide and the polypeptide including the catalytic region, or added to C-terminus of the polypeptide including the catalytic region. As a tag for purification and detection, β -galactosidase, protein A, IgG-binding region of protein A, chloramphenicol acetyltransferase, poly(Arg), poly(Glu), protein G, maltose-binding protein, glutathione-S-transferase, polyhistidine chain (His-tag), S peptide, DNA-binding protein domain, Tac antigen, thioredoxin, green fluorescent protein, an epitope of an antibody of interest [Akio Yamakawa, Experimental Medicine, 13, 469-474 (1995)], or the like can be used.

The amount of the polypeptide produced can be increased by a gene

amplification system using a dihydrofolate reductase gene or the like according to a method described in Japanese Patent Laid-Open Publication No. 2-227075.

For isolation and purification of the polypeptide of the present invention from a culture of the transformant for producing the polypeptide of the present invention, conventional methods for the isolation and purification of enzymes can be used.

For example, if the polypeptide of the present invention is accumulated as soluble forms in cells of the transformant for producing the polypeptide of the present invention, the cells are recovered from the culture by centrifuging the culture, then washed and disrupted with ultrasonic disrupter, French Press, Manton-Gaulin homogenizer, Dynamill or the like, to obtain a cell-free extract.

A purified preparation can be obtained by centrifuging the cell free extract to obtain the supernatant and then by subjecting the supernatant to solvent extraction, salting-out or desalting with sulfate ammonium etc., precipitation with organic solvent, anion-exchange chromatography on resin such as diethylaminoethyl (DEAE)-Sephadex, DIAION HPA-75 (manufactured by Mitsubishi Chemical Industries Ltd.) or the like, anion-exchange chromatography on resin such as S-Sephadex FF (manufactured by Pharmacia) or the like, hydrophobic chromatography on resin such as butyl Sephadex, phenyl Sephadex or the like, gel filtration using molecular sieve, affinity chromatography, chromatofocusing, and electrophoresis such as isoelectric focusing.

If said polypeptide is expressed as an inclusion body in cells, the cells are similarly recovered, disrupted and centrifuged to give a precipitated fraction. From the fraction the polypeptide is then recovered in a usual manner, and the inclusion body of the polypeptide is solubilized with a polypeptide denaturing agent. The solubilized solution is then diluted with or dialyzed against a solution not containing the polypeptide denaturing agent or a solution containing the polypeptide denaturing

agent at the low concentration enough not to denature the polypeptide whereby the solubilized polypeptide is renatured to have normal tertiary structure, and its purified preparation can be obtained by use of the same isolation and purification methods as described above.

If said polypeptide is extracellularly secreted, the culture is subjected to means such as centrifugation to give a soluble fraction. From the soluble fraction, a purified preparation of said polypeptide can be obtained in the same manner as for isolation and purification from the cell-free extract as described above.

The polypeptide may also be purified according to conventional methods for purifying glycosyltransferases (J. Evan Sadler et al., *Methods in Enzymology*, 83, 458).

Furthermore, the polypeptide of the present invention may be produced as a fusion protein with another protein so that it can be purified by affinity chromatography using a substance having affinity for the fused protein[Akio Yamakawa, *Experimental Medicine*, 13, 469-474 (1995)]. For example, the polypeptide of the present invention is produced as a fusion protein with protein A so that it can be purified by affinity chromatography using immunoglobulin G, according to the method of Lowe et al. [Proc. Natl. Acad. Sci., USA, 86, 8227 (1989), *Genes Develop.*, 4, 1288 (1990)] or methods described in Japanese Patent Laid-Open Publication Nos. 5-336963 and 6-823021/94. Furthermore, the polypeptide of the present invention is produced as a fusion protein with a FLAG peptide so that it can be purified by affinity chromatography using anti-FLAG antibody [Proc. Natl. Acad. Sci., USA, 86, 8227 (1989), *Genes Develop.*, 4, 1288 (1990)]. Furthermore, the polypeptide can also be purified by affinity chromatography using an antibody against said polypeptide itself.

In addition, the α 1,3-fucosyltransferase of the present invention may be produced using an *in vitro* transcription and translation system in a known manner [J.

Biomolecular NMR, 6, 129-134; Science, 242, 1162-1164; J. Biochem., 110, 166-168 (1991)].

Further, the polypeptide of the present invention may also be produced by chemical synthesis methods including Fmoc method (fluorenyl methyloxy carbonyl method), tBoc method (t-butyloxy carbonyl method), and so on. Also, it may be chemically synthesized using a peptide synthesizer commercially available from Advanced ChemTech, Perkin Elmer, Pharmacia Biotech, Protein Technology Instrument, Synthecell-Vega, PerSeptive, or Shimadzu Corporation.

The structural analysis of the purified polypeptide may be carried out by a conventional method used in the field of protein chemistry: for example, the method described in "Protein Structural Analysis for Gene Cloning" (Hisashi Hirano, Tokyo Kagaku Dojin, 1993).

The novel polypeptide of the present invention having an α 1,3-fucosyltransferase activity may be tested for its activity in a known manner [Methods in Enzymology, 83, 458; Methods in Enzymology, 179, 397; J. Biol. Chem., 269, 14730-14737 (1994); Japanese Patent Laid-Open Publication No. 06-823021].

(3) Production of a sugar chain having Fuc added to a GlcNAc or glucose residue via an α 1,3-linkage, and a complex carbohydrate containing the sugar chain

A sugar chain having Fuc added to a GlcNAc or glucose residue via an α 1,3-linkage, or a complex carbohydrate containing the sugar chain may be produced by culturing in a medium a transformant selected from the transformants derived from microorganisms, animal cells, plant cells, and insect cells obtained in (2) above to produce and accumulate the sugar chain or the complex carbohydrate in the culture, and then collecting the sugar chain or the complex carbohydrate from the culture.

The sugar chains having Fuc added to a GlcNAc residue via an α 1,3-linkage includes a sugar chain having the Lewis x or the Lewis y structure.

The culturing may be carried out according to the procedure mentioned in (2) above.

As for the above transformants, by coexpressing the polypeptide of the present invention and any recombinant glycoproteins (e.g. pharmaceutical recombinant glycoprotein) simultaneously in a transformant capable of synthesizing sugar chains, a sugar chain having Fuc attached to a GlcNAc or glucose residue via an α 1,3-linkage may be added to the recombinant glycoprotein.

Also, the animal or plant individual obtained in (2) above may be used to produce the sugar chain having Fuc added to a GlcNAc or glucose residue via an α 1,3-linkage, or the complex carbohydrate containing the sugar chain, according to the procedure mentioned in (2).

In the case of an animal individual, for example, a non-human transgenic animal having the DNA of the present invention may be fed to produce and accumulate therein the sugar chain having Fuc added to a GlcNAc or glucose residue via an α 1,3-linkage, or the complex carbohydrate containing the sugar chain. The sugar chain or the complex carbohydrate may then be collected from the animal, thereby obtaining the sugar chain having Fuc added to a GlcNAc or glucose residue via an α 1,3-linkage, or the complex carbohydrate containing the sugar chain.

The sugar chain or the complex carbohydrate may be produce and accumulated in the animal's milk, egg, and the like.

In the case of an plant individual, for example, a transgenic plant having the DNA of the present invention may be cultivated to produce and accumulate therein the sugar chain having Fuc added to a GlcNAc or glucose residue via an α 1,3-linkage, or the complex carbohydrate containing the sugar chain. The sugar chain or the complex carbohydrate may then be collected from the plant, thereby obtaining the sugar chain having Fuc added to a GlcNAc or glucose residue via an α 1,3-linkage, or the complex carbohydrate containing the sugar chain.

The polypeptide of the present invention obtained by the procedure mentioned in (2) above may be used as an enzyme source to produce, in an aqueous medium, a reaction product having Fuc added to a GlcNAc residue in the N-acetyllactosamine structure via an α 1,3-linkage, as follows.

Namely, a reaction product having Fuc added to a GlcNAc residue in the N-acetyllactosamine structure of an acceptor substrate via an α 1,3-linkage may be obtained by producing and accumulating the reaction product in an aqueous medium through an enzyme reaction using the polypeptide of the present invention obtained by the procedure mentioned in (2) as an enzyme source; GDP-Fuc; and the following acceptor substrate: N-acetyllactosamine ($\text{Gal}\beta 1\text{-4GlcNAc}$), an oligosaccharide having the N-acetyllactosamine structure at the nonreducing terminus, a complex carbohydrate having a sugar chain with the N-acetyllactosamine structure at the nonreducing terminus, their derivatives having the N-acetyllactosamine structure modified with sulfate groups, or their derivatives having the N-acetyllactosamine structure modified with sugars and having no sialic acid added to a galactose residue in the N-acetyllactosamine structure via an α 2,3-linkage; and then collecting the reaction product from the aqueous medium.

When the ability to produce 1 μmol Lacto-N-fucopentaose III ($\text{Gal}\beta 1\text{-4(Fuc}\alpha 1\text{-3)GlcNAc}\beta 1\text{-3Gal}\beta 1\text{-4Glc}$) from Lacto-N-neotetraose ($\text{Gal}\beta 1\text{-4GlcNAc}\beta 1\text{-3Gal}\beta 1\text{-4Glc}$) as a substrate at 37 °C for 1 minute is set to 1 unit (U), the enzyme source

may be used at a concentration of 0.1 mU/L to 10,000 U/L, preferably 1 mU/L to 1,000 U/L.

The aqueous medium includes water; a buffer such as phosphate buffer, carbonate buffer, acetate buffer, borate buffer, citrate buffer or Tris buffer; an alcohol such as methanol or ethanol; an ester such as ethyl acetate; a ketone such as acetone; and an amide such as acetamide. As an aqueous medium, it is also possible to use the medium for culturing microorganisms used as the enzyme source, the medium for culturing transformant mentioned in (2), and milk obtainable from a non-human transgenic animal mentioned in (2).

A surfactant or an organic solvent may be added to the aqueous medium, if necessary.

Any surfactant capable of promoting Fuc-containing carbohydrate production may be used, including a nonionic surfactant such as polyoxyethylene octadecylamine (e.g., Nimean S-215, manufactured by NOF Corporation); a cationic surfactant such as cetyltrimethylammonium bromide or alkyldimethyl benzylammonium chloride (e.g., Cation F2-40E, manufactured by NOF Corporation); an anionic surfactant such as lauroyl sarcosinate; and a tertiary amine such as alkyl dimethylamine (e.g., Tertiary Amine FB, manufactured by NOF Corporation). These surfactants may be used alone or in combination. They may be used generally at a concentration of 0.1 to 50 g/l.

The organic solvent includes xylene, toluene, fatty alcohol, acetone and ethyl acetate, which may be used generally at a concentration of 0.1 to 50 ml/l.

UDP-Fuc to be used may be commercially available; or produced through microorganism's action etc., which may be purified before use.

UDP-Fuc may be used at a concentration of 0.1 to 500 mM.

The derivative having the N-acetyllactosamine structure modified with sulfate groups or the derivative having an N-acetyllactosamine structure modified with saccharide and having no sialic acid added to a galactose residue in the N-acetyllactosamine structure via an α 2,3-linkage includes Fuc α 1-2Gal β 1-4GlcNAc, Gal α 1-3Gal β 1-4GlcNAc, Gal α 1-3(Fuc α 1-2)Gal β 1-4GlcNAc, GalNAc α 1-3(Fuc α 1-2)Gal β 1-4GlcNAc, Gal α 1-4Gal β 1-4GlcNAc, Gal β 1-4GlcNAc(6SO₃), a sugar chain having one of these oligosaccharide structures at its nonreducing terminus, and a complex carbohydrate containing the sugar chain.

The acceptor substrate may be used at a concentration of 0.01 to 500 mM.

The reaction may be carried out in the presence of an inorganic salt such as MnCl₂; β -mercaptoethanol; or polyethylene glycol, if necessary.

The reaction may be carried out in an aqueous medium at pH 5 to 10, preferably pH 6 to 8, at 20 °C to 50 °C for 1 to 96 hours.

The polypeptide of the present invention obtainable by the procedure mentioned in (2) above may also be used as an enzyme source to produce, in an aqueous medium, a reaction product having Fuc added to a glucose residue in the lactose structure via an α 1,3-linkage as follows.

Namely, a reaction product having Fuc added to a glucose residue in the lactose structure of an acceptor substrate via an α 1,3-linkage may be obtained by producing and accumulating the reaction product in an aqueous medium through an enzyme reaction using the polypeptide of the present invention obtained by the procedure mentioned in (2) as an enzyme source; GDP-Fuc; and the following acceptor substrate:

lactose (Gal β 1-4Glc), an oligosaccharide having the lactose structure at the nonreducing terminus, a complex carbohydrate having a sugar chain with the lactose structure at the nonreducing terminus, their derivatives having the lactose structure modified with sulfate groups, or their derivatives having the lactose structure modified with sugars and having no sialic acid added to a galactose residue in the lactose structure via an α 2,3-linkage; and then collecting the reaction product from the aqueous medium.

The derivative having the lactose structure modified with sulfate groups or the derivative having the lactose structure modified with sugars and having no sialic acid added to a galactose residue in the lactose structure via an α 2,3-linkage includes Gal α 1-3Gal β 1-4Glc, Gal α 1-3(Fuc α 1-2)Gal β 1-4Glc, GalNAc α 1-3(Fuc α 1-2)Gal β 1-4Glc, Gal α 1-4Gal β 1-4Glc, Gal β 1-4Glc(6SO₃); a sugar chain having one of these oligosaccharide structures at the nonreducing terminus, and a complex carbohydrate containing the sugar chain.

The reaction may be carried out under the same conditions as described for the reaction which provides the product having Fuc added to a GlcNAc residue in an N-acetyllactosamine structure of the receptive substrate via an α 1,3-linkage, with the exception of replacing the acceptor substrate to be used.

The sugar chains or the complex carbohydrates produced by the above procedure may be cleaved using a known enzymatic or chemical technique to obtain a partial sugar chain [The Japanese Biochemical Society ed., "Continued Biochemical Experiment Course," vol. 4, Complex Carbohydrate Study I, II, Tokyo Kagaku Dojin (1986); Naoyuki Taniguchi, Akimi Suzuki, Kiyoshi Furukawa, Kazuyuki Sugawara, ed., "Glycobiology Experimental Protocols," Shujunsha Co., Ltd. (1996)].

(4) Application of the DNA or oligonucleotide of the present invention to treatment, diagnosis of diseases, or the like.

The DNA of the present invention can be used for treatment of diseases (e.g., brain diseases, renal diseases, or cancers) using an antisense RNA/DNA technique [Bioscience & Industry, 50, 322 (1992); Chemistry, 46, 681 (1991); Biotechnology, 9, 358 (1992); Trends in Biotechnology, 10, 87 (1992); Trends in Biotechnology, 10, 152 (1992); Cell Technology, 16, 1463 (1997)] or a triple helix technique [Trends in Biotechnology, 10, 132 (1992)], or can be used for diagnosis of these diseases using Northern hybridization or PCR.

For example, the DNAn oligonucleotide or derivatives thereof according to the present invention mentioned in (1) above may be administered to inhibit production of the polypeptide of the present invention.

Namely, the DNAn oligonucleotide or derivatives thereof according to the present invention may be used to suppress the transcription of a DNA encoding the polypeptide of the present invention and the translation of an mRNA encoding the polypeptide of the present invention.

Also, the DNA of the present invention or the oligonucleotide prepared therefrom may be used to determine the expression level of DNA encoding the polypeptide of the present invention by Northern hybridization or PCR.

Further, the DNA of the present invention may be used as a probe to obtain a promoter region for the gene in a known manner [Department of Oncology, The Institute of Medical Science, The university of Tokyo ed., "New Experimental Protocols in Cell Technology," Shujunsha Co., Ltd. (1993)].

The promoter region includes all promoter regions involved in the transcription of a gene encoding the polypeptide of the present invention in mammalian cells.

Examples include promoter regions involved in the transcription of a gene encoding the polypeptide of the present invention in a human nerve cell, kidney cell, gastric epithelial cell, leukocyte, brain tumor cell, neuroblastoma cell, melanoma cell, renal cancer cell, gastric cancer cell, colon cancer cell or pancreatic cancer cell. The promoter can be used for the screening method mentioned below.

(5) Production of antibodies for recognizing the polypeptide of the present invention

(i) Preparation of polyclonal antibodies

The purified full-length or partial polypeptide obtained by the procedure mentioned in (2) above or a peptide having a partial amino acid sequence of the protein of the present invention may be used as an antigen to prepare a polyclonal antibody by administering an animal with the antigen.

Examples of the animals used include rabbits, goats, 3- to 20-week-old rats, mice, hamsters and the like.

Preferable dosage of antigen is 50 to 100 μ g per animal.

When a peptide is used as the antigen, it is preferred to use the peptide as the antigen after binding it covalently to a carrier protein, such as keyhole limpet haemocyanin, bovine thyroglobulin or the like.

Administration of the antigen is carried out 3 to 10 times at one- to two-week intervals after the first administration. A blood sample is recovered from the fundus of the eye 3 to 7 days after each administration, and the serum is tested, for example, by enzyme immunoassay [Enzyme-linked Immunosorbent Assay (ELISA), published by Igaku Shoin (1976); Antibodies - A Laboratory Manual, Cold Spring Harbor Laboratory (1988)] as to whether it is reactive with the antigen used for immunization.

A polyclonal antibody can be prepared by obtaining the serum from a non-human mammal whose serums shows a sufficient antibody titer against the antigen used for immunization, isolating and purifying it from the serum.

With regard to the method for the isolation and purification of the polyclonal antibody, centrifugation, salting-out method with 40 to 50 % saturated ammonium sulfate, caprylic acid precipitation method[Antibodies, A Laboratory manual, Cold Spring Harbor Laboratory, (1988)], or chromatographic methods using a DEAE-Sepharose column, an anion exchange column, a protein A or G column, a gel filtration column and the like may be employed alone or in combination.

- (ii) Preparation of a monoclonal antibody
- (a) Preparation of antibody-producing cells

The non-human mammal whose serum showed adequate antibody titer against a partial fragment of the polypeptide of the present invention used in immunization are used as a source of antibody-producing cells.

On day 3 to 7 after the final administering with the antigen to the non-human mammal with the antibody titer, the spleen is excised from the non-human mammal.

The spleen is cut into pieces in MEM medium (manufactured by Nissui Pharmaceuticals, Co.) and the pieces are then loosened with tweezers, followed by centrifugation at 1,200 rpm for 5 minutes, to discard the resulting supernatant.

The spleen cells in the resulting precipitated fraction are treated with a Tris-ammonium chloride buffer (pH 7.65) for 1 to 2 minutes to remove erythrocytes, followed by washing 3 times with MEM medium to give spleen cells as antibody-producing cells.

(b) Preparation of myeloma cells

As myeloma cells, cell lines obtained from mice or rats are used. For example, 8-azaguanine-resistant mice (BALB/c)-derived myeloma cell line P3-X63Ag8-U1 (hereinafter abbreviated to P3-U1) [Curr. Topics. Microbiol. Immunol., 81, 1 (1978), Europ. J. Immunol., 6, 511 (1976)], SP2/0-Ag14 (SP-2) [Nature, 276, 269 (1978)], P3-X63-Ag8653(653) [J. Immunol., 123, 1548 (1979)], P3-X63-Ag8(X63) [Nature, 256, 495 (1975)] etc. can be used. These cell lines are further subjected to subculture in 8-azaguanine medium [medium prepared by adding 8-azaguanine (15 µg/ml) to a medium (referred to hereinafter as normal medium) having glutamine (1.5 mM), 2-mercaptoethanol (5×10^{-5} M), gentamicin (10 µg/ml) and fetal calf serum (FCS)(a product of CSL Ltd.; 10%) added to RPMI-1640 medium], and 3 to 4 days before cell fusion, they are cultured in the normal medium and at least 2×10^7 cells are used for fusion.

(c) Preparation of hybridoma

The antibody-producing cells obtained in item (a) above and myeloma cells obtained in item (b) above are washed well with MEM medium or PBS (1.83 g of disodium phosphate, 0.21 g of monopotassium phosphate, 7.65 g of common salt, 1 L of distilled water, pH 7.2) and mixed such that the ratio of the antibody-producing cells/myeloma cells ranges from 5/1 to 10/1, and these cells are centrifuged at 1,200 rpm. for 5 minutes and the supernatant is discharged.

The cell pellet obtained as the precipitated fraction is well loosened, and a mixture containing of 2 g of polyethylene glycol-1000 (PEG-1000), 2 ml of MEM and 0.7 ml of dimethyl sulfoxide (DMSO) is added to the cells in a volume of 0.2 to 1 ml/ 10^8 antibody-producing cells with stirring at 37°C, and 1 to 2 ml of MEM medium is added thereto several times at 1- to 2-minute intervals.

After addition, MEM medium is added to adjust the total volume to 50 ml.

The solution thus prepared is centrifuged at 900 rpm. for 5 minutes, and the supernatant is discarded.

The cells obtained in the precipitated fraction are gently loosened and suspended by pipetting in 100 ml of HAT medium [the medium prepared by adding hypoxanthine (10^{-4} M), thymidine (1.5×10^{-5} M) and aminopterin (4×10^{-7} M) to the normal medium].

The suspension is divided into 96-well culture plates (100 μ l/well) and is cultured at 37°C in a 5% CO₂ incubator for 7 to 14 days.

After culturing, an aliquot of the supernatant is sampled and a hybridoma reacting specifically to a partial fragment of the polypeptide of the present invention is selected by enzyme immunoassays described in e.g. "Antibodies" [Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory, Chapter 14 (1988)].

Specifically, enzyme immunoassays are conducted as follows:

An appropriate plate is coated with a partial fragment of the polypeptide of the present invention, which was used as an antigen for immunization, followed by reaction with a culture supernatant of the hybridoma or with the purified antibody obtained in (d) below as a first antibody and then with anti-rat or anti-mouse immunoglobulin antibody as a second antibody labeled with biotin, an enzyme, a chemiluminescent substance or a radioisotope. Then, reaction depending on the labeling substance is conducted, and a hybridoma reacting specifically with the polypeptide of the present invention is selected as a hybridoma producing a monoclonal antibody against the polypeptide of the present invention.

Using the hybridoma, cloning is repeated two times by limiting dilution [for first dilution, HT culture medium (aminopterin-free HAT medium) is used; for second dilution, the normal medium is used]. A hybridoma showing a stable and strong antibody titer is selected as the hybridoma producing an antibody against the polypeptide of the present invention.

(d) Preparation of a monoclonal antibody

The hybridoma cells producing a monoclonal antibody against the polypeptide of the present invention, obtained in item (c) above, are injected at a dose of $5-20 \times 10^6$ cells/animal into the abdomens of 8 to 10-week-old mice or nude mice treated with 0.5 ml Pristane [animals raised for 2 weeks after intraperitoneal administration of 2,6,10,14-tetramethylpentadecane (Pristane)]. The hybridoma forms ascites tumor in 10 to 21 days.

From the mouse with the ascites tumor, the ascites is collected and centrifuged at 3,000 rpm for 5 minutes, to remove the solid matters from the fluid.

From the resulting supernatant, the monoclonal antibody can be purified and obtained according to the same method in the polyclonal antibody. Further, from the supernatant of the hybridoma which produces the monoclonal antibody, the monoclonal antibody can be purified and obtained according to the same method.

The class and subclass of the antibody are determined using a mouse monoclonal antibody typing kit or a rat monoclonal antibody typing kit. The protein content is determined by the Lowry method or calculated from absorbance at 280 nm.

(6) Use of the antibody of the present invention

(a) The antibody of the present invention can be used to detect the polypeptide of

the present invention. Specifically, it is used in detection methods such as ELISA/fluorescent antibody method using a microtiter plate, Western blotting method etc.

(b) The antibody of the present invention can be used for immunostaining of tissues of cells expressing the polypeptide of the present invention.

(c) The antibody of the present invention can be used for diagnosis or treatment of diseases such as inflammations, cancers etc.

(7) Application to screening method

Because the polypeptide of the present invention has a novel $\alpha 1,3$ -fucosyltransferase activity, when using a compound that enhances or inhibits this activity, it is possible to increase or decrease the amount of the Lewis x sugar chain, the Lewis y sugar chain or their modified sugar chains synthesized in cells.

In addition, the expression of the polypeptide can be controlled by a compound that promotes or suppresses the transcription process of a gene encoding the polypeptide or the translation process of the transcript into a protein, resulting in a regulation of the amount of the Lewis x sugar chain, the Lewis y sugar chain or modified sugar chains thereof synthesized in cells.

Such compounds may be useful for treatment of diseases including brain diseases, renal diseases or cancers; or for synthesis of the Lewis x sugar chain, the Lewis y sugar chain or modified sugar chains thereof.

These compounds may be obtained according to the following procedures (a) to (e).

(a) The polypeptide of the present invention having a novel α 1,3-fucosyltransferase activity (as a purified form, or cellular extract or culture supernatant of transformants expressing the polypeptide) prepared as mentioned in (2) above is used as an enzyme to determine the α 1,3-fucosyltransferase activity in the presence of a test sample in a known manner [Methods in Enzymology, 83, 458; Methods in Enzymology, 179, 397; J. Biol. Chem., 269, 14730-14737 (1994); Japanese Patent Laid-Open Publication No. 06-823021], thereby selecting and obtaining the compound that has an activity to enhance or inhibit the α 1,3-fucosyltransferase activity.

(b) Cells or the transformants mentioned in (2) above expressing the polypeptide of the present invention are cultured in the presence of a test sample for 2 hours to 1 week according to the culturing procedure mentioned in (2) above. Thereafter, the Lewis x sugar chain, the Lewis y sugar chain, or modified sugar chains thereof on the cell surface are detected with antibodies against these sugar chains, thereby selecting and obtaining the compound that has an activity to increase or decrease the amount of these sugar chains.

Examples of the detection method with antibodies include ELISA using a microtiter plate, a fluorescent antibody method, a Western blot method and immunohistological staining.

(c) Cells expressing the polypeptide of the present invention are cultured in the presence of a test sample for 2 hours to 1 week according to the culturing procedure mentioned in (2) above. Thereafter, an amount of the polypeptide in the cells is determined using the antibodies of the present invention mentioned in (5) above, thereby selecting and obtaining the compound that has an activity to increase or decrease the amount of the polypeptide.

Examples of the determination methods with antibodies include ELISA using a

microtiter plate, a fluorescent antibody method, a Western blot method and immunohistological staining.

(d) Cells expressing the polypeptide of the present invention are cultured in the presence of a test sample for 2 hours to 1 week according to the culturing procedure mentioned in (2) above. Thereafter, an amount of the gene transcript encoding the polypeptide in the cells is determined by Northern hybridization method or PCR mentioned in (4) above, thereby selecting and obtaining the compound that has an activity to increase or decrease the amount of the transcript.

(e) A plasmid carrying a DNA insert containing a reporter gene linked downstream of the promoter obtained in (4) above is constructed in a known manner, and then transformed into the animal cells mentioned in (2) according to the procedure of (2), thereby obtaining transformants. The transformants are cultured in the presence of a test sample for 2 hours to 1 week according to the culturing procedures mentioned in (2) above. Thereafter, the expression level of the reporter gene in the cells is determined in a known manner [Department of Oncology, The Institute of Medical Science, The university of Tokyo ed., "New Experimental Protocols in Cell Technology," Shujunsha Co., Ltd. (1993); Biotechniques, 20, 914 (1996); J. Antibiotics, 49, 453 (1996); Trends in Biochemical Sciences, 20, 448 (1995); Cell Technology, 16, 581 (1997)], thereby selecting and obtaining the compound that has an ability to increase or decrease the expression level of the reporter gene expressed.

The reporter genes include chloramphenicol acetyltransferase gene, β -galactosidase gene, luciferase gene, and green fluorescent protein (GFP) gene.

(8) Creation of a knockout animal

A vector carrying the DNA of the present invention may be used for creation of a mutated clone, in which DNA encoding the polypeptide of the present invention on its

chromosome is inactivated or replaced with any other sequence according to a known homologous recombination procedure [e.g., Nature, 326, 6110, 295 (1987); Cell, 51, 3, 503 (1987)], from an embryonic stem cell of a target animal, including cow, sheep, goat, pig, horse, chicken, or mouse. See, for example, Nature, 350, 6315, 243 (1991).

The embryonic stem cell clone thus created may be used for creation of a chimeric animal composed of the embryonic stem cell clones and normal cells by transferring the clone into the blastocyst of an animal's fertilized egg according to injection chimaera method or aggregation chimaera method. This chimeric animal may be mated with a normal animal to obtain an animal having any mutation in DNA encoding the polypeptide of the present invention on its chromosome in all cells of the entire body. Further, such animals may be mated with each other to obtain a homogeneous animal (knockout animal) having the mutation on both homologous chromosomes.

In this manner, a mutation may be introduced into any location in DNA encoding the polypeptide of the present invention on the chromosome in an animal individual. For example, a mutation such as base substitution, deletion or insertion may be introduced into the translated region of DNA encoding the polypeptide of the present invention on the chromosome, thereby resulting in a gene product having an altered activity. Introduction of a similar mutation into the expression control region can vary the level, stage and tissue specificity of the expression of the gene to be expressed. In addition, the combination with Cre-loxP system can more actively control the stage, site and level of the expression of the gene.

For example, the following cases are known: the deletion of a target gene in only a specific region of the brain using a promoter expressed in this region [Cell, 87, 7, 1317 (1996)], and the organ N-specific deletion of a target gene at a target stage using an adenovirus expressing Cre [Science, 278, 5335, (1997)].

Accordingly, an animal individual that allows the controlled expression of the DNA at any stage or in any tissue; or that has any insertion, deletion, or substitution in the translated region or the expression control region may be created for the DNA encoding the polypeptide of the present invention on the chromosome.

In such an animal, symptoms of various diseases caused by the polypeptide of the present invention may be induced at any stage, at any level, or at any site.

The knockout animal of the present invention is therefore a very useful animal model for treatment and prevention of various diseases caused by the polypeptide of the present invention. Particularly, it is very useful as an evaluation model for therapeutic or prophylactic agents against these diseases as well as functional foods or supplement foods.

This specification includes part or all of the contents as disclosed in the specification and/or drawings of Japanese Patent Application No. 10-213823 which is a priority document of the present application.

Brief Description of the Drawing

Figure 1 shows the result obtained by FACS analysis of the Namalwa cells transfected with a control plasmid (pAMo), a mouse Fuc-TIX expression plasmid (pAMo-mFT9), a mouse Fuc-TIV expression plasmid (pAMo-mFT4), or a human Fuc-TVI expression plasmid (pAMo-hFT6), which were subjected to indirect fluorescent antibody staining with anti-Lewis x sugar chain antibody (PM-81, 73-30), anti-Lewis y sugar chain antibody (AH-6), or anti-sialyl Lewis x sugar chain antibody (KM93). Shaded histograms are of Namalwa cells transfected with a control plasmid.

Figure 2 shows the result obtained by FACS analysis of the Namalwa KJM-1

cells transfected with a control plasmid (pAMo), a mouse Fuc-TIX expression plasmid (pAMo-mFT9), a human Fuc-TIV expression plasmid (pAMo-FT4), or a human Fuc-TVII expression plasmid (pAMo-FT7) which were subjected to indirect fluorescent antibody staining with anti-sialyl Lewis x sugar chain antibody (CSLEX-1, KM93). For control sample, A-PBS was used instead of the first antibody.

Figure 3 shows the result obtained by FACS analysis of the COS-1 cells transfected with a control plasmid (pCDM8), a mouse Fuc-TIX expression plasmid (pCDM8-mFT9), or a human Fuc-TIII expression plasmid (pCDM8-Le), which were subjected to indirect fluorescent antibody staining with anti-Lewis a sugar chain antibody (7LE). Shaded histograms are of COS cells transfected with a control plasmid.

Figure 4 shows the result of northern hybridization performed using Poly (A)⁺RNA from each mouse organ in order to determine the distribution of mouse Fuc-TIX transcripts. The results are shown only regarding brain and kidney which exhibited a signal.

Figure 5 shows the amount of mouse Fuc-TIX transcripts in each mouse organ which was detected by quantitative RT-PCR.

As control samples, the results regarding mouse Fuc-TIX transcript and mouse β -actin transcript are also shown.

A. is the figure showing the pattern of electrophoresis obtained by subjecting the RT-PCR samples to agarose gel electrophoresis (a. is concerned with the amount of Fuc-TIX transcripts and b. is concerned with that of Fuc-TIV.)

The bottom band in each gel represents one derived from internal control,

whereas the upper band represents one derived from Fuc-TIX transcripts or Fuc-TIV transcript. B. is the figure showing the amounts of mouse Fuc-TIX transcripts, mouse Fuc-TIV transcripts or mouse β -actin transcripts, which were determined using calibration curves made by standard plasmids. The amount represents that in 1 μ l of single stranded cDNA solution prepared according to the method described herein.

Standard DNA in A. represents the amount of the standard plasmids used for making the calibration curves. (1) is 40 fg, (2) is 20 fg, (3) is 10 fg, (4) is 5 fg, (5) is 2.5 fg and (6) is 1.25 fg.

Figure 6 shows photographs of *in situ* hybridization with slices of mouse brain tissues in order to determine the distribution of mouse Fuc-TIX transcripts. These results were obtained using a probe which was prepared with the primers represented by SEQ ID NO: 20 or 21. Using the antisense probe, Fuc-TIX transcripts was detected in perikaryon (A). On the other hand, using the sense probe as a negative control, no signal was exhibited (B).

Figure 7 shows the structure of a plasmid pBS-hFT9 (S2).

Both cDNA and Ap in the figure show a human Fuc-TIX cDNA and an ampicillin-resistance gene, respectively.

Figure 8 shows the structure of a targeting vector pFut9F[tkneo]. For comparison, the structure of pFut9WT-129 is also shown, which is a plasmid obtained by subcloning the Fuc-TIX gene. Each description of various squares is as shown in the figure. Thick black lines represent both a portion of intron 2 of the Fuc-TIX gene and a chromosomal gene located downstream of the Fuc-TIX gene. Thin black lines represent pBluescript SK-portion. Furthermore, in this figure, 5'UTR represents 5' untranslated region and 3'UTR represents 3' untranslated region. Sites corresponding

to primers used for PCR are also as shown in the figure.

Figure 9 shows the structure of mouse Fuc-TIX gene. The location of the mouse Fuc-TIX gene fragments contained in phage clones λ MFT9-11, λ MFT9-25 and λ MFT9-31 is also shown herein. In the figure, B represents *Bam*HI site, Sp represents *Spe*I site, and Sa represents *Sac*I site.

Figure 10 shows the position of the mouse Fuc-TIX gene (which is shown as *Fut9*) on the mouse fourth chromosome. Other marker genes are also shown together with the mouse Fuc-TIX gene. In this figure, only a portion of the mouse fourth chromosome is shown.

Figure 11 shows a process of creating a targeting vector pFut9F[tkneo].

Figure 12 shows the result of an electrophoresis to analyze the genotype of mice obtained by crossing two hetero mice. M represents molecular weight marker, and the numbers 1 to 7 represent the results of genotype analysis of each mouse.

Figure 13 shows the result of the reaction specificity of Fuc-TIX analyzed by HPLC. The shown result was obtained by adding the extract from Fuc-TIV expression cells (b) or Fuc-TIX expression cells (c) as an enzyme source to Gal β 1-4GlcNAc β 1-3Gal β 1-4GlcNAc β 1-3Gal β 1-4GlcNAc-2AB (which is shown as S in the figure) and reacting the mixture, followed by detecting the obtained product by HPLC. (a) is the result of the reaction between S and the extract from a cell into which a control vector was introduced.

Figure 14 shows the result obtained by reacting Fuc-TIX and a substrate Gal β 1-4GlcNAc β 1-3Gal β 1-4GlcNAc β 1-3Gal β 1-4GlcNAc-2AB, followed by analyzing the obtained products (P1, P2 and P3) by HPLC. The elution positions of

glucose homopolymer fluorescence-labeled with 2-aminobenzamide, which was used as a molecular weight marker, are shown at the top of the figure. The glucose unit of the glucose homopolymer is abbreviated as g.u. Each of (a) P1, (b) P2 and (c) P3 was treated with Jack bean β -galactosidase, and then each of the obtained products was analyzed by HPLC (The results were shown as (d), (e) and (f) respectively.)

Figure 15 shows the result obtained by treating the products (P1, P2 and P3) with various kinds of glycosidase and analyzing the obtained products by HPLC. (a) is the result of analysis of P1, (b) is the result of analysis of the product obtained by treating P1 with almond meal α 1,3/4-fucosidase, (c) is the result of analysis of a substrate Gal β 1-4GlcNAc β 1-3Gal β 1-4GlcNAc β 1-3Gal β 1-4GlcNAc-2AB (which is shown as S in the figure), (d) is the result of analysis of P2, and (e) is the result of analysis of the product obtained by treating P2 with almond meal α 1,3/4-fucosidase. (f) is the result of analysis of the product obtained by treating P2 with Jack bean β -galactosidase, (g) is the result of analysis of the product obtained by treating P2 with Jack bean β -galactosidase and then with Jack bean β -N-acetylhexosaminidase, (h) is the result of analysis of the product obtained by treating P2 with Jack bean β -galactosidase, Jack bean β -N-acetylhexosaminidase and almond meal α 1,3/4-fucosidase in sequence, (i) is the result of analysis of Gal β 1-4GlcNAc β 1-3Gal β 1-4GlcNAc-2AB, (j) is the result of analysis of P3, and (k) is the result of analysis of the product obtained by treating P3 with almond meal α 1,3/4-fucosidase.

Figure 16 shows the result of analysis of Namalwa cells by FACS, following an indirect fluorescent antibody staining of the Namalwa cells, into which a control vector, human Fuc-TIV expression plasmid or human Fuc-TIX expression plasmid were introduced, using anti-VIM2 sugar chain antibody (which is denoted as VIX-2 in the figure), Le^x sugar chain antibody 73-30 (which is denoted as 73-30 in the figure), or anti-CD 15 antibody (which is denoted as CD-15 Dako in the figure). Thin black lines show the result of staining Namalwa cells into which a control vector was introduced,

thick gray lines represent the result of staining Namalwa cells into which a human Fuc-TIV expression plasmid and thick black lines represent the result of staining Namalwa cells into which a human Fuc-TIX expression plasmid.

Best Mode for Carrying Out the Invention

Examples will now be shown as follows. Unless otherwise specified, genetic engineering techniques used herein are known techniques described in Molecular Cloning, 2nd Edit.

Example 1 Cloning of a novel mouse α 1,3-fucosyltransferase gene (cDNA)

(1) Preparation of mRNA from mouse brain

About 30 μ g of mRNA was prepared from BALB/c mouse brain using a mRNA extractor kit, OligotexTM-dT30^{<super>} (manufactured by Roche). Reagents and methods were employed as described in the instructions attached to the kit.

(2) Construction of a mouse brain cDNA library

Using 8 μ g of mRNA obtained from the mouse brain in (1) above and a kit (SUPERScript Choice System for cDNA Synthesis manufactured by GIBCO BRL), double-stranded cDNAs were synthesized with oligo-dT as primers.

*Sfi*I linkers were ligated to the both ends of the double-stranded cDNAs as described below.

[Addition of *Sfi* I linker]

A single-stranded DNA represented by SEQ ID NO:6 and a single stranded DNA represented by SEQ ID NO:7 were synthesized using a 380A DNA synthesizer (manufactured by Applied Biosystems).

Each of the synthesized single-stranded DNAs 50 μ g was independently

dissolved in a separate 50 μ l of buffer solution containing 50 mM Tris-HCl (pH 7.5), 10 mM $MgCl_2$, 5 mM dithiothreitol (hereinafter abbreviated as DTT), 0.1 mM EDTA and 1 mM ATP (hereinafter abbreviated as T4 kinase buffer). Then 30 units of T4 polynucleotide kinase (manufactured by Takara Shuzo Co., Ltd.) were added to each mixture, and allowed to carry out phosphorylation reaction for 16 hours at 37°C, thereby obtaining 11-bp and 8-bp linkers.

Four micrograms of the 11-bp linker, 2.9 μ g of the 8-bp linker, and the double-stranded cDNAs synthesized as described above were dissolved in 45 μ l of T4 ligase buffer. Then 1050 units of T4 DNA ligase were added to the mixture, and the mixture allowed to react for 16 hours at 16°C, so that the *Sfi*I linkers were added to each of the double-stranded DNAs.

The resulting reaction mixture was subjected to agarose gel electrophoresis, and a DNA fragment of about a 1.5 kb or more was recovered.

Twenty four micrograms of expression cloning vector of pAMo [J. Biol. Chem., 268, 22782 (1993), also called pAMoPRC3Sc (Japanese Patent Laid Open Publication No. 05-336963)], expression cloning vector (Expression Cloning Vector), were dissolved in 590 μ l of buffer containing 10 mM Tris-HCl (pH 7.5), 6 mM $MgCl_2$, 50 mM NaCl, 6 mM 2-mercaptoethanol (hereinafter abbreviated as Y-50 buffer). Then 80 units of *Sfi*I (manufactured by Takara Shuzo Co., Ltd. Unless otherwise specified, restriction enzymes manufactured by Takara Shuzo Co. Ltd were used) were added to the mixture and allowed to digest for 16 hours at 37°C.

Forty units of *Bam*H I were added to the reaction solution and allowed to digest for 2 hours at 37°C.

The reaction solution was then subjected to agarose gel electrophoresis, and a

DNA fragment of about 8.8 kb was recovered.

DNAs (derived from 8 µg of mRNA) with *Sfi* I linkers prepared as described above was dissolved in 250 µl of T4 ligase buffer. Then 2 µg of about the - 8.8 kb DNA fragments and 2000 units of T4 DNA ligase were added to the solution, followed by ligation reaction for 16 hours at 16°C.

After the reaction, 5 µg of transfer RNA (tRNA) was added to the reaction solution. After ethanol precipitation, the precipitate was dissolved in 20 µl of a buffer containing 10 mM Tris-HCl (pH 8.0) and 1 mM EDTA (sodium ethylenediamine tetraacetic acid) (hereinafter abbreviated as TE buffer).

Using the reaction solution, *Escherichia coli* strain LE 392 (Molecular Cloning, 2nd Edit) was transformed by the electroporation method [Nucleic Acids Res., 16, 6127 (1988)], and about a million ampicillin-resistant transformants were obtained, thereby constructing cDNA library.

(3) Cloning of a gene (cDNA) enhancing the reactivity of transformed cells with an anti-Lewis X sugar chain antibody (PM-81)

Plasmids were prepared from the cDNA library (*E.coli*) as constructed in (2) above using a /plasmid/maxi kit, which is a plasmid preparation kit (merchandise No. 41031, manufactured by Qiagen).

After ethanol precipitation, the plasmids were dissolved in TE buffer to 1 µg/µl.

The plasmids (40 µg) were introduced into Namalwa cells by electroporation method [Cytotechnology, 3, 133 (1990)].

After introducing 4 µg of the plasmids per 1.6×10^6 cells, the cells were

suspended in 8 ml of RPMI 1640 medium [the RPMI 1640 medium (manufactured by NISSUI PHARMACEUTICAL CO., LTD.) containing a 1/40 volume of 7.5% NaHCO_3 , 3 % of 200 mM L-glutamine solution (manufactured by GIBCO), 0.5% of penicillin / streptomycin solution (manufactured by GIBCO, 5000 units/ml of penicillin, 5000 $\mu\text{g/ml}$ of streptomycin), and were cultured in a CO_2 incubator for 24 hours at 37°C .

After culturing, G418 (manufactured by GIBCO) was added to the medium to 0.5 mg/ml followed by culturing for 10 days, thereby obtaining stable transformants.

The transformants were cultured in RPMI1640 containing 0.5 mg/ml of G418. The resulting approximately 4×10^7 cells were subjected to indirect fluorescent antibody staining using PM-81, which was an antibody for the Lewis X sugar chain.

Detailed techniques employed are as shown below.

About 4×10^7 stable transformed cells were added to a 50 ml centrifugation tube (2059 tube: manufactured by Falcon) for centrifugation ($130 \times g$, 10 minutes), and the cells were collected.

The collected cells were washed with 20 ml of phosphate buffer PBS containing 0.1% sodium azide (A-PBS: 8 g/l NaCl , 0.2 g/l KCl , 1.15 g/l Na_2HPO_4 (anhydrous), 0.2 g/l KH_2PO_4 , 0.1% sodium azide).

0.5 ml of the anti-Lewis x sugar chain antibody (PM-81) diluted to about 10 $\mu\text{g/ml}$ using A-PBS was added to the washed cells for suspension, then allowed to react for 1 hour at 4°C .

After the reaction, the cells were washed once with 20 ml of A-PBS. Subsequently the cells were suspended in 300 μl of a solution, which had been prepared

by diluting anti-mouse IgM antibodies (manufactured by CAPPEL) fluorescent-labeled with fluorescein isothiocyanate (FITC) at 1:16 with A-PBS. The suspension was allowed to react for 30 minutes at 4°C.

After the reaction, the cells were washed once with A-PBS, and then suspended in 1 ml of A-PBS. Cells with high fluorescent intensity (top 2.0%) were aseptically separated and collected using a fluorescence activated cell sorter (EPICS Elite Flow Cytometer; manufactured by COULTER).

The collected cells were cultured in RPMI1640 media, containing 0.5 mg/ml of G418. After growing, cells with high fluorescent intensity were aseptically separated and collected in the same manner as described above.

The above procedure was repeated to separate and concentrate cells with high fluorescent intensity.

In the second procedure, the cells with high fluorescent intensity (top 1.5%); in the third procedure, the cells with high fluorescent intensity (top 1.5 %); and in the forth procedure, the cells with high fluorescent intensity (top 1.0%) were separated and collected.

Therefore, cells with enhanced fluorescent intensity, that is, cells, in which the amount of the Lewis x sugar chain was increased, were recovered by the above separation procedure.

After the cells were cultured in RPMI1640 medium containing 0.5 mg/ml of G418, plasmids were recovered from about 2×10^6 cells by Hirt procedure [(Mol. Cell. Biol., 8, 2837 (1988))].

The plasmids were introduced into *Escherichia coli* strain LE397 by electroporation method [(Nucleic Acids Res., 16, 6127, (1988)], thereby recovering ampicillin-resistant transformants.

Plasmids were prepared from 40 transformants obtained as described above. Each of the plasmids was excised with restriction enzymes (*Hind* III and *Asp*718) to examine the structure of the inserted cDNA.

The plasmids were subjected to phenol-chloroform extraction followed by ethanol precipitation, thereby recovering the plasmids.

The plasmids were dissolved in 10 µl of TE buffer. Then each of the plasmids was introduced into Namalwa cells by electroporation method [Cytotechnology, 3, 133 (1990)].

After introducing 3 µl of the plasmids prepared as described above or 4 µg of pAMo (control plasmid) per 1.0×10^6 to 1.6×10^6 cells (200 µl) by electroporation method, the cells were suspended in 8 ml of RPMI1640 media and then cultured in a CO₂ incubator for 24 hours at 37°C.

After culturing, the medium was supplemented with G418 (manufactured by GIBCO BRL) to 0.5 mg/ml followed by culturing for another 10 to 14 days, thereby obtaining transformed cells.

The resultant transformed cells were subjected to indirect fluorescent antibody staining using an anti-Lewis x sugar chain antibody (PM-81). In the cells into which a plasmid named pAMo-mFT9 had been introduced, reactivity (peak value of histogram) against the anti-Lewis x sugar chain antibody (PM-81) increased by about 20 times, compared with the cells into which pAMo had been introduced.

The above results reveal that cDNA inserted in the plasmid pAMo-mFT9 causes increased reactivity of the transformed cells against the anti-Lewis x sugar chain antibody (PM-81).

Indirect fluorescent antibody staining using the anti-Lewis x sugar chain antibody (PM-81) was performed as follows.

About 1×10^6 transformed cells were added to a microtube (1.5 ml: manufactured by Eppendorf) and then the cells were collected by centrifugation (550 x g, 7 minutes).

The cells were washed with 0.9 ml of A-PBS, suspended by adding 20 μ l of the anti-Lewis x sugar chain antibody (PM-81) that had been diluted with A-PBS to about 10 μ g/ml, and then allowed to react for 1 hour at 4°C.

After the reaction, the cells were washed once with 0.9 ml of A-PBS, suspended by adding 20 μ l of a solution, which had been prepared by diluting anti-mouse IgM antibodies (manufactured by CAPPEL) fluorescent-labeled with FITC at 1:16 using A-PBS. Then the products were allowed to react for 30 minutes at 4°C.

After the reaction, the cells were washed once with 0.9 ml of A-PBS, and then suspended in 0.6 ml of A-PBS, followed by the analysis using a fluorescence activated cell sorter. In a control experiment, similar analysis was produced using A-PBS instead of the anti-Lewis x sugar chain antibody (PM-81).

(4) Determination of Nucleotide Sequence of a cDNA Inserted in a Plasmid pAMo-mFT9.

After making a restriction map of the cDNA contained in the plasmid pAMo-

mFT9 obtained in (3) above, DNA fragments derived from the cDNA were subcloned into pBluescript II SK(-), and the whole nucleotide sequence of the cDNA was determined. The nucleotide sequences were determined using a DNA sequencer 377 and a kit (both manufactured by Perkin-Elmer) according to the instructions attached to the kit.

By assembling the results together, the whole nucleotide sequence (2170 bp) of the cDNA contained in the plasmid pAMo-mFT9 was determined.

The nucleotide sequence of the cDNA is shown in SEQ ID NO:3.

The cDNA encoded a polypeptide consisting of 359 amino acids having a structure characteristic to glycosyl transferases. The polypeptide shared 35% to 38% homology to five types of human α 1,3-fucosyltransferases that had been cloned so far at the amino acid level, suggesting that the polypeptide was a novel α 1,3-fucosyltransferase. The amino acid sequence of the polypeptide was shown in SEQ ID NO:1.

The polypeptide was considered to contain an N-terminal cytoplasmic region comprising 10 amino acids, which is followed by a transmembrane domain, rich in hydrophobicity, comprising 20 amino acids, a stem region comprising at least 25 amino acids, and a C-terminal region, which is most of the remaining part including catalytic region. It was estimated that the stem region comprised at least 25 amino acids based on the findings (J. Biol. Chem., 269, 14730-14737, 1994, J. Biol. Chem., 270, 8712-8722, 1995, Glycobiology, 7, 921-927, 1997) regarding comparison of the amino acid sequence homology between the novel and other α 1,3-fucosyltransferases, and regarding the stem and catalytic regions of other α 1,3-fucosyltransferases. Accordingly, a polypeptide containing a sequence of amino acid position 56 to 359 should contain the catalytic region.

Hereinafter the cDNA is called mouse Fuc-TIXcDNA, a polypeptide encoded by the cDNA is called mouse Fuc-TIX.

Example 2 Synthesis of the Lewis x sugar chain and the Lewis y sugar chain in a Human Culture Cell into which a Mouse Fuc-TIX Expression Plasmid obtained in Example 1 has been introduced.

A control plasmid (pAMo) and a mouse Fuc-TIX expression plasmid (pAMo-mFT9) were separately dissolved in TE buffer to 1 $\mu\text{g}/\mu\text{l}$, introduced into Namalwa cells by eletroporation method, thereby obtaining transformed cells.

The transformed cells were subjected to indirect fluorescent antibody staining using an anti-Lewis x sugar chain antibodies (PM-81 or 73-30), an anti-Lewis y sugar chain antibody (AH-6), and an anti-sialyl Lewis x sugar chain antibody (KM93).

Indirect fluorescent antibody staining was performed according to the methods described in Example 1 (3). When compared to the cells into which pAMo had been introduced, the cells into which pAMo-mFT9 had been introduced showed an approximately 20-fold increase in reactivity (peak value of histogram) against each of the anti-Lewis x sugar chain antibodies (PM-81 and 73-30), and an approximately 7-fold increase in the reactivity against the anti-Lewis y sugar chain antibody (AH-6).

On the other hand, almost no change was observed in the reactivity against the anti-sialyl Lewis x sugar chain antibody (KM93) (see Fig. 1).

For comparison, similar analyses were performed for Namalwa cells expressing other α 1,3-fucosyltransferases (mouse Fuc-TIV or human Fuc-TVI). That is, Namalwa cells, into which a mouse Fuc-TIV expression plasmid (pAMo-mFT4) or a

human Fuc-TVI expression plasmid (pAMo-hFT6) had been introduced, were prepared. Then the cells were examined for the reactivity against the above antibodies (see Fig. 1).

Similarly, Namalwa KJM-1 cells, into which a control plasmid (pAMo), a mouse Fuc-TIX expression plasmid (pAMo-mFT9), a human Fuc-TIV expression plasmid (pAMo-FT4), or a human Fuc-TVII expression plasmid (pAMo-FT7) had been introduced, were obtained. The cells were subjected to indirect fluorescent antibody staining using the anti-Lewis x sugar chain antibody (KM380) and an anti-sialyl Lewis x sugar chain antibodies (CSLEX-1 or KM93) (see Fig. 2).

Further, COS-1 cells, into which a control plasmid (pCDM8), a mouse Fuc-TIX expression plasmid (pCDM8-mFT9), or a human Fuc-TIII expression plasmid (pCDM8-Le) had been introduced, were prepared. The cells were subjected to indirect fluorescent antibody staining using the anti-Lewis a sugar chain antibody (7LE, manufactured by SEIKAGAKU CORPORATION) (see Fig. 3).

Methods to construct each expression plasmid and methods to introduce it into COS-1 cells are described in Example 3.

The results suggest that Fuc-TIX can synthesize the Lewis x sugar chain and the Lewis y sugar chain in transformed cells but cannot synthesize the sialyl Lewis x sugar chain and the Lewis a sugar chain. This enzymatic property differs from that of any α 1,3-fucosyltransferases that has been cloned so far. Therefore Fuc-TIX was found to be a novel α 1,3-fucosyltransferase having novel substrate specificity.

The substrate specificity of Fuc-TIX is analogous to that of Fuc-TIV among α 1,3-fucosyltransferases that have been cloned so far. However there is a clear difference between Fuc-TIV and Fuc-TIX in that Fuc-TIV synthesizes sialyl Lewis x sugar chain

while Fuc-TIX does not synthesize it.

Moreover, these results show that by expressing Fuc-TIX in cells sugar chains containing the Lewis x sugar chain or the Lewis y sugar chain, and a complex sugar chains containing the said sugar chains can be newly synthesized.

Therefore, it is concluded that Fuc-TIX expressing cells are used as hosts to produce and secrete useful glycoproteins so that the Lewis x sugar chain or the Lewis y sugar chain can be added to the glycoproteins to be produced and secreted.

Example 3 *In vitro* Substrate Specificity of Mouse Fuc-TIX

In vitro substrate specificity of Fuc-TIX encoded by the mouse Fuc-TIX cDNA obtained in Example 1 was examined as follows.

To express the mouse Fuc-TIX in animal cells, the mouse Fuc-TIX cDNA was subcloned into an expression vector pCDM8 for animal cells as described below.

That is, a 1.2-kb *Hind*III – *Ase*I fragment containing an open reading frame (ORF) of the mouse Fuc-TIX cDNA was isolated from pAMo-mFT9. The cut ends were blunt-ended with T4 DNA polymerase, then subcloned into an *Eco*RV site of pBluescript SK(-).

A plasmid, in which the cDNA was subcloned in a direction such that the 5' and 3' sides of the cDNA was present near *Hind*III and *Pst*I sites of the cloning sites, respectively, was selected. The plasmid was excised with *Hind*III and *Pst*I to isolate a 1.2-kb fragment containing the mouse Fuc-TIX cDNA.

The 1.2-kb fragment was subcloned between *Hind*III and *Pst*I of pCDM8 to construct a mouse Fuc-TIX expression plasmid pCDM8-mFT9.

To compare substrate specificity of the novel α 1,3-fucosyltransferase with other α 1,3-fucosyltransferases, expression plasmids pCDM8-Le (human Fuc-TIII), pCDM8-mFT4, and pCDM8-hFT6 were constructed (Glycoconjugate J., 12, 802-812, 1995, J. Biol. Chem., 269, 29271-29278, 1994), into which a human Fuc-TIII cDNA, a mouse Fuc-TIV cDNA, and a human Fuc-TVI cDNA were subcloned into pCDM8, respectively.

pCDM8-mFT4 was constructed as described below.

mRNAs were prepared from Balb/c mouse stomach in the same manner as described in Example 1, and cDNAs were synthesized.

PCR was performed for the cDNAs using primers shown in SEQ ID NOS:8 and 9, thereby amplifying ORF of the mouse Fuc-TIV cDNA.

The each primer used for the amplification has an *Eco*RI recognition site at its end. The amplified fragments were excised with *Eco*RI, then subcloned into an *Eco*RI site of a vector pBluescript SK(-) to construct pBS-mFT4.

On the other hand, the vector pCDM8 was excised with *Hind* III, and then the excised ends were blunt-ended with T4 DNA polymerase. Subsequently a vector in which the *Hind*III site was converted to an *Eco*RI site was constructed by ligating an *Eco*RI linker with the digested vector.

An *Eco*RI fragment containing the mouse Fuc-TIV cDNA of pBS-mFT4 was subcloned into the *Eco*R I site of the vector, thereby constructing pCDM8-mFT4.

Each α 1,3-fucosyltransferase expression plasmid (15 μ g) was introduced into 1 x

10⁷ COS-1 cells.

This introduction was performed by electroporation method using a gene pulser (manufactured by Bio-Rad) according to the Bio-Rad's instructional manual attached thereto. At this time, 1 µg of a luciferase expression vector, which was constructed by inserting β-actin promoter into a *Hind* III site of a vector pSVOA / L [Experimental Medicine, 7, 96, (1989)] was co-introduced as an index of gene transfer efficiency.

After the gene introduction, COS-1 cells were dispensed into three dishes for cell culture with a diameter of 15 cm and then cultured for 48 hours.

Total RNA was extracted from the cells in one of the three dishes in the same manner as described in Example 4, subjected to quantitative RT-PCR, measuring the amount of transcription for each α1,3-fucosyltransferase gene.

The cells in the remaining two dishes were collected, suspended in a solution (20 mM HEPES (pH 7.4), 2% TrironX-100), then ultrasonicated for a short time period, thereby preparing cell lysate. The protein concentration of the cell lysate was measured using a micro BCA protein assay reagent kit (manufactured by PIERCE).

The enzymatic activities of luciferase and α1,3-fucosyltransferase were measured using the cell lysate.

Luciferase activity was measured by methods described in the document (J. Biol. Chem., 269, 29271-29278, 1994) to test the efficiency of the gene introduction.

In any COS-1 cells into which genes had been introduced, the luciferase activity was almost constant within an error margin of ± 20%, and no significant difference was observed in gene introduction efficiency among the fucosyltransferase genes.

Moreover, the introduction efficiency and the expression level of each fucosyltransferase gene measured by RT-PCR were almost the same.

To normalize the gene introduction efficiency precisely, each cell lysate was diluted to give a constant luciferase activity per volume.

Preparation of pyridylaminated oligosaccharide substrates and measurement of the activity were performed according to a known technique (Japanese Patent Laid Open Publication No. 06-823021, J. Biol. Chem. 269, 14730-14737, 1994).

That is, the activity was measured by allowing reaction to occur in 10 μ l of assay solution [50 mM cacodylic acid-HCl (pH 6.8), 5 mM ATP (SIGMA), 75 μ M GDP-Fuc (SIGMA), 10 mM L-Fuc (SIGMA), 25 μ M pyridylaminated oligosaccharide substrate, the above cell lysate] for 2 hours at 37°C, subjecting the products to high-performance liquid chromatography (HPLC) to identify the products.

Substrates used herein were the followings: Lacto-N-neotetraose (Gal β 1-4GlcNAc β 1-3Gal β 1-4Glc; hereinafter referred to as LNnT) and Lacto-N-tetraose (Gal β 1-3GlcNAc β 1-3Gal β 1-4Glc; hereinafter referred to as LNT), both manufactured by Oxford Glycosystem and fluorescent-labeled with aminopyridine; and Sialyllacto-N-neotetraose (NeuAc α 2-3Gal β 1-4GlcNAc β 1-3Gal β 1-4Glc; hereinafter referred to as α 2,3-sialyl LNnT) that had been fluorescent labeled with aminopyridine, which was prepared by the reaction using a secreted α 2,3-sialyltransferase (ST3Gal IV) and LNnT fluorescent-labeled with aminopyridine as a substrate.

Standard substrates used herein were the followings: Lacto-N-fucopentaose II (Gal β 1-3(Fuc α 1-4)GlcNAc β 1-3Gal β 1-4Glc; hereinafter referred as LNFP-II) and Lacto-N-fucopentaose III, (Gal β 1-4(Fuc α 1-3)GlcNAc β 1-3Gal β 1-4Glc; hereinafter

referred as LNFP-III, both manufactured by Oxford Glycosystem and fluorescent-labeled with aminopyridine; and Sialyllacto-N-fucopentaose III) (NeuAc α 2-3Gal β 1-4(Fuc α 1-3)GlcNAc β 1-3Gal β 1-4Glc; α 2,3-sialyl LNFP-III) that had been prepared by the reaction using a secreted enzyme of Fuc-TVI and α 2,3-sialylLNnT fluorescent-labeled with aminopyridine as a substrate.

The substrates were fluorescent-labeled according to a conventional method (Agric. Biol. Chem., 54, 2169, 1990).

Each of the substrates was allowed to react in assay solution with or without GDP-Fuc (sugar donator), then analyzed with HPLC. The peaks that appeared only in the assay solution containing GDP-Fuc were considered to be products.

After completion of the reaction, the assay solution was treated for 3 minutes at 100°C, then centrifuged at 10,000 x g for 5 minutes, obtaining the supernatant. An aliquot of the supernatant was subjected to HPLC.

HPLC was performed using a TSK-gel ODS-80Ts column (4.6 x 300 mm, TOSOH CORPORATION) under the following conditions: effluent was 0.02 M ammonium acetate buffer (pH 4.0), elution temperature was 35°C, and flow rate was 1ml/min.

The products were detected using a fluorescent spectrum photometer FP-920 (JASCO Corporation) at excitation wavelength of 320 nm and emission wavelength of 400 nm.

Determination of the products were identified based on an index wherein elution time of a product is identical to that of a standard sugar chain.

The products were determined by comparing fluorescent intensities using pyridylaminated lactose as a standard.

The amount of reaction products was normalized based on the amount of transcription of each α 1,3-fucosyltransferase gene measured as described above, and the result was determined as activity.

Relative activity of each α 1,3-fucosyltransferase against each substrate was obtained, when the activity of human Fuc-TVII, to the substrate α 2,3-sialylLNnT as a substrate, was taken as 100.

Table 1 shows the results. For COS-1 cells, to which a control plasmid (pCDM8) had been introduced, no activity was detected when any substrates were used.

Table 1 Relative activity of α 1,3-fucosyltransferases for each substrate

Substrate	Mouse Fuc-TIX	Mouse Fuc-TIV	Human Fuc-TIII	Human Fuc-TVII
LNT	0	0	123.3	0
LNnT	83.8	51.6	32.3	63.7
α 2,3-sialyl LNnT	0	4.5	16.4	100

Mouse Fuc-TIX showed strong activity for LNnT only.

Human Fuc-TIII showed activity for all substrates, LNT, LNnT, and α 2,3-sialyl LNnT, with its strongest activity for LNT.

Mouse Fuc-TIV showed strong activity for LNnT, and weak activity for α 2,3-sialyl LNnT.

Human Fuc-TVI showed activity for α 2,3-sialyl LNnT and LNnT, with its strongest activity for α 2,3-sialyl LNnT.

Since *in vitro* substrate specificity of Fuc-TIX differs from the substrate specificity of any α 2,3-fucosyltransferases that had been purified or cloned so far, Fuc-TIX was proved to be an α 1,3-fucosyltransferase having novel substrate specificity.

In vitro substrate specificity of Fuc-TIX matched well with that of Fuc-TIX in the cells shown in Example 2. Moreover, comparison with other α 1,3-fucosyltransferases, revealed that Fuc-TIX showed strong activity to transfer fucose to GlcNAc residue of LNnT via α 1,3-linkage. Therefore, it was demonstrated that Fuc-TIX was useful to synthesize the Lewis x sugar chains.

Example 4 Expression of the Fuc-TIX gene in various organs

(1) Northern blot analysis

Poly (A) ⁺ RNA was isolated from each organ of a mouse (brain, thymus, stomach, liver, spleen, kidney, large intestine, uterus, ovary, lung, testis, small intestine, and epididymis) in the same manner as described in Example 1. Five μ g of the isolated Poly (A) ⁺ RNA was denatured by heating at 65°C for 5 minutes in a denaturation solution (50% (v/v) formamide, 2.2 M formaldehyde, 20 mM MOPS (3-(N-morpholino) propanesulfonate (pH 7.0), 5 mM sodium acetate, 1 mM EDTA), and then subjected to electrophoresis with 1% agarose gel containing 2.2 M formaldehyde.

After electrophoresis, the RNAs in the gel were blotted on a nitrocellulose filter (Optimal BA-S85; Schleicher & Schuell), and then fixed by heating under reduced pressure for 1 hour at 80°C.

The filter was dipped in a hybridization solution [5 x SSPE (750 mM NaCl, 50

mM NaH₂PO₄, 5 mM EDTA; pH 7.4), 5 x Denhart's solution (0.1% ficoll, 0.1% poly(vinyl)pyrrolidone, 0.1% bovine serum albumin), 1% SDS (sodium dodecyl sulfate), 0.2 mg/ml of salmon sperm DNA (Pharmacia Biotech)] to perform pre-hybridization.

After pre-hybridization, a probe was added to the solution, followed by hybridization at 65°C.

The probe used herein was prepared by labeling a *Hind*III-*Ase*I fragment containing ORF of mouse Fuc-TIX in pAMo-mFT9 with ³²P using a multi prime DNA labelling system (Amersham).

After hybridization, the filter was washed twice with 0.1 x SSC (15 mM NaCl, 1.5 mM sodium citrate) containing 0.1% SDS, followed by exposure of the filter to an imaging plate, by which bands of mouse Fuc-TIX mRNAs were detected using a Bio-imaging analyzer BAS2000 (FUJI PHOTO FILM CO.,LTD).

Two types of bands, 5.5- and 3.0-kb bands, were detected in brain and kidney, but no band was detected in other organs. Therefore, it was found that the Fuc-TIX gene was mainly expressed in kidney and brain. Figure 4 shows the result of Northern blot analysis for brain and kidney.

(2) Determination of Fuc-TIX transcripts in various organs using RT-PCR

Quantitative RT-PCR was conducted to determine the expression level of the Fuc-TIX gene in each organ.

The standard plasmid used to make a calibration curve was pBS-mFT9 which had been prepared by subcloning an approximately 1.8-kb *Hind*III-*Kpn*I fragment containing the Fuc-TIX cDNA of pAMo-mFT9 into between *Hind*III and *Kpn*I of a vector pBluescript SK(-).

pBS-mFT9d lacking 127 bp between *XcmI* and *Bpu1120I* in the Fuc-TIX cDNA was constructed by cleaving pBS-mFT9 with restriction enzymes *XcmI* and *Bpu1120I*, blunt-ending the product with T4 DNA polymerase, followed by re-ligation.

The resultant pBS-mFT9d was used as an internal control plasmid for normalization of samples in RT-PCR.

Mouse β -actin cDNA was obtained according to the method employed to obtain the mouse Fuc-TIV cDNA as described in Example 3. The mouse β -actin cDNA was used as control to be an index for cDNA synthesis.

Using single strand cDNAs derived from mRNA of mouse stomach as templates, PCR was performed with primers shown in SEQ ID NOS:10 and 11, thereby amplifying a mouse β -actin cDNA.

The primer of SEQ ID NO:10 used for the amplification had an *EcoRI* recognition sequence at its end; the primer of SEQ ID NO:11 had a *HindIII* recognition sequence at its end. The amplified fragments were excised with *EcoRI* and *HindIII*, subcloned into between *EcoRI* site and *HindIII* site of a vector pBluescript SK(-) to construct pBS-m β -actin as a standard plasmid for β -actin gene.

pBS-m β -actind lacking 208 bp between *MscI*-*BstEII* in the β -actin cDNA was constructed by excising pBS-m β -actin with restriction enzymes *MscI* and *BstEII*, blunt-ending the ends with T4 DNA polymerase, followed by re-ligation. The obtained pBS-m β -actind was used as an internal control plasmid.

For comparison, the distribution of expression of the mouse Fuc-TIV gene was also studied. pBS-mFT4 constructed in Example 3 was used as a standard plasmid.

Further, pBS-mFT4d lacking 168 bp between *Eco*NI-*Csp*45I in the mouse Fuc-TIV cDNA was constructed by excising pBS-mFT4 with restriction enzymes *Eco*NI and *Csp*45I, blunt-ending the ends with T4 DNA polymerase, followed by re-ligation. The resultant pBS-mFT4d was used as an internal control plasmid.

Total RNA was extracted from each tissue of an adult BALB/c mouse (brain, thymus, stomach, liver, spleen, kidney, large intestine, uterus, ovary, lung, heart, testis, small intestine and epididymis) by the acid guanidium thiocyanate phenol – chloroform method (Anal. Biochem. 162, 156-159).

Five units/ml each of deoxyribonuclease I (manufactured by Life Technologies) was added to 6 µg each of the total RNA and allowed to react for 5 minutes at room temperature.

After reaction, the enzyme was inactivated by heating the product for 15 minutes at 65°C.

cDNA was synthesized for each of the resulting total RNA by SUPERScript™ Preamplification System for First Strand cDNA System (Life Technologies) using oligo (dT) primers. After reaction in 20 µl of the reaction solution, the solution was diluted 50-fold with water and stored at –80°C until use.

PCR was performed using DNA polymerase AmpliTaq Gold™ (Parkin Elmer) in 50 µl of reaction solution [10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl₂, 0.2 mM dNTP, 0.001% (w/v) gelatin, 0.2 µM gene specific primer] containing 10 µl of the abovementioned cDNA derived from each tissue and 10 µl (10 fg) of the internal control plasmid.

The nucleotide sequences of Fuc-TIX specific primers are shown in SEQ ID

NOS: 12 and 13, those of β -actin specific primers are shown in SEQ ID NOS: 14 and 15, and those of Fuc-TIV specific primers are shown in SEQ ID NOS: 16 and 17.

Using these primers, a 530-bp fragment can be amplified for the Mouse Fuc-TIX cDNA, a 403-bp fragment from pBS-mFT9d, a 792-bp fragment for the β -actin cDNA, and a 584-bp fragment from pBS-m β -actind. Moreover, a 511-bp fragment can be amplified for the mouse Fuc-TIV cDNA, and a 343-bp fragment from pBS-mFT4d.

PCR reaction was performed by 38 to 42 cycles for Fuc-TIX and Fuc-TIV; 22 to 26 cycles for β -actin. Each of the reaction cycles consisted of heating for 11 minutes at 95°C, 1 minute at 95°C, 1 minute at 65°C, and then 2 minutes at 72°C.

After 10 μ l of the reaction solution was subjected to electrophoresis with 1% agarose gel, the gel was stained with ethidium bromide, and then photographed. The picture was then scanned by NIH image system to measure the intensity of the staining of the amplified fragments, thereby determining the level of amplification.

PCR was performed using 1.25 fg, 2.5 fg, 5 fg, 10 fg, 20 fg, or 40 fg of the standard plasmids instead of cDNA derived from the tissues. The amount of the amplified fragments was measured, then the amount of cDNA and the amount of the corresponding amplified fragment were plotted so as to make a calibration curve.

The amount of the cDNA in each of the tissues was calculated from the calibration curve and the amount of the fragments amplified with cDNA in each tissue, and the obtained the amount of the cDNA in each tissue is considered to be transcription level of mRNA in each tissue. Since the β -actin gene is thought to be generally expressed in each tissue, its expression level should be at the same level in any tissues. That is, differences in the expression level of the β -actin gene among the tissues may be due to differences in efficiency of the cDNA synthetic reaction. Therefore, the

expression level of the β -actin gene was also taken into consideration upon comparison of the expression level of the Fuc-TIX gene.

Figure 5 shows the results.

It was found that the Fuc-TIX gene is expressed most abundantly in kidney, followed by brain. Further, the Fuc-TIX gene was also expressed in stomach, large intestine, uterus, and epididymis. However, no expression was observed in thymus, liver, spleen, ovary, lung, heart, testis, and small intestine. The expression pattern of the mouse Fuc-TIX gene differed clearly from that of the mouse Fuc-TIV gene (see Fig. 5).

Example 5 Analysis of the expression pattern of the mouse Fuc-TIX gene in brain by *in situ* hybridization

A part of the mouse Fuc-TIX cDNA was amplified using primer sets whose nucleotide sequences are shown in SEQ ID NOS: 18 and 19. Then the amplified fragment was subcloned into a vector pCR3 for TA cloning (Invitrogen).

Similarly, a partial fragment of the mouse Fuc-TIX cDNA was amplified using other primer sets whose nucleotide sequences are shown in SEQ ID NOS:20 and 21, and then subcloned into pCR3.

After checking the directions of the amplified fragments in the plasmids, these plasmids were excised with *HindIII*. Next using digoxigenin-labeled mix (Boehringer Mannheim), *in vitro* transcription was conducted with SP6 RNA polymerase to make digoxigenin-labeled antisense or sense riboprobe. Whether a riboprobe is an antisense or sense riboprobe depends on the direction of the inserted fragment. Further, digoxigenin-labeled antisense or sense probe was made by *in vitro* transcription with T7 RNA polymerase in the same manner as described above, after excising these plasmids

with *Xho*I. Again, whether a riboprobe is an antisense or sense riboprobe depends on the direction of the inserted fragment.

The brain tissue of an adult BALB/c mouse was treated in 4% paraformaldehyde overnight to immobilize, then embedded in paraffin.

The brain tissue embedded in the paraffin was dissected into sections. Then the paraffin was removed from the sections, and the sections were hydrated.

The sections of the brain tissue were treated with 0.2 M hydrochloric acid for 20 minutes so as to inactivate alkaline phosphatase, which had originally been present in the tissue. Subsequently 4 µg/ml of protease K (Boehringer Mannheim) was added to the sections, and the mixture was allowed to react for 15 minutes at 37°C.

Next the sections were treated in 4% paraformaldehyde / PBS (w/v) for 10 minutes for immobilization, and immersed in 0.2% glycine / PBS (w/v) for 10 minutes to avoid non-specific staining.

After dehydrating the sections, the riboprobes were hybridized on the sections in a hybridization solution [50% formaldehyde, 10% dextran sulfate, 1 x Denhardt's solution, 10 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.6 M NaCl, 200 µg/ml yeast tRNA] for 16 hours at 50°C.

The sections were washed twice with 2 x SSC for 15 minutes at room temperature, then washed with 0.1 x SSC for 30 minutes at 50°C.

Signals showing the hybridization with the probes were detected using anti-digoxigenin antibodies and NBT/BCIP solution (Boehringer Mannheim).

Figure 6 shows an example of the results.

When anti-sense probes were used, staining of neuron cell bodies of the neurons in hippocampus were observed, that is, expression of Fuc-TIX mRNA was detected, whereas no expression was detected in glial cells.

On the other hand, when sense probes were used as negative control, no stained cells were observed

Accordingly, it was suggested that the mouse Fuc-TIX gene was expressed in cell bodies of the neurons, but not in the glial cells.

Example 6 Cloning of human Fuc-TIX chromosomal DNA

Human Fuc-TIX chromosomal DNA corresponding to mouse Fuc-TIX cDNA was cloned.

First, clones containing human Fuc-TIX chromosomal DNA were obtained by screening a human chromosomal DNA library (PAC library) with PCR using primers, specific to the mouse Fuc-TIX gene, whose nucleotide sequences are shown in SEQ ID NOS: 22 and 23.

Each of 405,504 clones derived from the PAC library was cultured, one clone per well, in 1,056 384-well plates (16 wells long, 24 wells wide). Next the 1,056 plates were piled: 12 plates long (X axis: 1 to 12), 8 plates wide (Y axis: A to H), and 11 plates high (Z axis: 1 to 11). Finally 88 pools were prepared by mixing all clones in each row of 12 plates in the X axis per (Z, Y) coordinates.

In addition, 132 pools were separately prepared by mixing all clones in each row of 8 plates in the direction of the Y axis per (Z, X) coordinates.

PCR was performed for the 88 pools using the above primers so as to find out which pools of the (Z, Y) coordinates used as templates resulted in the amplification of human Fuc-TIX gene fragments. As a result, clones containing the human Fuc-TIX gene were confirmed to be present in a pool of the (Z, Y) coordinates: (8, H).

Similarly, PCR was performed for 12 pools of the specified Z axis 8 containing coordinates (8, 1-12), which were selected from the above 132 pools. Thus clones containing the human Fuc-TIX gene were found to exist in a pool of the (Z, X) coordinates: (8, 12).

These results revealed that clones containing the human Fuc-TIX gene were present in a pool the (Z, Y, X) coordinates: (8, H, 12).

Each of 384 clones present on the plate of the specified coordinates (8, H, 12) was picked simultaneously with a needle point holder for 384-well (16 wells long, 24 wells wide) plate. Then the clones were inoculated both in a vertical slot plate consisting of 24 vertical slots (each of vertical 16 wells of a 384 well plate are connected, forming 24 vertical slots) and in a horizontal slot plate consisting of 16 horizontal slots (each of horizontal 24 wells of a 384 well plate are connected, forming 16 horizontal slots), both containing 2 x TY media; and cultured overnight.

Similarly, PCR was performed using 1 µl of culture fluid derived from each of the 40 types of slots as a template. Next the coordinates of an intersection of vertical and horizontal slots showing the amplification of human Fuc-TIX gene fragments were determined to specify the coordinates on which clones containing human Fuc-TIX genes were present.

A plasmid DNA was isolated from the clones of the specified coordinates,

excised with *Hind*III or *Eco*RI, then subjected to Southern hybridization using a mouse Fuc-TIX cDNA fragment as a probe. How to prepare the probe is as described below.

PCR was performed using the mouse Fuc-TIX cDNA as a template and primers shown in SEQ ID NOS: 24 and 25, thereby amplifying mouse Fuc-TIX cDNA fragments.

Subsequently, the fragment was labeled with ^{32}P using a multi prime DNA labeling system (Amersham) to make a probe.

As a result of Southern hybridization, an approximately 2.7-kb *Hind*III fragment and an approximately 1.5-kb *Eco*RI fragment hybridized to the mouse Fuc-TIX cDNA.

Based on the result of hybridization, it was deduced that these fragments had been derived from the human Fuc-TIX chromosome DNA. About the 2.7-kb *Hind* III fragment was subcloned into *Hind*III site of a vector pBluescript SK (-) to construct pBS-hgFT9H.

Further, about the 1.5-kb *Eco*RI fragment was subcloned into *Eco*RI site of a vector pBluescript SK (-), thereby constructing pBS-hgFT9E.

The nucleotide sequence of the human Fuc-TIX chromosomal DNA (2,822 bp) was determined by assembling the nucleotide sequences of pBS-hgFT9H and pBS-hgFT9E, which were determined in the same way as in Example 1. The obtained nucleotide sequence was shown in SEQ ID NO:4.

The human Fuc-TIX chromosome DNA possessed an ORF encoding a polypeptide consisting of 359 amino acids. This amino acid sequence showed 99.2% homology to that of mouse Fuc-TIX (as shown in SEQ ID NO:2): that is, 356 out of 359

amino acids were identical to each other. Therefore, it was concluded that a region of 1289th to 2368th in SEQ ID NO:4 was a nucleotide sequence encoding human Fuc-TIX with no intron.

The amino acid sequence of human Fuc-TIX is shown in SEQ ID NO:2.

Example 7 Cloning of human Fuc-TIX cDNA

cDNA was synthesized from Poly (A)⁺ RNA of human gastric mucosa using a cDNA synthesis system (manufactured by GIBCO BRL). An *EcoRI* – *NotI* – *SalI* adaptor (SuperScript Choice System for cDNA Synthesis; manufactured by GIBCO BRL) was added to the both ends. Next the product was inserted into *EcoRI* site of a cloning vector λ ZAP II (λ ZAP II / *EcoRI* / CIAP Cloning Kit, manufactured by STRATAGENE), followed by *in vitro* packaging with a Gigapack III Gold Packaging Extract (manufactured by Stratagene) to construct a cDNA library.

PCR was performed using the PAC clone containing the human Fuc-TIX chromosome DNA obtained in Example 6 as a template and primers shown in SEQ ID NOS:26 and 27, thereby amplifying human Fuc-TIX chromosome DNA fragments.

The fragments were labeled with ³²P using a multi prime DNA labeling system (Amersham) to make a probe.

Using the probe, plaque hybridization was performed for 5 x 10⁵ clones of the cDNA library constructed as described above.

In this hybridization, filters were washed twice in a buffer containing SSPE at a 2-fold concentration [SSPE at a 1-fold concentration contained 180 mM sodium chloride, 10 mM sodium dihydrogenphosphate, 1 mM ethylenediaminetetraacetic acid (EDTA), pH 7.4] and 0.1% SDS at 65°C by immersing in this buffer for 10 minutes,

washed once in a buffer containing SSPE at a 1-fold concentration and 0.1% SDS at 65°C by immersing in this buffer for 15 minutes, and washed twice in a buffer containing 0.2 x SSPE and 0.1% SDS at 65°C by immersing in this buffer for 10 minutes.

As a result of the plaque hybridization, four independent clones capable of hybridizing to the probe were obtained. Plasmids were obtained from each of the clones by *in vivo* excision according to Stratagene's manual, and subjected to analysis with restriction enzymes and determination of the nucleotide sequences.

Determination of the sequences revealed that one of the obtained plasmids, pBS-hFT9 (S2) contained about a 2.7-kb cDNA shown in SEQ ID NO:5.

The cDNA encoded a polypeptide having the same amino acid sequence (shown in SEQ ID NO:2) as that of the polypeptide encoded by human Fuc-TIX chromosome.

The *Escherichia coli* SOLR™ Strain / pBS-hFT9 (S2) containing pBS-hFT9 (S2) was deposited with National Institute of Bioscience and Human Technology, Agency of Industrial Science and Technology (1-3, Higashi 1-chome, Tsukuba-shi, Ibaraki-ken, Japan) on July 10, 1998; and the assigned accession number was FERM BP-6416.

Figure 7 shows the structure of pBS-hFT9 (S2).

Example 8 Generation of Fuc-TIX gene knockout mouse

(1) Isolation of mouse Fuc-TIX gene

λFIXII/129 genomic library (manufactured by Stratagene) was screened by plaque hybridization using the probe used in Example 4 (1). Thus about 6×10^4 clones were screened to detect four positive clones.

After the second and the third screening, respective single clones were obtained. Then PCR was performed using a primer (CB-55) having the nucleotide sequence represented by SEQ ID NO:12 and a primer (CB-56) having the nucleotide sequence represented by SEQ ID NO:13, both specific to mouse Fuc-TIX gene, followed by analysis with cleavage by restriction enzymes. Thus it was confirmed that the four clones were all identical to each other and each contained the whole coding region and the whole 3' un-translated region of the Fuc-TIX cDNA. This phage clone is called λ MFT9-31.

λ MFT9-31 DNA was digested with *SalI* to prepare chromosomal DNA containing the Fuc-TIX gene. The chromosomal DNA was subcloned into *SalI* site of pBluescript SK-, thereby constructing a plasmid pFut9WT-129.

The chromosomal DNA containing the Fuc-TIX gene was about 20 kb in length. The nucleotide sequence of the chromosomal DNA was determined. The chromosomal DNA contained part of intron 2 of the mouse Fuc-TIX gene (about 4-kb), exon 3 of the mouse Fuc-TIX gene (consisting of 8-bp 5' non-translation region, the whole coding region, and the whole 3' untranslated region), and about 14-kb chromosome region following the exon 3. The structure of the chromosomal DNA in the plasmid pFut9WT-129 is shown in Fig. 8. Further, the clone contained almost no 5' untranslated region region.

The following experiments were conducted to obtain 5' untranslated region of the gene.

A DNA fragment containing 5' untranslated region of mouse Fuc-TIX cDNA was obtained using 5' RACE method. λ FIXII/129 genomic library was screened using the DNA as a probe to obtain two independent positive clones (hereinafter referred to as λ MFT9-11 and λ MFT9-25).

Chromosomal DNAs containing Fuc-TIX gene were excised from DNAs derived from λ MFT9-11 and λ MFT9-25 by digestion with *SalI*, and were subcloned respectively into *SalI* site of pBluescript SK(-). The chromosomal DNAs contained in λ MFT9-11 and λ MFT9-25 were about 12 kb and about 16 kb in length, respectively. As a result of determination of the nucleotide sequences, it was shown that λ MFT9-11 and λ MFT9-25 contained exon 1 and exon 2, respectively.

These results revealed that the mouse Fuc-TIX gene consisted of three exons. The sequences of exon/intron boundary sites followed the GT-AG rule. The upstream region of exon 1 was thought to contain a promoter region of the mouse Fuc-TIX gene. The sequences of exons 1 to 3, and the nucleotide sequence of the region upstream of exon 1 expected to contain the promoter region, are shown in SEQ ID NOS:28 to 31, respectively. The structure of the mouse Fuc-TIX gene is shown in Fig. 9.

The chromosomal localization of the mouse Fuc-TIX gene (which was shown as *Fut 9* in Fig. 10) was examined by PCR using interspecific backcross DNA panel as a template according to a conventional method (Mamm. Genome, 5, 253, 1994).

DNA having a nucleotide sequence represented by SEQ ID NO:13 (CB-56) and DNA having a nucleotide sequence represented by SEQ ID NO:32 (CB-197) were used as primers (See Fig. 8). CB-197 is a primer set in intron 2.

PCR reaction was performed by 35 cycles, each consisting of 1 minute at 94°C, 1 minute at 64°C, and 3 minutes at 72°C; using 50 μ l of a reaction solution panel [10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl₂, 0.2 mM dNTP, 0.001% (w/v) gelatin, 0.2 μ M gene specific primers, 1 μ l of DNA polymerase AmpliTaq Gold™ (Perkin Elmer)] containing chromosomal DNA (10 ng) of interspecific backcross DNA.

As a result of this PCR, it was shown that the mouse Fuc-TIX gene was located on the chromosome 4 (Fig. 10) and present neighboring to marker genes (*Aop2-rs2*, *D4Ert519e*, *D4Ert582e*). Moreover, the mouse Fuc-TIX gene was located 1.1 ± 1.1 cM distal to D4Mit149 than the marker gene *D4Ert389e* and 4.25 ± 2.1 cM proximal to *D4Abble*.

(2) Construction of a targeting vector for homologous recombination

The 3' half of the coding region and the whole 3' untranslated region of the mouse Fuc-TIX gene were replaced by a neomycin-resistant gene to make a targeting vector pFut9F[tkneo] for generating a knockout mouse lacking the mouse Fuc-TIX gene as described below (Figs. 8 and 11).

The chromosomal DNA containing the Fuc-TIX gene, which was inserted in the plasmid pFut9WT-129, was separated to three fragments (B1, B2, and B3), and each fragment was subcloned.

A *Bam*HI fragment (about 1.8 kb) was prepared by digestion of the plasmid pFut9WT-129 with *Bam*HI. The fragment was inserted into *Bam*HI site of pBluescript SK(-) to construct a plasmid pB1.

A *Bam*HI fragment (about 6.0 kb) was prepared by digestion of the plasmid pFut9WT-129 was excised with *Bam*HI. The fragment was inserted into *Bam*HI site of pBluescript SK(-) to construct a plasmid pB2.

A *Bam*HI fragment (15 kb) was prepared by digestion of the plasmid pFut9wt-129 with *Bam*HI. The ends of this fragment were joined to form a ring, constructing a plasmid pB3.

Using the resulting pB2, the 3' half of the coding region and the whole 3'

untranslated region of the mouse Fuc-TIX gene were replaced by a neomycin-resistant gene to construct a plasmid pB2-Neo.

The plasmid pB2 was cleaved with *Xho*I, thereby obtaining a 9.0-kb *Xho*I fragment. The DNA fragment was treated with DNA polymerase Klenow fragment for blunting the *Xho*I-cleaved ends, followed by self-ligation to construct a plasmid pB2 lacking *Xho*I cleavage site.

The plasmid was partially digested with *Sac*I, thereby obtaining *Sac*I fragment (about 6.0-kb). The DNA fragment was treated with DNA polymerase Klenow fragment for blunting the *Sac*I-cleaved ends, and self-ligated after addition of *Xho*I linkers to construct pB2-*Xho*I.

pB2-*Xho*I was excised with *Xho*I, thereby obtaining a 6.1-kb *Xho*I fragment. In addition, pMC1NeopolyA (manufactured by Stratagene) was excised with *Xho*I and *Sal*I, obtaining a 1.2-kb *Xho*I – *Sal*I fragment containing a neomycin-resistant gene. The 6.1-kb *Xho*I fragment derived from pB2-*Xho*I and the 1.2-kb *Xho*I – *Sal*I fragment derived from pMC1NeopolyA were ligated to construct a plasmid pB2-Neo.

Moreover, a thymidine kinase gene, which is a marker for negative selection, was ligated to the 3' terminal of the B3 fragment in pB3 to construct a plasmid pBS as described below.

pB3 was cleaved with *Xho*I, thereby obtaining a 15-kb *Xho*I fragment. In addition, a plasmid MC-1-TK (Nature, 336, 348, 1988) was cleaved with *Xho*I and *Sal*I to prepare a 1.8-kb *Xho*I – *Sal*I fragment containing a thymidine kinase gene. The 15-kb *Xho*I fragment derived from pB3 and the 1.8-kb *Xho*I – *Sal*I fragment derived from MC-1-TK were ligated to make a plasmid pB3-tk.

pB2-Neo and pB3-tk, both constructed as described above, were excised with *Bam*HI, obtaining a 4.0-kb *Bam*HI fragment and a 17-kb *Bam*HI fragment, respectively. The 4.0-kb *Bam*HI fragment derived from pB2-Neo and the 17-kb *Bam*HI fragment derived from pB3-tk were ligated to construct a plasmid pFut9F[tkneo].

(3) Preparation of homologously recombined embryonic stem cell (ES cell) clones

The plasmid pFut9F[tkneo] constructed in (2) above was cleaved with *Not*I. The resulting DNA fragment (25 µg) was mixed with 0.8 ml of ES cells that had been prepared with PBS to 2.5×10^7 cells/ml.

The *Not*I-cleaved DNA fragment was introduced into ES cells by electroporation using a Gene Pulser (manufactured by BioRad) under conditions of 0.35 kV and 950 µF.

The ES cells were inoculated 1×10^7 cells per 10 cm culture dish on which feeder cells had previously been inoculated. Then the cells were cultured in 15% FBS-DMEM media containing 10^3 units/ml of ESGRO (manufactured by GIBCO), 100 mM β-mercaptoethanol, 100 units/ml of penicillin (manufactured by GIBCO), and 100 µg/ml of streptomycin (manufactured by GIBCO). From day 2, 200 µg/ml of G418 (manufactured by GIBCO) and 2 µM Gancyclovir (manufactured by Syntex) were added to the media, followed by selection of cells with introduced genes.

Colonies appeared 8 to 10 days after starting the selection were isolated. A total of 144 types of ES cell clones were isolated. Next, chromosomal DNAs were isolated from 39 types of the ES cells according to a conventional method, and then cells containing the targeting vectors integrated by homologous recombination were selected by PCR.

Chromosomal DNAs were isolated as described below.

The cells cultured in a 24-well plate were lysed by adding 500 µl of a lysis buffer [10 mM Tris-HCl (pH 7.8), 1 mM EDTA, 0.1 M NaCl, 0.1% SDS], followed by phenol extraction and ethanol precipitation to isolate chromosomal DNAs.

PCR was performed using DNA (CB-197) having a nucleotide sequence shown in SEQ ID NO:32 that had been set in the region upstream of the mouse Fuc-TIX gene inserted in the targeting vector, and DNA (CB-199) having a nucleotide sequence shown in SEQ ID NO:33 that had been set in neomycin-resistant gene as primers (See Fig. 8).

PCR was performed under the following conditions.

That is, PCR was performed by 30 cycles, each consisting of heating at 94°C for 1 minute, at 98°C for 20 seconds, at 68°C for 8 minutes; using 50 µl of a reaction solution [1 x LA PCR™ buffer II (Mg²⁺ free), 2.5 mM MgCl₂, dNTPs (0.4 mM each), the above primer (0.2 µM each), 2 units of Takara LA Taq™] containing the chromosomal DNA isolated from the ES cells.

As for ES cells in which the latter half of the exon 3 of the mouse Fuc-TIX gene is disrupted by homologous recombination of the mouse Fuc-TIX gene and the targeting vector, about a DNA fragment (about 3 kb) would be amplified. Analysis of the 39 types of the ES cell clones confirmed the amplification of the about 3-kb DNA fragment in 3 types of the ES cell clones. Therefore, it was concluded that in these 3 types of the ES cell clones, the mouse Fuc-TIX gene was disrupted as expected.

(4) Generation of knockout mouse lacking the mouse Fuc-TIX gene

The uterus was excised from C57BL/6 mice (4 weeks old female) on day 3.5 after crossing, followed by collection of blastocysts. The 3 types of the ES cells having the

disrupted mouse Fuc-TIX gene were introduced respectively into the blastocysts (about 15 ES cells per blastocyst) using a micromanipulator. Subsequently the blastocysts were transplanted, to the both sides of the uterus (10 blastocysts per side) of surrogate mice (ICR) in which false pregnancy had been induced.

Consequently, 95 progeny were obtained, 44 of which (31 male mice, 13 female mice) were determined to be chimeric mice based on their coat color. Heterozygous mice were obtained by crossing these chimeric mice with normal C57BL/6 mice, followed by crossing these hetero mice with each other, thereby obtaining knockout mice.

Chromosomal DNAs were extracted from tails of the progeny obtained by crossing the heterozygous mice, and subjected to PCR to determine the genetic type.

Long PCR was performed using simultaneously primers CB-197 and CB-199, and DNA (CB-280) having a nucleotide sequence shown in SEQ ID NO:34 (See Fig. 8). As for wild type mice, only an approximately 3.5-kb band that is amplified by CB-197 and CB-280 was detected; as for mice with the deficient Fuc-TIX gene homozygously, only an approximately 3.0-kb band that is amplified by CB-197 and CB-199 was detected; as for heterozygous mice, both of the approximately 3.5-kb band that is amplified by CB-197 and CB-280, and the approximately 3.0-kb band that is amplified by CB-197 and CB-199 were detected.

Fig. 12 shows an example of the result of PCR analysis. The No. 5 mouse was demonstrated to be a mouse with the deficient Fuc-TIX gene (Fuc-TIX gene knockout mouse).

Thirty-four progeny were obtained by crossing the heterozygous mice. The progeny consisted of 11 wild type mice, 17 heterozygous mice, and 6 Fuc-TIX gene

knockout mice (4 male and 2 female mice).

The Fuc-TIX gene knockout mice are extremely useful in analysis of physiological and pathological functions of the Fuc-TIX gene.

Example 9 Analysis of reaction specificity of Fuc-TIX

Poly-N-acetyllactosamine sugar chain is a sugar chain with the structure having N-acetyllactosamine as repeating unit bound via a β 1, 3- linkage [(Gal β 1-4GlcNAc β 1-3)_n; n represents 2 or more], and appears not only in N-glycoside linked and O-glycoside linked sugar chains of glycoproteins, but also in sugar chains of glycolipids and in oligosaccharides.

Using a poly-N-acetyllactosamine sugar chain, it was examined that to which GlcNAc in the sugar chains, human Fuc-TIX and 5 types of human α 1,3-fucosyltransferase (Fuc-TIII, Fuc-TIV, Fuc-TV, Fuc-TVI, and Fuc-TVII) that had been cloned so far transferred fucose.

pBS-hFT9(S2) obtained in Example 7 was excised with *Pst*I and *Hind*III, followed by blunt-ending with DNA polymerase Klenow fragment. After blunt ending, *Sfi*I linkers prepared in Example 1 (2) were added to the product, thereby obtaining a fragment of about 1.6 kb.

The expression vector pAMo was cleaved with *Sfi*I, obtaining an approximately 8.7-kb *Sfi*I fragment.

The fragment of the about 1.6 kb derived from pBS-hFT9(S2) and the *Sfi*I fragment of about 8.7 kb derived from pAMo were ligated to make pAMo-FT9, an expression plasmid for human Fuc-TIX.

Control plasmid (pAMo) and the human Fuc-TIX expression plasmid pAMo-FT9 were introduced into Namalwa cells according to the method shown in Example 1 (3), thereby obtaining stable transformants.

Namalwa cells expressing each of the other 5 types of human α 1,3-fucosyltransferases (Fuc-TIII, Fuc-TIV, Fuc-TV, Fuc-TVI, and Fuc-TVII) were obtained according to the previous report (Glycoconjugate J., 13, 802-812, Biochem. Biophys. Res. Commun., 237, 131-137, 1997).

The resultant transformants (about 1×10^7) were collected in microtubes (1.5 ml, manufactured by Eppendorf), followed by centrifugation at $550 \times g$ for 7 minutes to collect the cells.

The collected cells were washed with 0.9 ml of PBS. The washed cells were suspended in 100 μ l of a solution which consisted of 20 mM HEPES (pH 7.2) and 1% TrironX-100, then allowed to stand at 4°C for 10 minutes. Subsequently the cells were disrupted using a ultrasonicator (Bioruptor; manufactured by COSMO BIO CO., LTD.)

After disruption of the cells, each supernatant was obtained by centrifugation at $550 \times g$ for 7 minutes and used as an enzyme sample.

A poly-N-acetyllactosamine sugar chain ($\text{Gal}\beta 1\text{-4GlcNAc}\beta 1\text{-3 Gal}\beta 1\text{-4GlcNAc}\beta 1\text{-3Gal}\beta 1\text{-4GlcNAc}$) consisting of 6 sugars was fluorescently labeled with 2-aminobenzamide to make a sugar chain ($\text{Gal}\beta 1\text{-4GlcNAc}\beta 1\text{-3Gal}\beta 1\text{-4GlcNAc}\beta 1\text{-3Gal}\beta 1\text{-4GlcNAc-2AB}$: abbreviated as S in Figs. 13 and 15, and table 3), which was used as a substrate

Florescent labeling was performed using a Signal™ 2-AB glycan labeling kit (manufactured by Oxford GlycoScience). A poly-N-acetyllactosamine sugar chain (Gal β 1-4GlcNAc β 1-3Gal β 1-4GlcNAc β 1-3Gal β 1-4GlcNAc) was prepared according to WO98/03524.

The activity was measured as follows.

Samples were allowed to react in 20 μ l of an assay solution [50 mM cacodylate (pH 6.8), 5 mM ATP, 10 mM L-fucose, 75 μ M UDP-Fuc (manufactured by SIGMA), 25 mM MnCl₂, 15 μ M fluorescently labeled sugar chain substrate, 6 μ l of the cell lysate above] at 37°C for 2 hours, followed by treatment at 100°C for 3 minutes to stop the reaction. Next 200 μ l of water was added to the samples, and the supernatant was obtained by centrifugation at 10,000 x g for 5 minutes. Using an aliquot of the supernatant (10 μ l), products were analyzed by HPLC under the following conditions.

HPLC:

Column – TSK-gel ODS-80TsQA column (4.6 x 250 mm; TOSOH CORPORATION)

Eluate – 0.02 M ammonium acetate (pH 4.0) containing 7% methanol

Elution temperature – 50°C

Flow rate – 1.0 ml/min.

Detection – Fluorescence spectrum photometer FB-920 (manufactured by JASCO Corporation) (excitation wavelength: 330 nm, radiation wavelength: 420 nm)

An example of the result of HPLC analysis is shown in Fig. 13. In Fig. 13 (a), an extract derived from the cells containing control plasmid introduced thereto was used as an enzyme sample; in Fig. 13 (b), an extract derived from the cells expressing Fuc-TIV was used as an enzyme sample; and in Fig. 13 (c), an extract derived from the cells expressing Fuc-TIX was used as an enzyme sample.

It was shown that three types of products (P1, P2 and P3) were produced when the extract derived from the cells expressing Fuc-TIV or Fuc-TIX was used as an enzyme sample.

Fluorescent labeling with 2-aminobenzamide resulted in ring opening of the reduced terminal GlcNAc, so that possible products were the following three types:

Gal β 1-4(Fuc α 1-3)GlcNAc β 1-3Gal β 1-4GlcNAc β 1-3Gal β 1-4GlcNAc-2AB, Gal β 1-4GlcNAc β 1-3Gal β 1-4(Fuc α 1-3)GlcNAc β 1-3Gal β 1-4GlcNAc-2AB, and Gal β 1-4(Fuc α 1-3)GlcNAc β 1-3Gal β 1-4(Fuc α 1-3)GlcNAc β 1-3Gal β 1-4GlcNAc-2AB.

Structure of the products was confirmed in the manner as described below.

Each product (P1, P2 or P3) was collected and dried completely using SpeedVac (manufactured by SAVANT). Subsequently the dried product was dissolved in water, followed by centrifugation to remove insoluble fraction, then subjected to the following analysis.

The molecular weight of each of the products (P1, P2 and P3) were compared by HPLC analyzing under the following conditions.

HPLC:

Column – GlycoSep™ N HPLC column (4.6 x 250 mm, manufactured by Oxford GlycoScience)

Eluate – 0.25 M ammonium formate buffer (pH 4.4) containing 65% acetonitrile

Elution temperature – 30°C

Flow rate – 1.0 ml/min.

Detection – Fluorescence spectrum photometer FP-920 (manufactured by

JASCO Corporation) (excitation wavelength: 330 nm, radiation wavelength: 420 nm)

Molecular weight marker – glucose homo polymer fluorescently labeled with 2-aminobenzamide (manufactured by Oxford GlycoScience)

The results are shown in Figs. 14 (a) to (c).

P1 and P2 were eluted at the same position (see Figs. 14 (a) and (b)). Based on the elution time of P3, it was demonstrated that P3 was larger than P1 or P2 by about one glucose (See Fig. 14 (c)).

Accordingly, P1 and P2 were thought to correspond to either Gal β 1-4(Fuc α 1-3)GlcNAc β 1-3Gal β 1-4GlcNAc β 1-3Gal β 1-4GlcNAc-2AB or Gal β 1-4GlcNAc β 1-3Gal β 1-4(Fuc α 1-3)GlcNAc β 1-3Gal β 1-4GlcNAc-2AB and P3 to correspond to Gal β 1-4(Fuc α 1-3)GlcNAc β 1-3Gal β 1-4(Fuc α 1-3)GlcNAc β 1-3Gal β 1-4GlcNAc-2AB.

Each of the collected products (P1, P2 and P3) was treated in 50 mM sodium citrate buffer (pH 3.5) containing 300 mU/ml of Jack bean β -galactosidase (manufactured by Oxford GlycoScience) at 37°C for 15 hours. Then the reaction solution was analyzed by HPLC using a GlycoSep™ N HPLC column (4.6 x 250 mm; manufactured by Oxford GlycoScience) in the same manner as described above.

The results are shown in Figs. 14 (d) to (f).

The elution positions of the products P1 and P3 were not changed before and after the treatment with Jack bean β -galactosidase (see Figs. 14 (a) and (d), or (c) and (f)). However, the product P2 showed a decrease in molecular weight by about one glucose after treatment with Jack bean β -galactosidase (see Figs. 14 (b) and (e)). These results suggested that the structure of the product P2 was Gal β 1-4GlcNAc β 1-3Gal β 1-4(Fuc α 1-3)GlcNAc β 1-3Gal β 1-4GlcNAc-2AB. Therefore, it was concluded that the

structure of the product P1 was Gal β 1-4(Fuc α 1-3) GlcNAc β 1-3Gal β 1-4GlcNAc β 1-3Gal β 1-4GlcNAc-2AB.

Various types of glycosidase were used to confirm the structure configurations of the products in detail.

Each of the collected products (P1, P2 and P3) was treated in 50 mM sodium citrate buffer (pH 5.0) containing 0.2 mU/ml of almond meal α 1,3/4-fucosidase (manufactured by Oxford GlycoScience) at 37°C for 15 hours. Then the reaction solution was analyzed by HPLC using a TSK-gel ODS-80Ts QA column (4.6 x 250 mm; TOSOH CORPORATION) in the same manner as described above (Fig. 15).

As a result, the elution position of the product P1 changed before and after treatment with almond meal α 1,3/4-fucosidase (see Figs. 15 (a) and (b)), and the elution position after treatment with the enzyme was same as that of the substrate (see Figs. 15 (b) and (c)).

The elution position of the product P2 remained unchanged before and after treatment with almond meal α 1,3/4-fucosidase (see Figs. 15 (d) and (e)).

The elution position of the product P3 changed before and after treatment with almond meal α 1,3/4-fucosidase (see Figs. 15 (j) and (k)), and the elution position after treatment with the enzyme was same as that of the product P2 (see Figs. 15 (k) and (d)).

These results indicated that the structure of the products P1, P2 and P3 were Gal β 1-4(Fuc α 1-3)GlcNAc β 1-3Gal β 1-4GlcNAc β 1-3Gal β 1-4GlcNAc-2AB, Gal β 1-4GlcNAc β 1-3Gal β 1-4(Fuc α 1-3) GlcNAc β 1-3Gal β 1-4GlcNAc-2AB, and Gal β 1-4(Fuc α 1-3)GlcNAc β 1-3Gal β 1-4(Fuc α 1-3) GlcNAc β 1-3Gal β 1-4GlcNAc-2AB, respectively.

To further confirm the structure of the product P2, the product P2 was treated in order with Jack bean β -galactosidase, Jack bean β -N-acetylhexosaminidase, and almond meal α 1,3/4-fucosidase. Then the reaction solution was analyzed by HPLC using a TSK-gel ODS-80TsQA column (4.6 x 250 mm, TOSOH CORPORATION) under the same conditions as described above.

The product P2 was treated in 50 mM sodium citrate buffer (pH 5.0) containing 600 mU/ml of Jack bean β -galactosidase (manufactured by Oxford GlycoScience) at 37°C for 15 hours, followed by treatment at 100°C for 5 minutes to stop the reaction.

Ten U/ml of Jack bean β -N-acetylhexosaminidase (manufactured by Oxford GlycoScience) was added to an aliquot of the resulting reaction solution, and allowed to react at 37°C for 15 hours, followed by treatment at 100°C for 5 minutes to stop the reaction.

Moreover 0.2 mU/ml of almond meal α 1,3/4-fucosidase (manufactured by Oxford GlycoScience) was added to the resultant reaction solution, and allowed to react at 37°C for 15 hours, followed by treatment at 100°C for 5 minutes to stop the reaction.

Figure 15 (f) shows the HPLC pattern obtained when the product P2 was treated only with Jack bean β -galactosidase; Fig. 15 (g) shows the HPLC pattern when the product P2 was treated in order with Jack bean β -galactosidase and Jack bean β -N-acetylhexosaminidase; and Fig. 15 (h) shows the HPLC pattern when the product P2 was treated in order with Jack bean β -galactosidase, Jack bean β -N-acetylhexosaminidase, and almond meal α 1,3/4-fucosidase.

The elution position of the product P2 treated in order with Jack bean β -galactosidase, Jack bean β -N-acetylhexosaminidase, and almond meal α 1,3/4-

fucosidase (See Fig. 15 (h)) was the same as that of a sugar chain (Gal β 1-4GlcNAc β 1-3Gal β 1-4GlcNAc-2AB), which was prepared from a poly-N-acetyllactosamine sugar chain consisting of 4 sugars (Gal β 1-4GlcNAc β 1-3Gal β 1-4GlcNAc) by fluorescent labeling with 2-aminobenzamide (see Fig. 15 (i)).

Therefore, it was confirmed that the structure of the product P2 was Gal β 1-4GlcNAc β 1-3Gal β 1-4(Fuc α 1-3)GlcNAc β 1-3Gal β 1-4GlcNAc-2AB.

The poly-N-acetyllactosamine sugar chain consisting of 4 sugars was prepared by fluorescent labeling using SignalTM 2-AB glycan labelling kit (manufactured by Oxford GlycoScience) according to WO98/03524.

After treatment with almond meal α 1,3/4-fucosidase, the product P3 was treated in order with Jack bean β -galactosidase, Jack bean β -N-acetylhexosaminidase and almond meal α 1,3/4-fucosidase under the same conditions as that employed for the product P2. Therefore, it was confirmed that the structure of P3 was Gal β 1-4(Fuc α 1-3)GlcNAc β 1-3Gal β 1-4(Fuc α 1-3)GlcNAc β 1-3Gal β 1-4GlcNAc-2AB.

The enzyme reaction was performed using the poly-N-acetyllactosamine sugar chain (S) as a substrate. When an extract derived from Namalwa cells expressing Fuc-TIV was used as an enzyme, the major product was P2 (the VIM-2 sugar chain) (see Fig. 13 (b) and Table 2); and when an extract derived from Namalwa cells expressing Fuc-TIX was used as an enzyme, the major product was P1 (the Le^x sugar chain) (see Fig. 13 (c) and Table 2).

Similar analysis revealed that when an extract derived from Namalwa cells expressing Fuc-TIII, Fuc-TV, or Fuc-TVI was used as an enzyme, the major product was P2 (VIM 2 sugar chain) (Table 2). The use of an extract derived from Namalwa cells expressing Fuc-TVII as an enzyme resulted in no product (Table 2).

Table 2. Enzyme activity for a Poly-N-acetyllactosamine sugar chain

Enzyme	Production (%)		
	P1	P2	P3
Fuc-TIII	2.0	98.0	0.0
Fuc-TIV	22.2	72.0	5.8
Fuc-TV	7.5	92.5	0.0
Fuc-TVI	8.3	88.7	3.0
Fuc-TVII	0.0	0.0	0.0
Fuc-TIX	82.7	13.4	3.9

The production of each of the products is shown as a relative value when total amount of products (P1, P2 and P3) produced by each enzyme is assumed to be 100 %.

These results demonstrated that Fuc-TIII, Fuc-TIV, Fuc-TV, and Fuc-TVI fucosylated the inner GlcNAc residue in the poly-N-acetyllactosamine sugar chain, and had strong activity to synthesize VIM-2 sugar chain synthesis; whereas Fuc-TIX fucosylated to the distal GlcNAc residue, and had strong activity to synthesize the Le^x sugar chain. Fuc-TIX was shown to be α 1,3-fucosyltransferase having activity clearly different from that of other an α 1,3-fucosyltransferase. Furthermore, it was found that the Le^x sugar chain can be efficiently synthesized on the terminal of the poly-N-acetyllactosamine sugar chain using Fuc-TIX.

The enzymatic activities of Fuc-TIV, Fuc-TVI and Fuc-TIX were measured using the product P1 or P2 as a substrate in addition to the above substrate (S).

Table 3 shows the results.

Fuc-TIV and Fuc-TVI synthesized the product P3 using the product P1 as a good substrate, while Fuc-TIX synthesized the product P3 using the product P2 as a good substrate.

Therefore, it was concluded that the product P3 (the dimeric Le^x sugar chain) was efficiently produced by cooperation of Fuc-TIX and the other α 1,3-fucosyltransferases

(for example, Fuc-TIV or Fuc-TVI).

Table 3. Enzymatic activity for the Poly-N-acetyllactosamine sugar chain and the Monofucosylpoly-N-acetyllactosamine sugar chains

Substrate	Product	Fuc-TIV	Fuc-TVI	Fuc-TIX
S	P1	1.6	2.3	7.2
S	P2	4.1	16.4	1.6
S	P3	0.5	0.8	0.7
P1	P3	2.8	7.6	1.0
P2	P3	1.0	1.0	5.0

Enzymatic activities of Fuc-TIV and of Fuc-TVI are shown as relative activities with the activity for P2 assumed to be 1. Enzymatic activity of Fuc-TIX is shown as relative activity with the activity for P1 assumed to be 1.

Example 10 Synthesis of the VIM-2 sugar chain in human culture cells transfected with a human Fuc-TIX expression plasmid.

Using an anti-VIM-2 sugar chain antibody (anti-CDw65 antibody, manufactured by Serotec) and anti-Le^x sugar chain antibodies [73-30 (manufactured by SEIKAGAKU CORPORATION) and anti-CD15 antibody (C3D-1, manufactured by Dako)], indirect fluorescent antibody staining was performed for Namalwa cells expressing human Fuc-TIV or human Fuc-TIX, and for Namalwa cells transfected with the control vector pAMo, which were constructed in Example 9. The VIM-2 sugar chain is a sugar chain having the structure consisting of Gal β 1-4GlcNAc β 1-3Gal β 1-4(Fuc α 1-3) GlcNAc on non-reduced terminal of a sugar chain.

Indirect fluorescent antibody staining was performed according to the method described in Example 1 (3). Anti-VIM-2 sugar chain antibodies, 73-30 and C3D-1 were used after dilution at 1:50, 1:100, and 1:50.

Fig. 16 shows the results.

Namalwa cells expressing Fuc-TIV showed a significant increase in reactivity against the anti-VIM-2 sugar chain antibody compared to Namalwa cells transfected with pAMo, whereas Namalwa cells expressing Fuc-TIX showed a slight increase in reactivity against the antibody. In contrast, reactivity against the anti-Le^x sugar chain antibodies [73-30 and anti-CD15 antibody] was greater for Namalwa cells expressing Fuc-TIX than those expressing Fuc-TIV.

These results demonstrated that Fuc-TIV had possessed strong activity for synthesizing VIM-2 sugar chain in the transformed cells. Further, Fuc-TIX was found to have strong activity for synthesizing Le^x sugar chain, but weak activity for VIM-2 sugar chain synthesis in the transformed cells. These results are well consistent with the data of *in vitro* activity in Example 9.

It was shown that reaction specificity of Fuc-TIV and Fuc-TIX in the cells were also different from each other evidently.

Industrial Applicability

This invention relates to a novel polypeptide having an α 1,3-fucosyltransferase activity with a novel substrate specificity, that is characterized by the activity to synthesize the Lewis x sugar chains and Lewis y sugar chains, but not the sialyl Lewis x sugar chains; a method for producing the polypeptide; a DNA encoding the polypeptide; a method for producing the DNA; a recombinant vector obtained by inserting the DNA thereto; a transformant having the recombinant vector; an antibody recognizing the polypeptide; a method for determining or immunostaining the polypeptide of the present invention using the antibody; a method for producing a fucose-containing sugar chain using the polypeptide; a method for producing a fucose-containing sugar chain using the transformant containing the recombinant vector; a method for screening a substance that changes the expression of a gene encoding the

polypeptide; a method for screening a substance that changes the activity of the polypeptide; a method for diagnosing diseases, such as encephalopathy, renal diseases, cancers, and so on using the DNA or the antibody; and a therapy for diseases, such as encephalopathy, renal diseases, cancers, and so on using the DNA, a substance that changes the expression of a gene encoding, the polypeptide, or a substance that changes the activity of the polypeptide.

Sequence Listing Free Text

SEQ ID NO:6 – explanation of artificial sequence: synthetic DNA
SEQ ID NO:7 – explanation of artificial sequence: synthetic DNA
SEQ ID NO:8 – explanation of artificial sequence: synthetic DNA
SEQ ID NO:9 – explanation of artificial sequence: synthetic DNA
SEQ ID NO:10 – explanation of artificial sequence: synthetic DNA
SEQ ID NO:11 – explanation of artificial sequence: synthetic DNA
SEQ ID NO:12 – explanation of artificial sequence: synthetic DNA
SEQ ID NO:13 – explanation of artificial sequence: synthetic DNA
SEQ ID NO:14 – explanation of artificial sequence: synthetic DNA
SEQ ID NO:15 – explanation of artificial sequence: synthetic DNA
SEQ ID NO:16 – explanation of artificial sequence: synthetic DNA
SEQ ID NO:17 – explanation of artificial sequence: synthetic DNA
SEQ ID NO:18 – explanation of artificial sequence: synthetic DNA
SEQ ID NO:19 – explanation of artificial sequence: synthetic DNA
SEQ ID NO:20 – explanation of artificial sequence: synthetic DNA
SEQ ID NO:21 – explanation of artificial sequence: synthetic DNA
SEQ ID NO:22 – explanation of artificial sequence: synthetic DNA
SEQ ID NO:23 – explanation of artificial sequence: synthetic DNA
SEQ ID NO:24 – explanation of artificial sequence: synthetic DNA

SEQ ID NO:25 – explanation of artificial sequence: synthetic DNA

SEQ ID NO:26 – explanation of artificial sequence: synthetic DNA

SEQ ID NO:27 – explanation of artificial sequence: synthetic DNA

SEQ ID NO:32 – explanation of artificial sequence: synthetic DNA

SEQ ID NO:33 – explanation of artificial sequence: synthetic DNA

SEQ ID NO:34 – explanation of artificial sequence: synthetic DNA

All of publications, patents, and patent applications cited in this specification are all incorporated as references into this specification in their entirety.

Page 110

CLAIMS

What is claimed is:

1. A polypeptide having an activity to transfer fucose to an N-acetylglucosamine residue in an N-acetyllactosamine (Gal β 1-4GlcNAc) structure existing in a nonreducing terminus of a sugar chain via an α 1,3-linkage, but not having an activity to transfer fucose to an N-acetylglucosamine residue in an α 2,3-sialyl N-acetyllactosamine (NeuAc α 2-3Gal β 1-4GlcNAc) structure existing in a nonreducing terminus of a sugar chain via an α 1,3-linkage.
2. A polypeptide selected from the following (a), (b) and (c):
 - (a) a polypeptide comprising the amino acid sequence represented by SEQ ID NO: 1 or 2,
 - (b) a polypeptide comprising amino acid sequence of residues 56 to 359 represented by SEQ ID NO: 1 or 2,
 - (c) a polypeptide comprising an amino acid sequence wherein one or more amino acids are deleted, substituted, or added in the amino acid sequence of the polypeptide of (a) or (b), having an activity to transfer fucose to an N-acetylglucosamine residue in an N-acetyllactosamine (Gal β 1-4GlcNAc) structure existing in a nonreducing terminus of a sugar chain via an α 1,3-linkage, but not having an activity to transfer fucose to the α 2,3-sialyl N-acetyllactosamine (NeuAc α 2-3Gal β 1-4GlcNAc) structure existing in a nonreducing terminus of a sugar chain via an α 1,3-linkage.
3. The polypeptide according to claim 1 or 2, wherein the activity of transferring fucose to an N-acetylglucosamine residue in the Gal β 1-4GlcNAc structure existing in a nonreducing terminus of a sugar chain via an α 1,3-linkage is the Lewis x sugar chain [Gal β 1-4(Fuc α 1-3)GlcNAc] and the Lewis y sugar chain

[Fuc α 1-2Gal β 1-4(Fuc α 1-3)GlcNAc] synthesizing activity, and the activity of transferring fucose to an N-acetylglucosamine residue in the NeuAc α 2-3Gal β 1-4GlcNAc structure existing in a nonreducing terminus of a sugar chain via an α 1,3-linkage is the sialyl Lewis x sugar chain [NeuAc α 2-3Gal β 1-4(Fuc α 1-3)GlcNAc] synthesizing activity.

4. A DNA selected from the following (a), (b), (c), (d), (e), (f), (g) and (h):
 - (a) a DNA encoding the polypeptide selected from the polypeptides according to claims 1, 2 and 3,
 - (b) a DNA having nucleotides 280 to 1194 of a nucleotide sequence represented by SEQ ID NO: 3,
 - (c) a DNA having nucleotides 115 to 1194 of a nucleotide sequence represented by SEQ ID NO: 3,
 - (d) a DNA having nucleotides 1454 to 2368 of a nucleotide sequence represented by SEQ ID NO: 4,
 - (e) a DNA having nucleotides 1289 to 2368 of a nucleotide sequence represented by SEQ ID NO: 4,
 - (f) a DNA having nucleotides 460 to 1374 of a nucleotide sequence represented by SEQ ID NO: 5,
 - (g) a DNA having nucleotides 295 to 1374 of a nucleotide sequence represented by SEQ ID NO: 5, and
 - (h) a DNA hybridizing under stringent conditions with DNA selected from (a), (b), (c), (d), (e), (f) and (g); and said DNA encodes a polypeptide having an activity to transfer fucose to an N-acetylglucosamine residue in an N-acetylglucosamine (Gal β 1-4GlcNAc) structure existing in a nonreducing terminus of a sugar chain via an α 1,3-linkage, but not having an activity to transfer fucose to an α 2,3-sialyl N-acetylglucosamine (NeuAc α 2-3Gal β 1-4GlcNAc) structure existing in a nonreducing terminus of a sugar chain via an α 1,3-linkage.

5. A recombinant DNA obtained by integrating the DNA according to claim 4 into a vector.
6. The recombinant DNA according to claim 5 wherein it is plasmid pAMo-mFT9 or plasmid pBS-hFT9 (S2).
7. A transformant having the recombinant DNA according to claim 5 or 6.
8. The transformant according to claim 7 wherein it is a transformant selected from microorganisms, animal cells, plant cells, insect cells, non-human transgenic animals, and transgenic plants.
9. The transformant according to claim 8 wherein the microorganism belongs to *Escherichia*.
10. The transformant according to claim 8 wherein the animal cell is selected from mouse myeloma cells, rat myeloma cells, mouse hybridoma cells, CHO cell, BHK cell, African green monkey kidney cells, Namalwa cell, Namalwa KJM-1 cell, human fetal kidney cells, and human leukemia cells.
11. The transformant according to claim 8 wherein the insect cell is selected from *Spodoptera frugiperda* ovarian cells, *Trichoplusia ni* ovarian cells, and silkworm ovarian cells.
12. A method for producing a polypeptide selected from the polypeptides according to claims 1, 2 and 3, which comprises culturing in a medium a transformant having a recombinant DNA obtained by inserting a DNA encoding the polypeptide into a vector; producing and accumulating said polypeptide in said medium; and collecting said polypeptide from said medium.

13. A method for producing a polypeptide selected from the polypeptides according to claims 1, 2 and 3, which comprises feeding a non-human transgenic animal having a recombinant DNA obtained by inserting a DNA encoding the polypeptide into a vector; producing and accumulating said polypeptide in said non-human transgenic animal; and collecting said polypeptide from said non-human transgenic animal.
14. The method for producing the polypeptide according to claim 13, wherein the production and accumulation of said polypeptide is carried out in the milk of said non-human transgenic animal.
15. A method for producing a polypeptide selected from the polypeptides according to claim 1, 2 and 3, which comprises growing a transgenic plant having a recombinant DNA obtained by inserting a DNA encoding the polypeptide into a vector; producing and accumulating said polypeptide in said transgenic plant; and collecting said polypeptide from said transgenic plant.
16. A method for producing a polypeptide selected from the polypeptides according to claims 1, 2 and 3, which comprises using a DNA encoding the polypeptide, and synthesizing said polypeptide by an *in vitro* transcription-translation system.
17. A method for producing a reaction product wherein fucose is added to an N-acetylglucosamine residue in the N-acetylglucosamine structure of an acceptor substrate via an α 1,3-linkage, using a polypeptide selected from the polypeptides according to claims 1, 2 and 3 as an enzyme source; which comprises placing the following (a), (b) and (c) in an aqueous medium:
 - (a) said enzyme source,
 - (b) an acceptor substrate selected from: (i) N-acetylglucosamine(Gal β 1-4GlcNAc),
(ii) oligosaccharides having the N-acetylglucosamine structure in a nonreducing

terminus thereof, (iii) complex carbohydrates having the N-acetylglucosamine structure in a nonreducing terminus of sugar chains, (iv) their derivatives wherein the N-acetylglucosamine structure is modified by sulfate group, and (v) their derivatives wherein the N-acetylglucosamine structure is modified by sugar, but a galactose residue in the N-acetylglucosamine structure is not modified by sialic acid via an α 2,3-linkage, and

(c) guanosine-5' -diphosphate fucose;

producing and accumulating the reaction product, in the aqueous medium; and collecting said reaction product from said aqueous medium.

18. The method for producing the reaction product according to claim 17 wherein a derivative is selected from sugar chains having, in a nonreducing terminus thereof, any one of the following oligosaccharide structures: Fuc α 1-2Gal β 1-4GlcNAc, Gal α 1-3Gal β 1-4GlcNAc, Gal α 1-3(Fuc α 1-2)Gal β 1-4GlcNAc, GalNAc α 1-3(Fuc α 1-2)Gal β 1-4GlcNAc, Gal α 1-4Gal β 1-4GlcNAc, Gal β 1-4GlcNAc(6SO₃); and complex carbohydrates containing said sugar chains.

19. A method for producing a reaction product wherein fucose is added to a glucose residue in a lactose structure of an acceptor substrate via an α 1,3-linkage, using a polypeptide selected from the polypeptides according to claim 1, 2 and 3 as an enzyme source; which comprises placing the following (a), (b) and (c) in an aqueous medium:

(a) said enzyme source,

(b) an acceptor substrate selected from (i) lactose (Gal β 1-4Glc), (ii)

oligosaccharides having a lactose structure in a nonreducing terminus thereof,

(iii) complex carbohydrates having a lactose structure in a nonreducing

terminus of sugar chains, (iv) their derivatives wherein a lactose structure is

modified by sulfate group, and (v) their derivatives wherein a lactose structure

is modified by sugar(s), but a galactose residue in the lactose structure is not

- modified by sialic acid via an α 2,3-linkage, and
- (c) guanosine-5' -diphosphate fucose;
- producing and accumulating the reaction product, in said aqueous medium; and
- collecting said reaction product from said aqueous medium.
20. The method for producing the reaction product according to claim 19 wherein a derivative is selected from sugar chains having, in a nonreducing terminus thereof, any one of the following oligosaccharide structures: Gal α 1-3Gal β 1-4Glc, Gal α 1-3(Fuc α 1-2)Gal β 1-4Glc, GalNAc α 1-3(Fuc α 1-2)Gal β 1-4Glc, Gal α 1-4Gal β 1-4Glc, Gal β 1-4Glc(6SO₃); and complex carbohydrates containing said sugar chains.
21. A method for producing a sugar chain having a structure wherein fucose is added to an N-acetylglucosamine residue or a glucose residue via an α 1,3-linkage, or a complex carbohydrate containing said sugar chain; which comprises, culturing in a medium a transformant selected from the transformants derived from microorganisms, animal cells, plant cells, and insect cells according to claim 8; producing and accumulating the sugar chain or the complex carbohydrate in said medium; and
- collecting said sugar chain or said complex carbohydrate from said medium.
22. A method for producing a sugar chain having structure wherein fucose is added to an N-acetylglucosamine residue or a glucose residue via an α 1,3-linkage, or a complex carbohydrate containing said sugar chain; which comprises, feeding a non-human transgenic animal according to claim 8;
- producing and accumulating the sugar chain or the complex carbohydrate in the non-human transgenic animal; and
- collecting said sugar chain or said complex carbohydrate from said non-human transgenic animal.

23. A method for producing a sugar chain having a structure wherein fucose is added to an N-acetylglucosamine residue or a glucose residue via an α 1,3-linkage, or a complex carbohydrate containing said sugar chain; which comprises, growing a transgenic plant according to claim 8;
producing and accumulating the sugar chain or the complex carbohydrate in said transgenic plant; and
collecting said sugar chain or said complex carbohydrate from said transgenic plant.
24. The production method according to any one of claims 17 to 23 wherein the complex carbohydrate is selected from glycoproteins, glycolipids, proteoglycans, glycopeptides, lipopolysaccharides, peptideglycans and glycosides wherein a sugar chain binds to compounds such as steroids.
25. The method for producing the sugar chain or the complex carbohydrate according to claim 22 wherein the generation and accumulation of said sugar chain or said complex carbohydrate is carried out in the milk of said non-human transgenic animal.
26. A method for determining the expression level of a gene encoding a polypeptide selected from the polypeptides according to claims 1, 2 and 3, by hybridization using DNA encoding the polypeptide.
27. An oligonucleotide selected from the following oligonucleotides:
an oligonucleotide having an identical sequence to 10 to 50 contiguous nucleotides in a nucleotide sequence of DNA selected from a DNA encoding the polypeptide selected from the polypeptides according to claims 1, 2 and 3; a DNA having the nucleotide sequence represented by SEQ ID NO: 3; a DNA having the nucleotide sequence represented by SEQ ID NO: 4; and a DNA having the nucleotide sequence

represented by SEQ ID NO: 5; and,

an oligonucleotide having a complementary sequence to said oligonucleotide and

a derivative of each of said oligonucleotides.

28. The oligonucleotide according to claim 27, wherein said oligonucleotide derivative is selected from the following oligonucleotide derivatives: an oligonucleotide derivative obtained by converting a phosphodiester bond into a phosphorothioate bond in an oligonucleotide; an oligonucleotide derivative obtained by converting a phosphodiester bond into a N3'-P5' phosphoamidate bond in an oligonucleotide; an oligonucleotide derivative obtained by converting a ribose and phosphodiester bond into a peptide-nucleic-acid bond in an oligonucleotide; an oligonucleotide derivative obtained by substituting uracil with C-5 propynyl uracil in an oligonucleotide; an oligonucleotide derivative obtained by substituting uracil with C-5 thiazolyl uracil in an oligonucleotide; an oligonucleotide derivative obtained by substituting cytosine with C-5 propynylcytosine in an oligonucleotide; an oligonucleotide derivative obtained by substituting cytosine with phenoxazine-modified cytosine in an oligonucleotide; an oligonucleotide derivative obtained by substituting ribose with 2'-O-propylribose in a DNA; and an oligonucleotide derivative obtained by substituting ribose with 2'-methoxyethoxyribose in the oligonucleotide.
29. A method for determining the expression level of a gene encoding a polypeptide selected from the polypeptides according to claims 1, 2 and 3 by polymerase chain reaction, using the oligonucleotide according to claim 27 or 28.
30. A method for detecting encephalopathy, renal diseases and cancers, using the method according to claim 26 or 29.
31. A method for suppressing the transcription of a DNA encoding a polypeptide

selected from the polypeptides according to claims 1, 2 and 3, using a DNA selected from a DNA encoding the polypeptide, a DNA having the nucleotide sequence represented by SEQ ID NO: 3, a DNA having the nucleotide sequence represented by SEQ ID NO: 4, and a DNA having the nucleotide sequence represented by SEQ ID NO: 5.

32. A method for suppressing the translation of an mRNA encoding a polypeptide selected from the polypeptides according to claims 1, 2 and 3, using a DNA selected from a DNA encoding the polypeptide, a DNA having the nucleotide sequence represented by SEQ ID NO: 3, a DNA having the nucleotide sequence represented by SEQ ID NO: 4, and a DNA having the nucleotide sequence represented by SEQ ID NO: 5.
33. A method for suppressing the transcription of a DNA encoding the polypeptide according to claim 1, 2 or 3, using the oligonucleotide according to claim 27 or 28.
34. A method for suppressing the translation of an mRNA encoding the polypeptide according to claim 1, 2 or 3, using the oligonucleotide according to claim 27 or 28.
35. An antibody recognizing a polypeptide selected from the polypeptides according to claims 1, 2 and 3.
36. An immunoassay which detects a polypeptide selected from the polypeptides according to claims 1, 2 and 3, using the antibody according to claim 35.
37. An immunohistological staining method which detects a polypeptide selected from the polypeptides according to claims 1, 2 and 3, using the antibody according to claim 35.

38. A reagent for immunohistological staining which contains the antibody of claim 35.
39. An agent for diagnosing encephalopathy, renal diseases and cancers, which contains the antibody of claim 35.
40. A method for screening a substance that changes the activity of a polypeptide selected from the polypeptides according to claims 1, 2 and 3, which comprises contacting said polypeptide with test samples.
41. A method for screening a substance that changes the expression of a gene encoding a polypeptide selected from the polypeptides according to claims 1, 2 and 3, which comprises contacting a cell expressing said polypeptide with test samples, and measuring the amount of the Lewis x or Lewis y sugar chain using an anti-Lewis x or anti-Lewis y antibody.
42. A method for screening a substance that changes the expression of a gene encoding a polypeptide selected from the polypeptides according to claims 1, 2 and 3, which comprises contacting a cell expressing said polypeptide with test samples, and measuring the amount of said polypeptide using the antibody of claim 35.
43. A promoter DNA for the transcription of a gene encoding a polypeptide selected from the polypeptides according to claims 1, 2 and 3.
44. The promoter DNA according to claim 43 which functions in a cell selected from neurons, kidney cells, gastric epithelium cells, leukocyte cells, cerebral tumor cells, neuroblastoma cells, melanoma cells, renal cancer cells, stomach cancer cells, colon cancer cells, and pancreatic cancer cells.
45. The promoter DNA according to claim 43 or 44 which is derived from human or

mouse.

46. A method for screening a substance that changes the efficiency of transcription by a promoter DNA selected from the promoter DNAs according to claims 43, 44 and 45, which comprises transforming an animal cell with a plasmid comprising the promoter DNA and a reporter gene ligated downstream of said promoter DNA; contacting transformant with a test sample; and measuring the amount of the translation product of said reporter gene.
47. The screening method according to claim 46 wherein the reporter gene is a gene selected from chloramphenicol acetyltransferase genes, β -galactosidase genes, luciferase genes and green fluorescent protein genes.
48. A non-human knockout animal wherein a DNA encoding the polypeptide selected from the polypeptides according to claims 1, 2 and 3 is deleted or mutated.
49. The non-human knockout animal according to claim 48 wherein the non-human knockout animal is a mouse.

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 7




Figure 8




Figure 9




Figure 10




Figure 11





Figure 12

M 1 2 3 4 5 6 7



3.5 kb
3.0 kb

Figure 13




Figure 14




Figure 15







Figure 16



DECLARATION, POWER OF ATTORNEY AND PETITION

I (We), the undersigned inventor(s), hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I (We) believe that I am (we are) the original, first, and joint (sole) inventor(s) of the subject matter which is claimed and for which a patent is sought on the invention entitled

A NOVEL POLYPEPTIDE

the specification of which

☐ is attached hereto.

☐ was filed on _____ as

Application Serial No. _____

and amended on _____.

☒ was filed as PCT international application

Number PCT/JP99/ 04092

on July 29, 1999,

and was amended under PCT Article 19

on _____ (if applicable).

I (We) hereby state that I (We) have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above; that I (We) do not know and do not believe that this invention was ever known or used before my invention or discovery thereof, or patented or described in any printed publication in any country before my invention or discovery thereof, or more than one year prior to this application, or in public use or on sale in the United States for more than one year prior to this application; that this invention or discovery has not been patented or made the subject of an inventor's certificate in any country foreign to the United States on an application filed by me or my legal representatives or assigns more than twelve months before this application.

[illegible][illegible]

(Filing Date)

(Filing Date)

I (We) hereby claim the benefit under Section 120 of Title 35 United States Code, of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Section 112 of Title 35 United States Code, I (We) acknowledge the duty to disclose material information as defined in Section 1.56(a) of Title 37 Code of Federal Regulations, which occurred between the filing date of the prior application and national or PCT international filing date of this application:

<210> 33

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic DNA

<400> 33

acattgggtg gaaacattcc ag

22

<210> 34

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic DNA

<400> 34

tttgctacat caattagctc ccct

24

I(We) hereby request that all correspondence regarding this application be sent to the firm of FITZPATRICK, CELLA, HARPER & SCINTO whose Post office address is: 30 Rockefeller Plaza, New York, N.Y.
10112-3801 U.S.A.

I (We) declare further that all statements made herein of my (our) knowledge are true and that all statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Hisashi NARIMATSU

NAME OF FIRST SOLE INVENTOR

Signature of Inventor

January 22, 2001

Date

Residence: Tokyo, Japan JPX

Citizen of: Japan

Post Office Address: 5-1082-1,
Mukohara, Higashiyamato-shi,
Tokyo 207-0013 Japan

Takashi KUDO

NAME OF SECOND JOINT INVENTOR

Signature of Inventor

January 22, 2001

Date

Residence: Tokyo, Japan JPX

Citizen of: Japan

Post Office Address: _____
Gurisin Tsurumaki 303,
4-25-28, Nakanokamicho,
Hachioji-shi, Tokyo 192-0041
Japan

300

Katsutoshi SASAKI

NAME OF THIRD JOINT INVENTOR

Katsutoshi Sasaki

Signature of Inventor

January 22, 2001

Date

Residence: Kanagawa, Japan *TPX*

Citizen of: Japan

Post Office Address: _____

Leo Palace Sonan 202,
2-15-17, Sonan, Sagamihara-shi,
Kanagawa 228-0812 Japan

NAME OF FOURTH JOINT INVENTOR

Signature of Inventor

Date

Residence: _____

Citizen of: _____

Post Office Address: _____

NAME OF FIFTH JOINT INVENTOR

Signature of Inventor

Date

Residence: _____

Citizen of: _____

Post Office Address: _____

Application Serial No.	Filing Date	Status (pending, patented, abandoned)

And I (We) hereby appoint: Joseph M. Fitzpatrick, Registration No. 17,398; Lawrence F. Scinto, Registration No. 18,973; William J. Brunet, Registration No. 20,452; Robert L. Baechtold, Registration No. 20,860; John A. O'Brien, Registration No. 24,367; John A. Krause, Registration No. 24,613; Henry J. Renk, Registration No. 25,499; Peter Saxon, Registration No. 24,947; Anthony M. Zupcic, Registration No. 27,276; Charles P. Baker, Registration No. 26,702; Stevan J. Bosses, Registration No. 22,291; Edward E. Vassallo, Registration No. 29,117; Ronald A. Clayton, Registration No. 26,718; Lawrence A. Stahl, Registration No. 30,110; Laura A. Bauer, Registration No. 29,767; Leonard P. Diana, Registration No. 29,296; David M. Quinlan, Registration No. 26,641; Nicholas N. Kallas, Registration No. 31,530; William M. Wannisky, Registration No. 28,373; Lawrence Alaburda, Registration No. 31,583; Lawrence S. Perry, Registration No. 31,865; Robert H. Fischer, Registration No. 30,051; Christopher Philip Wrist, Registration No. 32,078; Gary M. Jacobs, Registration No. 28,861; Michael K. O'Neill, Registration No. 32,622; Bruce C. Haas, Registration No. 32,734; Scott K. Reed, Registration No. 32,433; Scott D. Malpede, Registration No. 32,533; John A. Mitchell, Registration No. 19,032; Fredrick M. Zullo, Registration No. 32,452; Richard P. Bauer, Registration No. 31,588; Warren E. Olsen, Registration No. 27,290; Abigail F. Cousins, Registration No. 29,292; Jennifer A. Tegfeldt, Registration No. 31,310; Steven E. Warner, Registration No. 33,326; Thomas J. O'Connell, Registration No. 33,202; Aaron C. Deditch, Registration No. 33,865; Penina Wollman, Registration No. 30,816; David L. Schaeffer, Registration No. 32,716; Jack S. Cubert, Registration No. 24,245; Mark A. Williamson, Registration No. 33,628; John T. Whelan, Registration No. 32,448; Patricia M. Drost, Registration No. 29,790; Jean K. Dudek, Registration No. 30,938; Raymond R. Mandra, Registration No. 34,382; Dominick A. Conde, Registration No. 33,856; Steven C. Bauman, Registration No. 33,832; Pasquale A. Razzano, Registration No. 25,512; John W. Behringer, Registration No. 23,086; Robert C. Kline, Registration No. 17,739; Carolyn H. Blankenship, Registration No. 35,449; Richard F. Jaworski, Registration No. 33,515; Lawrence W. Nelson, Registration No. 34,684; Benjamin C. Hsing, Registration No. 34,528; Leo J. Jennings, Registration No. 32,902; Mark J. Itri, Registration No. 36,171; William C. Hwang, Registration No. 36,169; and John C. Phillips, Registration No. 35,322.

09/744748

JC02 Rec'd PCT/PTO 29 JAN 2001

1241.17

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
HISASHI NARIMATSU ET AL.)	Examiner: Not Yet Assigned
Application Based on)	Group Art Unit: Unassigned
PCT/JP99/04092)	
Filed: Herewith)	
For: A NOVEL POLYPEPTIDE)	January 26, 2001

Assistant Commissioner for Patents
Washington, D.C. 20231


STATEMENT UNDER 37 C.F.R. § 1.821(f)

Sir:

The content of the paper copy Sequence Listing and computer-readable form are the same.

Applicants' undersigned attorney may be reached in our New York office by telephone at (212) 218-2100. All correspondence should continue to be directed to our below listed address.

Respectfully submitted,


Attorney for Applicants
Registration No. 42,667

FITZPATRICK, CELLA, HARPER & SCINTO
30 Rockefeller Plaza
New York, New York 10112-3801
Facsimile: (212) 218-2200

SEQUENCE LISTING

<110> KYOWA HAKKO KOGYO CO., LTD.

<120> NOVEL PEPTIDE

<130> H10-0981N2

<150> JP 98/213823

<151> 1998-07-29

<160> 34

<170> PatentIn Ver. 2.0

<210> 1

<211> 359

<212> PRT

<213> Mouse

<400> 1

Met Thr Ser Thr Ser Lys Gly Ile Leu Arg Pro Phe Leu Ile Val Cys

1

5

10

15

Ile Ile Leu Gly Cys Phe Met Ala Cys Leu Leu Ile Tyr Ile Lys Pro

20

25

30

Thr Asn Ser Trp Val Phe Ser Pro Met Glu Ser Ala Ser Ser Val Leu

35

40

45

Lys Met Lys Asn Phe Phe Ser Thr Lys Thr Asp Tyr Phe Asn Glu Thr

50

55

60

Thr Ile Leu Val Trp Val Trp Pro Phe Gly Gln Thr Phe Asp Leu Thr

65

70

75

80

Ser Cys Gln Ala Met Phe Asn Ile Gln Gly Cys His Leu Thr Thr Asp

85

90

95

Arg Ser Leu Tyr Asn Lys Ser His Ala Val Leu Ile His His Arg Asp

100

105

110

Ile Ser Trp Asp Leu Thr Asn Leu Pro Gln Gln Ala Arg Pro Pro Phe

115

120

125

Gln Lys Trp Ile Trp Met Asn Leu Glu Ser Pro Thr His Thr Pro Gln

130

135

140

Lys Ser Gly Ile Glu His Leu Phe Asn Leu Thr Leu Thr Tyr Arg Arg

145

150

155

160

Asp Ser Asp Ile Gln Val Pro Tyr Gly Phe Leu Thr Val Ser Thr Asn

165

170

175

Pro Phe Val Phe Glu Val Pro Ser Lys Glu Lys Leu Val Cys Trp Val

180

185

190

Val Ser Asn Trp Asn Pro Glu His Ala Arg Val Lys Tyr Tyr Asn Glu

195

200

205

Leu Ser Lys Ser Ile Glu Ile His Thr Tyr Gly Gln Ala Phe Gly Glu

210

215

220

Tyr Val Asn Asp Lys Asn Leu Ile Pro Thr Ile Ser Thr Cys Lys Phe

225

230

235

240

Tyr Leu Ser Phe Glu Asn Ser Ile His Lys Asp Tyr Ile Thr Glu Lys

245

250

255

Leu Tyr Asn Ala Phe Leu Ala Gly Ser Val Pro Val Val Leu Gly Pro

260

265

270

Ser Arg Glu Asn Tyr Glu Asn Tyr Ile Pro Ala Asp Ser Phe Ile His

275

280

285

Val Glu Asp Phe Asn Ser Pro Ser Glu Leu Ala Lys Tyr Leu Lys Glu

290

295

300

Val Asp Lys Asn Asn Lys Leu Tyr Leu Ser Tyr Phe Asn Trp Arg Lys

305

310

315

320

Asp Phe Thr Val Asn Leu Pro Arg Phe Trp Glu Ser His Ala Cys Leu

325

330

335

Ala Cys Asp His Val Lys Arg His Gln Glu Tyr Lys Ser Val Gly Asn

340

345

350

Leu Glu Lys Trp Phe Trp Asn

355

<210> 2

<211> 359

<212> PRT

<213> human

<400> 2

Met Thr Ser Thr Ser Lys Gly Ile Leu Arg Pro Phe Leu Ile Val Cys

1

5

10

15

Ile Ile Leu Gly Cys Phe Met Ala Cys Leu Leu Ile Tyr Ile Lys Pro

20

25

30

Thr Asn Ser Trp Ile Phe Ser Pro Met Glu Ser Ala Ser Ser Val Leu

35

40

45

Lys Met Lys Asn Phe Phe Ser Thr Lys Thr Asp Tyr Phe Asn Glu Thr

50

55

60

Thr Ile Leu Val Trp Val Trp Pro Phe Gly Gln Thr Phe Asp Leu Thr

65

70

75

80

Ser Cys Gln Ala Met Phe Asn Ile Gln Gly Cys His Leu Thr Thr Asp

85

90

95

Arg Ser Leu Tyr Asn Lys Ser His Ala Val Leu Ile His His Arg Asp

100

105

110

Ile Ser Trp Asp Leu Thr Asn Leu Pro Gln Gln Ala Arg Pro Pro Phe

115

120

125

Gln Lys Trp Ile Trp Met Asn Leu Glu Ser Pro Thr His Thr Pro Gln

130

135

140

Lys Ser Gly Ile Glu His Leu Phe Asn Leu Thr Leu Thr Tyr Arg Arg

145

150

155

160

Asp Ser Asp Ile Gln Val Pro Tyr Gly Phe Leu Thr Val Ser Thr Asn

165	170	175	
Pro Phe Val Phe Glu Val Pro Ser Lys Glu Lys Leu Val Cys Trp Val			
180	185	190	
Val Ser Asn Trp Asn Pro Glu His Ala Arg Val Lys Tyr Tyr Asn Glu			
195	200	205	
Leu Ser Lys Ser Ile Glu Ile His Thr Tyr Gly Gln Ala Phe Gly Glu			
210	215	220	
Tyr Val Asn Asp Lys Asn Leu Ile Pro Thr Ile Ser Ala Cys Lys Phe			
225	230	235	240
Tyr Leu Ser Phe Glu Asn Ser Ile His Lys Asp Tyr Ile Thr Glu Lys			
245	250	255	
Leu Tyr Asn Ala Phe Leu Ala Gly Ser Val Pro Val Val Leu Gly Pro			
260	265	270	
Ser Arg Glu Asn Tyr Glu Asn Tyr Ile Pro Ala Asp Ser Phe Ile His			
275	280	285	
Val Glu Asp Tyr Asn Ser Pro Ser Glu Leu Ala Lys Tyr Leu Lys Glu			
290	295	300	

Val Asp Lys Asn Asn Lys Leu Tyr Leu Ser Tyr Phe Asn Trp Arg Lys
 305 310 315 320

Asp Phe Thr Val Asn Leu Pro Arg Phe Trp Glu Ser His Ala Cys Leu
 325 330 335

Ala Cys Asp His Val Lys Arg His Gln Glu Tyr Lys Ser Val Gly Asn
 340 345 350

Leu Glu Lys Trp Phe Trp Asn
 355

<210> 3

<211> 2170

<212> DNA

<213> Mouse

<220>

<221> CDS

<222> (115)..(1191)

<400> 3

ctttccctcg ctgggatcgc tttagaatgt gataactcac gcattctgata gcaccgtgga 60

gtagttcagc actcatctct gctttccatg ctatgttctc tacactgaaa aatt atg 117

Met

1

aca tca aca tcc aaa ggc att ctt cgc cca ttt cta atc gtc tgc atc 165

Thr Ser Thr Ser Lys Gly Ile Leu Arg Pro Phe Leu Ile Val Cys Ile

5

10

15

atc ctg ggc tgc ttc atg gca tgt ctg ctc att tat atc aag ccc acc 213

Ile Leu Gly Cys Phe Met Ala Cys Leu Leu Ile Tyr Ile Lys Pro Thr

20

25

30

aac agc tgg gtc ttc agt cca atg gag tct gca agt tct gtg ctg aaa 261

Asn Ser Trp Val Phe Ser Pro Met Glu Ser Ala Ser Ser Val Leu Lys

35

40

45

atg aaa aat ttc ttc tcc aca aaa act gat tat ttt aac gaa act acc 309

Met Lys Asn Phe Phe Ser Thr Lys Thr Asp Tyr Phe Asn Glu Thr Thr

50

55

60

65

att ctg gtt tgg gta tgg cca ttt ggg cag acc ttt gac ctt aca tcc 357

Ile Leu Val Trp Val Trp Pro Phe Gly Gln Thr Phe Asp Leu Thr Ser

70

75

80

tgc caa gca atg ttc aat atc caa ggg tgc cat ctc aca aca gac cgc 405

Cys Gln Ala Met Phe Asn Ile Gln Gly Cys His Leu Thr Thr Asp Arg

85

90

95

tca ttg tac aac aaa tcc cat gcg gtc ctg att cac cat aga gac atc 453

Ser Leu Tyr Asn Lys Ser His Ala Val Leu Ile His His Arg Asp Ile

100

105

110

agc tgg gat ctg act aac tta cct cag cag gcc agg cca ccc ttt cag 501

Ser Trp Asp Leu Thr Asn Leu Pro Gln Gln Ala Arg Pro Pro Phe Gln

115

120

125

aaa tgg att tgg atg aat tta gag tca ccc act cac acc ccc caa aag 549

Lys Trp Ile Trp Met Asn Leu Glu Ser Pro Thr His Thr Pro Gln Lys

130

135

140

145

agt ggc att gaa cac ttg ttc aac ctg act cta act tat cgc cgt gat 597

Ser Gly Ile Glu His Leu Phe Asn Leu Thr Leu Thr Tyr Arg Arg Asp

150

155

160

tca gat atc caa gtg cct tat ggc ttc ttg acg gtg agc aca aat ccc 645

Ser Asp Ile Gln Val Pro Tyr Gly Phe Leu Thr Val Ser Thr Asn Pro

165

170

175

ttt gtg ttt gaa gtg cca agc aag gag aag ttg gtg tgc tgg gtt gtg 693

Phe Val Phe Glu Val Pro Ser Lys Glu Lys Leu Val Cys Trp Val Val

180

185

190

agt aac tgg aac cct gag cat gcc agg gtc aag tat tac aac gag ctc 741

Ser Asn Trp Asn Pro Glu His Ala Arg Val Lys Tyr Tyr Asn Glu Leu

195

200

205

agc aag agt att gaa atc cac acc tat ggc caa gca ttc gga gaa tac 789

Ser Lys Ser Ile Glu Ile His Thr Tyr Gly Gln Ala Phe Gly Glu Tyr

210

215

220

225

gtg aac gat aaa aat ctg att ccc acc ata tct act tgt aaa ttt tat 837

Val Asn Asp Lys Asn Leu Ile Pro Thr Ile Ser Thr Cys Lys Phe Tyr

230	235	240	
ctt tca ttt gaa aac tca att cac aaa gat tac atc aca gaa aag ctc			885
Leu Ser Phe Glu Asn Ser Ile His Lys Asp Tyr Ile Thr Glu Lys Leu			
245	250	255	
tac aat gca ttt ttg gct ggt tca gta cct gtt gtc ctg ggt cca tct			933
Tyr Asn Ala Phe Leu Ala Gly Ser Val Pro Val Val Leu Gly Pro Ser			
260	265	270	
agg gaa aac tat gag aat tat att cca gct gat tca ttc att cat gtg			981
Arg Glu Asn Tyr Glu Asn Tyr Ile Pro Ala Asp Ser Phe Ile His Val			
275	280	285	
gaa gat ttt aac tct ccc agt gag tta gca aaa tat ctg aag gaa gtt			1029
Glu Asp Phe Asn Ser Pro Ser Glu Leu Ala Lys Tyr Leu Lys Glu Val			
290	295	300	305
gac aaa aac aat aag ttg tac ctt agt tac ttt aac tgg aga aag gat			1077
Asp Lys Asn Asn Lys Leu Tyr Leu Ser Tyr Phe Asn Trp Arg Lys Asp			
310	315	320	

ttt act gta aac cta cca cgg ttt tgg gaa tca cat gca tgc ctg gca 1125

Phe Thr Val Asn Leu Pro Arg Phe Trp Glu Ser His Ala Cys Leu Ala

325

330

335

tgc gac cat gta aaa agg cat caa gaa tat aag tct gtt ggt aat tta 1173

Cys Asp His Val Lys Arg His Gln Glu Tyr Lys Ser Val Gly Asn Leu

340

345

350

gag aaa tgg ttt tgg aat taaagtgcc atcattgtca cagtgaaaaa 1221

Glu Lys Trp Phe Trp Asn

355

gattaatgag acataattca agttttcagg ataagaagaa acacgtgca tttggggcac 1281

cgtttaattt tcctgccctc ccttgaggac catgtatatt ttggtgaaat ttttaagaga 1341

tcagaattag caatcactca atttggtttt aaattatcct gtatatatgt gataacgagc 1401

actggaaata atttatttgt cactctcatt tataaacatt gtttttacat tttatagttg 1461

actgtaaagt aaatttatga tttacttggt tctacatcaa tcagatcttt aatctatttg 1521

ggagataaaa atacatatcc taaaatatga gggacttttt gccagattatt ataaagtata 1581

gattctagct tgtataatgc taacaaagaa gaattatiga atcacttaat tcttaatctc 1641

tttgacttca aagtigaaca ctactgacaa ctgatagagt ttttacttgt accacatttg 1701

tgaaggggag ctaattgatg tagcaaataa gaaagatatg aagcagaaat gttattagac 1761

ttcacattca tttttattaa gttgttttagc aaatgtagat tcccaatatt ttaagttaaa 1821

gaaaacaaga atttcagat aaacaattta tatggtttta gggagatttg attgtttggt 1881

ttgtgggttt agtccctaataa aatacctaag agaatctttt gatagttccc tttcaaatca 1941

tgaagataac cactatitita aaaataaata atttcctctt ataacaataa aaaaatgata 2001

tcttcaaata caaataaatg tataaattat accatttata gaacgctagt tacttcattc 2061

atttgaaata ttttttccaa agcatccata ttttaagtttt attttactgt atttggttaat 2121

aatagaagt aaaacttgaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2170

<210> 4

<211> 2822

<212> DNA

<213> human

<220>

<221> CDS

<222> (1289)..(2365)

<400> 4

aagcttiigct actcagagag tctcatatgc ttttaagaaaa actacatagc aaaagaaggt 60

gcttttttita atgttcacat atatttaggt aattaaatga aggataattt ctcccgtttt 120

ttggaaggaa acatctaatag ttictatgct agtttctgtc aaaatttcaa aatactttaa 180

tgagictgaa atttataggc catattatit tcgtaagaga agcaacatga atttcaaata 240

acccgtgaga attttatcaa taaacagttt ttgcaaatai atttttgtgt tcatagccat 300

aaagaggcat gaatgccgaa gagaataaaa ctgaaaaca ctttttctt taaaaataaa 360

gccttcactc atcttttttag ccacaatctg ctaaaattca tgacatcaaa gttgttcttc 420

atgaaatata gccctttttt gagaatttgt ttatttttat aataccgata tcatcttaat 480

acaagaaaa acttttttaa agcccttagg ctatgtaagt gagaacgtt tccaatgca 540

aatagaacat ttgattatta catcttggtg gatatcggtg gtactaataa attattaaaa 600

gtaaacaaag aaaactgtaa gaaaaatata taaataaaaa caaaacactg tgagttttga 660

atttataaaa ttigcctgag tgtacttggt ttttaaaaat gatatcaatc aagagttgcc 720

atTTTTTtac cagatgatta tactaatgca ttigcaaact gtgaaggtaa atttataacg 780

agaaaaacaa aaacataacg tttttaaaaa cagtttagtt ttctaacgaa ttccatctga 840

accacaaagt tatggtacag tctcaatatg cgagttaaata agtgattata tcaactggga 900

gatgttcaca aatctgatgt ggttacaaaa tactaaaaat tttagtcatg gctttagcga 960

tgacagtcta ggttgtgcca cttttctaca agcaaataaa agtagaactg ttaaggatag 1020

catigaaaaa aacgttactt ggtttgaaga tatgctggta cttttagaag agtttttggg 1080

aaacttcctt ttgaaagctg tttcttggct ttgaggaaag ttctgtttct ctcaatggtt 1140

tgataacact gaaaaggaaa atgctgttga ttactacttg tttatctcat atttatgatt 1200

ttaaataatat ctccaatata tttatgattt tctcttcatt cccaccgcta cctccccttc 1260

tgtctttctc tatttcgtag gaaaaatt atg aca tca aca tcc aaa gga att 1312

Met Thr Ser Thr Ser Lys Gly Ile

1

5

ctt cgc cca ttt tta att gtc tgc att atc ctg ggc tgt ttc atg gca 1360

Leu Arg Pro Phe Leu Ile Val Cys Ile Ile Leu Gly Cys Phe Met Ala

10

15

20

tgt ctt ctc att tac atc aaa cct acc aac agc tgg atc ttc agt cca 1408

Cys Leu Leu Ile Tyr Ile Lys Pro Thr Asn Ser Trp Ile Phe Ser Pro

25

30

35

40

atg gaa tca gcc agc tct gtg ctg aaa atg aaa aac ttc ttt tcc acc 1456

Met Glu Ser Ala Ser Ser Val Leu Lys Met Lys Asn Phe Phe Ser Thr

45

50

55

aaa act gat tat ttt aat gaa act act att ctg gtg tgg gtg tgg cca 1504

Lys Thr Asp Tyr Phe Asn Glu Thr Thr Ile Leu Val Trp Val Trp Pro
60 65 70

ttt ggg cag acc ttt gac ctt aca tcc tgc caa gca atg ttc aac atc 1552

Phe Gly Gln Thr Phe Asp Leu Thr Ser Cys Gln Ala Met Phe Asn Ile
75 80 85

caa gga tgc cat ctc aca acg gac cgt tca ctg tac aac aaa tcc cat 1600

Gln Gly Cys His Leu Thr Thr Asp Arg Ser Leu Tyr Asn Lys Ser His
90 95 100

gca gtt ctg atc cat cac cga gac atc agt tgg gat ctg aca aat tta 1648

Ala Val Leu Ile His His Arg Asp Ile Ser Trp Asp Leu Thr Asn Leu
105 110 115 120

cct cag caa gct agg cca ccc ttc cag aaa tgg att tgg atg aat ttg 1696

Pro Gln Gln Ala Arg Pro Pro Phe Gln Lys Trp Ile Trp Met Asn Leu
125 130 135

gaa tca cca act cac act ccc caa aag agt ggc att gag cac ttg ttt 1744

Glu Ser Pro Thr His Thr Pro Gln Lys Ser Gly Ile Glu His Leu Phe

140

145

150

aac ctg act ctg act tac cgc cgt gat tca gat atc caa gtg cct tat 1792

Asn Leu Thr Leu Thr Tyr Arg Arg Asp Ser Asp Ile Gln Val Pro Tyr

155

160

165

ggc ttc ttg acg gta agc aca aat ccc ttc gtg ttt gaa gtg cca agc 1840

Gly Phe Leu Thr Val Ser Thr Asn Pro Phe Val Phe Glu Val Pro Ser

170

175

180

aaa gag aaa ttg gtg tgc tgg gtt gtg agt aac tgg aac cct gag cat 1888

Lys Glu Lys Leu Val Cys Trp Val Val Ser Asn Trp Asn Pro Glu His

185

190

195

200

gcc aga gtc aag tat tac aat gag cta agc aaa agc att gaa atc cat 1936

Ala Arg Val Lys Tyr Tyr Asn Glu Leu Ser Lys Ser Ile Glu Ile His

205

210

215

acc tac ggg caa gca ttt gga gaa tat gtc aat gat aaa aat ttg att 1984

Thr Tyr Gly Gln Ala Phe Gly Glu Tyr Val Asn Asp Lys Asn Leu Ile

220

225

230

cct acc ata tct gct tgt aaa ttt tat ctt tcc ttt gaa aat tca atc 2032

Pro Thr Ile Ser Ala Cys Lys Phe Tyr Leu Ser Phe Glu Asn Ser Ile

235

240

245

cac aag gat tac atc acg gaa aag cta tac aat gct ttt ctg gct ggc 2080

His Lys Asp Tyr Ile Thr Glu Lys Leu Tyr Asn Ala Phe Leu Ala Gly

250

255

260

tct gta cct gtt gtt ctg gga cca tct agg gaa aac tat gag aat tat 2128

Ser Val Pro Val Val Leu Gly Pro Ser Arg Glu Asn Tyr Glu Asn Tyr

265

270

275

280

att cca gca gat tca ttc att cat gtg gaa gat tat aac tct ccc agt 2176

Ile Pro Ala Asp Ser Phe Ile His Val Glu Asp Tyr Asn Ser Pro Ser

285

290

295

gag cta gca aag tat ctg aag gaa gtc gac aaa aac aat aag tta tac 2224

Glu Leu Ala Lys Tyr Leu Lys Glu Val Asp Lys Asn Asn Lys Leu Tyr

300

305

310

ctt agt tac ttt aac tgg agg aag gat ttc act gta aat ctt cca cga 2272

Leu Ser Tyr Phe Asn Trp Arg Lys Asp Phe Thr Val Asn Leu Pro Arg

315

320

325

ttt tgg gaa tca cat gca tgt ttg gct tgc gat cat gtg aaa agg cat 2320

Phe Trp Glu Ser His Ala Cys Leu Ala Cys Asp His Val Lys Arg His

330

335

340

caa gaa tat aag tct gtt ggt aat tta gag aaa tgg ttt tgg aat 2365

Gln Glu Tyr Lys Ser Val Gly Asn Leu Glu Lys Trp Phe Trp Asn

345

350

355

taaaattttt catcacttgc acacttgata aatatittga tgagatatca tccaagtatt 2425

gaggataaga agagatgcaa catactactt ttgtgtcaca atttatittt atcaccttct 2485

ctagggtaac gtgtatatitt ttgttgagat ttttaaaagc tcagcatgag caatcattcc 2545

attcggtttt aaattatcct gtatatacct aattatgtgc actggagagt aatttattct 2605

tcattatcat ttgtaaacat tgcittttca catttttgta gttgtccata atgtaagctt 2665

gtggtttgat tattgtttcc acactgatca gctgtttaat ctatttgga aatgaagatg 2725

cacatcttaa agtatgaaaa attttcacta agtattacaa tgtctagttc caactttgca 2785

tactataaca gaggaagaac atgttgcgat tgaattc 2822

<210> 5

<211> 2676

<212> DNA

<213> human

<220>

<221> CDS

<222> (295)..(1371)

<400> 5

gcgcgcgcgg cgcagcagct ccagattcac tgctctcccc tgcagctccc cgcgcccccg 60

ccgctgtcgc tgcctcgggtg tccccagcc ccagtcgcgc tcttaggaca gcgccgccac 120

cgccgcctgg ccctgcctgc ctctgcgcc gcgcagccct cgcgagcgcc ccggatggcg 180

ctttaccctt aggaccgatt tagaatgtaa taactcaagg atttgataat acagtgaagt 240

agtataacaa ctgtctacgt gcttcccatg atatgttctc tatattgaaa aatt atg 297

Met

1

aca tca aca tcc aaa gga att ctt cgc cca ttt tta att gtc tgc att 345

Thr Ser Thr Ser Lys Gly Ile Leu Arg Pro Phe Leu Ile Val Cys Ile

5

10

15

atc ctg ggc tgt ttc atg gca tgt ctt ctc att tac atc aaa cct acc 393

Ile Leu Gly Cys Phe Met Ala Cys Leu Leu Ile Tyr Ile Lys Pro Thr

20

25

30

aac agc tgg atc ttc agt cca atg gaa tca gcc agc tct gtg ctg aaa 441

Asn Ser Trp Ile Phe Ser Pro Met Glu Ser Ala Ser Ser Val Leu Lys

35

40

45

atg aaa aac ttc ttt tcc acc aaa act gat tat ttt aat gaa act act 489

Met Lys Asn Phe Phe Ser Thr Lys Thr Asp Tyr Phe Asn Glu Thr Thr

50

55

60

65

att ctg gtg tgg gtg tgg cca ttt ggg cag acc ttt gac ctt aca tcc 537

Ile Leu Val Trp Val Trp Pro Phe Gly Gln Thr Phe Asp Leu Thr Ser

70

75

80

tgc caa gca atg ttc aac atc caa gga tgc cat ctc aca acg gac cgt 585

Cys Gln Ala Met Phe Asn Ile Gln Gly Cys His Leu Thr Thr Asp Arg

85

90

95

tca ctg tac aac aaa tcc cat gca gtt ctg atc cat cac cga gac atc 633

Ser Leu Tyr Asn Lys Ser His Ala Val Leu Ile His His Arg Asp Ile

100

105

110

agt tgg gat ctg aca aat tta cct cag caa gct agg cca ccc ttc cag 681

Ser Trp Asp Leu Thr Asn Leu Pro Gln Gln Ala Arg Pro Pro Phe Gln

115

120

125

aaa tgg att tgg atg aat ttg gaa tca cca act cac act ccc caa aag 729

Lys Trp Ile Trp Met Asn Leu Glu Ser Pro Thr His Thr Pro Gln Lys

130

135

140

145

agt ggc att gag cac ttg ttt aac ctg act ctg act tac cgc cgt gat 777

Ser Gly Ile Glu His Leu Phe Asn Leu Thr Leu Thr Tyr Arg Arg Asp

150

155

160

tca gat atc caa gtg cct tat ggc ttc ttg acg gta agc aca aat ccc 825

Ser Asp Ile Gln Val Pro Tyr Gly Phe Leu Thr Val Ser Thr Asn Pro

165

170

175

ttc gtg ttt gaa gtg cca agc aaa gag aaa ttg gtg tgc tgg gtt gtg 873

Phe Val Phe Glu Val Pro Ser Lys Glu Lys Leu Val Cys Trp Val Val

180

185

190

agt aac tgg aac cct gag cat gcc aga gtc aag tat tac aat gag cta 921

Ser Asn Trp Asn Pro Glu His Ala Arg Val Lys Tyr Tyr Asn Glu Leu

195

200

205

agc aaa agc att gaa atc cat acc tac ggg caa gca ttt gga gaa tat 969

Ser Lys Ser Ile Glu Ile His Thr Tyr Gly Gln Ala Phe Gly Glu Tyr

210

215

220

225

gtc aat gat aaa aat ttg att cct acc ata tct gct tgt aaa ttt tat 1017

Val Asn Asp Lys Asn Leu Ile Pro Thr Ile Ser Ala Cys Lys Phe Tyr

230

235

240

ctt tcc ttt gaa aat tca atc cac aag gat tac atc acg gaa aag cta 1065

Leu Ser Phe Glu Asn Ser Ile His Lys Asp Tyr Ile Thr Glu Lys Leu

245

250

255

tac aat gct ttt ctg gct ggc tct gta cct gtt gtt ctg gga cca tct 1113

Tyr Asn Ala Phe Leu Ala Gly Ser Val Pro Val Val Leu Gly Pro Ser

260

265

270

agg gaa aac tat gag aat tat att cca gca gat tca ttc att cat gtg 1161

Arg Glu Asn Tyr Glu Asn Tyr Ile Pro Ala Asp Ser Phe Ile His Val

275

280

285

gaa gat tat aac tct ccc agt gag cta gca aag tat ctg aag gaa gtc 1209

Glu Asp Tyr Asn Ser Pro Ser Glu Leu Ala Lys Tyr Leu Lys Glu Val

290

295

300

305

gac aaa aac aat aag tta tac ctt agt tac ttt aac tgg agg aag gat 1257

Asp Lys Asn Asn Lys Leu Tyr Leu Ser Tyr Phe Asn Trp Arg Lys Asp

310

315

320

ttc act gta aat ctt cca cga ttt tgg gaa tca cat gca tgt ttg gct 1305

Phe Thr Val Asn Leu Pro Arg Phe Trp Glu Ser His Ala Cys Leu Ala

325

330

335

tgc gat cat gtg aaa agg cat caa gaa tat aag tct gtt ggt aat tta 1353

Cys Asp His Val Lys Arg His Gln Glu Tyr Lys Ser Val Gly Asn Leu

340

345

350

gag aaa tgg ttt tgg aat taaaattttt catcacttgc acacttgata 1401

Glu Lys Trp Phe Trp Asn

355

aatattttga tgagatatca tccaagtatt gaggataaga agagatgcaa catactactt 1461

ttgtgtcaca atttattttt atcacccctct ctagggtaac gtgtatatatt tggaggagat 1521

ttttaaaagc tcagcatgag caatcattcc attcggtttt aaattatcct gtatatacct 1581

aattatgtgc actggagagt aatttattct tcattatcat ttgtaaacat tgcittttca 1641

catttttgta gtgtccata atgtaagctt gtggtttgat tattgtttcc acactgatca 1701

gctgtttaat ctatttgga aatgaagatg cacatcttaa agtatgaaaa attttcacta 1761

agtattacaa tgtctagttc caactttgca tactataaca gaggaagaac atgttgcat 1821

tgaattctaa cccttttgac tcctaagatg aatgaagtg ataactgtct ctatttgatc 1881

tatttttttt accgttttat cacatttgtg aaggtgaaat tattcatgga gtgaataaga 1941

aagatatgaa gcagaactgt tctattcagg aagctattag acttctcatt tatttttcatt 2001

aagctgattt gcagctactt attctcatgg tcttaaatta aattattcaa gtattttttaa 2061

atatccaatt tgttgatgatt ttcagcacct gggaagtaat cccaataata ctttagaaaa 2121

tctaagacag ttctttctgc tactgatgac actcattgtc ataataaaac aaataatttc 2181

ctcaaataac aaagaaaaat gataacctata aatatattta taaatgggtgt catttatgaa 2241

caatgtttta ttaigtatca atttaagatt tttttctgaa gccctaatat ttaaaatggc 2301

cttattttac catatggata taagatttgg ctcataatga tgagccctat catttgattt 2361

gagttctatc atttaagaga gcctaaataa aattatcatc aaggtattaa atataagacg 2421

ttaaataataa taaagtgggg atatataaaa aacacacagt gtiagcacag agtaagatct 2481

caatgcacat ttgttggatg aataaataaa tgcaattgaa ttcccagaaa aatgattgtt 2541

tcaaggaagt gacagticta ctttagaagt actaattgga gatgactttt atatccatt 2601

ttggtaatta ttcatata gcacatatga ccatgatgtt cagggttta tagaaccaaa 2661

taaacctacc attac 2676

<210> 6

<211> 11

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic DNA

<400> 6

ctttagagca c 11

<210> 7

<211> 8

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic DNA

<400> 7

ctctaaag

8

<210> 8

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic DNA

<400> 8

ctggattcta tccagtcaa ggcgagggtt tg

32

<210> 9

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic DNA

<400> 9

ctgaattctc atcgctggaa ccagtctgcc aag

33

<210> 10

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic DNA

<400> 10

ctgaattcac agcttctttg cagctccttc g

31

<210> 11

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic DNA

<400> 11

ctaagcttgt gtaaaacgca gctcagtaac ag

32

<210> 12

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic DNA

<400> 12

cagctgggat ctgactaact tacc

24

<210> 13

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic DNA

<400> 13

ccacatgaat gaatgaatca gctgg

25

<210> 14

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic DNA

<400> 14

gatatcgctg cgctggctgt cgac

24

<210> 15

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic DNA

<400> 15

caagaaggaa ggctggaaaa gaggc

24

<210> 16

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic DNA

<400> 16

gcttcttgac ggtgagcaca aatc

24

<210> 17

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic DNA

<400> 17

tgcttggcca taggtgtgga ttic

24

<210> 18

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic DNA

<400> 18

gcttcttgac ggtgagcaca aatc

24

<210> 19

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic DNA

<400> 19

tgcttggcca taggtgtgga ttic

24

<210> 20

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic DNA

<400> 20

gattcccacc atatctactt gtaa

24

<210> 21

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic DNA

<400> 21

tgaatcagct ggaatataat tctc

24

<210> 22

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic DNA

<400> 22

aggccaccct ttcagaaatg

20

<210> 23

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic DNA

<400> 23

agttttccct agatggaccc

20

<210> 24

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic DNA

<400> 24

ctgaattctg gctgggatcg ctttagaatg tg

32

<210> 25

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic DNA

<400> 25

ctgaattcaa atgaatgaag taactagcgt tc

32

<210> 26

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic DNA

<400> 26

aaattatgac atcaacatcc aaagg

25

<210> 27

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic DNA

<400> 27

ccaacagact tatattcttg atgcc

25

<210> 28

<211> 891

<212> DNA

<213> Mouse

<400> 28

cttttagctgg tcaaccccag tgaagaacaa acacagccag cagatacaag ggactggaga 60

aggttgccctg cattgagctc cctgctgtcg ccttctggct ggacagtccg tgccaaatag 120

cgccctggggg ggtgggggtg ggggacagca ataaggaact gacagaagcg gttgctgcaa	180
gtccacagtt tgacctaaaa ggagagtga ggagggtggc agactaagag tctgcatatc	240
ggagacgcag caatggaacc agtggctatg tgtgcgcgca caggtgccac aggcctggag	300
agcaatgctg tgtctctgca gcctcccgac tcaacacacg cgttggcttg ctgaaactgc	360
atccgcagcc gagcgtgggt actcccaggc acagtcaccg gaggaagagc caaaggaaag	420
ggcgcgaagg gggtagcat ggagcggcag ggtattgggg caagaccac aggcctcattt	480
tggagctcct ctggtaggaa cctgtaccg gctgctatgc tctcccttc tcttcccaac	540
tctcggtgat catctccatc tcccctcgcg catcccttc cccctccctg ctttctttgc	600
tctccctccc tgcgcgtgc ctgctccct cccctctcc ctggctgctc tgggcagcag	660
caacctcggc agcccgggag atgggaagag agcgcgcggg gcgctgcagc tctggagccc	720
tggatctttc ctacccgggt gccttgagac cccgccgcg ctctcgctc ttggctaccc	780
ccggactccg gctacgctac taggacagcg ccgccaccac cgccagccct cgtcccgcgc	840
gcgccgcgct gccctccgc gccctggatg gagctttcct cgttgggac g	891

<210> 29

<211> 87

<212> DNA

<213> Mouse

<400> 29

ctttagaatg tgataactca cgcactctgat agcaccgtgg agtagttcag cactcatctc 60

tgctttccat gctatgttct ctacact 87

<210> 30

<211> 2036

<212> DNA

<213> Mouse

<400> 30

gaaaaattat gacatcaaca tccaaaggca ttcttcgccc atttctaata gtctgcatca 60

tcctgggctg ctatcatggca tgtctgctca tttatatcaa gccaccaaac agctgggtct 120

tcagtccaat ggagtcigca agttctgtgc tgaaaatgaa aaatttcttc tccacaaaaa 180

ctgattlatti taacgaaact accattctgg ttgggtatg gccatttggg cagaccttg 240

accttacatc ctgccaagca atgttcaata tccaagggtg ccatctcaca acagaccgct 300

cattgtacaa caaatcccat gcggtcctga ttaccatag agacatcagc tgggatctga 360

ctaacttacc tcagcaggcc aggccaccct ttcagaaatg gatttggatg aatttagagt	420
caccactca cccccccaa aagagtggca ttgaacactt gtccaacctg actctaactt	480
atgccgtga ttcagatata caagtgcctt atggcttctt gacggtgagc acaaatccct	540
ttgtgttga agtgccaagc aaggagaagt tgggtgtgctg ggttgtgagt aactggaacc	600
ctgagcatgc cagggtcaag tattacaacg agctcagcaa gattatigaa atccacacct	660
atggccaagc attcggagaa tacgtgaacg ataaaaatct gatccccacc atatctactt	720
gtaaatttta tctttcattt gaaaactcaa ttcacaaaga ttacatcaca gaaaagctct	780
acaatgcatt tttggctggt tcagtacctg ttgtcctggg tccatctagg gaaaactatg	840
agaattatat tccagctgat tcattcattc atgtggaaga ttttaactct cccagtgagt	900
tagcaaaata tctgaaggaa gttgacaaaa acaataagtt giaccttagt tactttaact	960
ggagaaagga ttttactgta aacctaccac ggttttggga atcacatgca tgcctggcat	1020
gcgacatgt aaaaaggcat caagaatata agtctgttgg taatttagag aaatggtttt	1080
ggaattaaag tgtccatcat tgtcacagtg aaaaagatta atgagacata attcaagttt	1140
tcaggataag aagaaacacg ctgcatttgg ggcaccgttt aattttcctg ccctcccttg	1200
aggacatgt atatttttgt gaaattttta agagatcaga attagcaatc actcaatttg	1260

gttttaaatt atcctgtata tatgtgataa cgagcactgg aaataattta tttgtcactc	1320
tcatttataa acattgtttt tacattttat agttgactgt aaagtaaatt tatgatttac	1380
ttgtttctac atcaatcaga tctttaatct atttgggaga taaaaataca ttcctaaaa	1440
tatgaggac tttttgccaa gtattataaa gtagattc tagcttgtat aatgctaaca	1500
aagaagaatt attgaatcac ttaattctta atctcttga ctcaaagtt gaacactact	1560
gacaactgat agagttttta ctgtaccac atttgtgaag gggagctaatt tgatgtagca	1620
aataagaaag atatgaagca gaaatgttat tagacttcac attcattttt attaagttgt	1680
ttagcaaag tagattccca atattttaag ttaaagaaaa caagaatttt cagataaaca	1740
atttatatgg ttttagggag atttgattgt ttgtttgtg ggtttagtcc ctaataatac	1800
ctaagagaat cttttgatag ttccctttca aatcatgaag ataaccacta ttttaaaaat	1860
aaataatttc ctcttataac aataaaaaaa tgatatcttc aaatacaaat aaatgtataa	1920
attataccat ttatagaacg ctagttactt cattcatttg aaatattttt tccaaagcat	1980
ccatatttaa gttttatttt actgtatttg ttaataaata gaagtaaaac ttgaaa	2036

<210> 31

<211> 2056

<212> DNA

<213> Mouse

<400> 31

ggtaccaaac atcaaatttt ttgcatgacc ccttcagtc tgggccatca actgcaattg 60

aggctgtacc ttcactaatg gctgttgctg gccttttaca gtgtcaggcc ttagctgctc 120

tccatgacca ctttgtgtct tcaaattccag taccatctca aactagaggc aagaggcaga 180

gagcacacta tagatggtag aagatttttt taaaacctca tgcccaccct tactaacatg 240

cctcatctaa caaggtcata ttccttaatt ctccccta atgttgcaacc actggcacc 300

aacaaaattt attagcctaa ggaggttcct ctacttaaa ctactacact tataaaaaaca 360

caatcaaagg atatgaaatt gaggtgggga tagggttaga ttatggaagg atttaggagg 420

tagggggtaa tatacatata tgtataaagc ccaaragtct caactatatg arrattatat 480

aatcactaca ttaaagtcgg ggatayccta atcatatatg aggaaatttg tttttgttg 540

ttattttatt tatttacatt taaaatgtaa atctgccc atgtattccct ctccccttg 600

tctggaagtt tgtactttat taattctcag taaccacaat taattaaaca gttactgcca 660

tttgcaaact tcatgattca tctctgagta agagtgtga gtgggatatt atgcttcac 720

aatcattacc tttccatggt ctttaaataa ttaataatcg gtgggtctac ctgggtgtact	780
gctgtgtgta catgctggac acagcaacat gtgctctaga agctgaggcg tctggcccat	840
tggcccttac tgaatagatg gtcctcttat tctgatcatc aaaaagacat gaaaccaa	900
gttttcattg gcatgcatgc tgaacatgaa agagtctaac aagttagaga cactgtcaaa	960
tagtaactta tcactaaaat ttaactttta tttttcttca agtaaaacaa tacaggaaga	1020
gatagaagtt tttcaataat atgtaaggct gacttggtgc agtaaaaatg tttttcacac	1080
tgcattcata actgagacag cttttatctt aatatgagta catttggtat ataaggcata	1140
attatgtaaa gtaaaaigtc taaattatct tagagactaa gaccttttag cacatgaaga	1200
tttctacatt cagaaaagca gtgtgagccc atggacacat gcttggtgca catacacaca	1260
cacacacaca cacacacccc agaacttctt tttccagtg cttgtctaag aagtacaggg	1320
atacttactg tatcatttga agagagttaa actagactac tttttctacc tgtatcatta	1380
cacacatcat ccacttgctt cctgtctgct gcctatttcc aatcagaatg cgaagattat	1440
gaaacaaaat gcaaggttca cagaaatata gtacagcgat actctgattg tcgttatatt	1500
tactaaatgt gtgaatttat tccttgattc ttgagtgtaa gaggagcccc taaatatact	1560
ttctatatgt atttgaatcg tagtctaaaa gtaaatttcg aggattgact tgtagtccaa	1620

caaaataaac aaaaacttgg caaagtgagg ctctatctat ctatctatct atctatccat	1680
ccatctatcc tttctttctc tctcttccctt ctctcttccct tcttcccttc ctctcttccct	1740
tcttcccttc ctctcttccct ccttcttttt ctccctacca ttctttctgt cgttctatct	1800
attacacaca tgtagtctat ctatacatct catcatctct actgtgtgtc atctacccca	1860
tgtagaatat atatittatg tggcgcttca gagaaagaga gctaaaatct gtagacgcaa	1920
acaacatgtg ccccttctac cacatttacc acaaaccctt ccccaaaaaa ctacatcgta	1980
gagaatttgg gtccacagac aactctgccc ctctattttt agtttaattt taatcacccc	2040
ccaccttgac cccgga	2056

<210> 32

<211> 24

<212> DNA

<213> Artificial Sequence


<220>

<223> Description of Artificial Sequence: synthetic DNA

<400> 32

aagcctaata cttgctctca gtcg	24
----------------------------	----

United States Patent & Trademark Office
Office of Initial Patent Examination -- Scanning Division



Application deficiencies found during scanning:

☒ Page(s) 6 of Drawings ^{was} ~~were~~ not present
for scanning. (Document title)

☒ Page(s) 48/48 of Sequence Listing ^{was} ~~were~~ not present
for scanning. (Document title)

☒ Scanned copy is best available. *drawing Figure 13 is dark*